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A tremendous amount of research has been dedicated to elucidating the functional 
mechanism of glutamate receptors. AMPA receptors in particular were the first in 
which structure was correlated to function; specifically, the structures of the isolated 
ligand binding domain (LBD) bound to different agonists, partial agonists, and 
antagonists, were compared to whole cell electrophysiological recordings. A 
correlation between the degree of lobe closure and maximal currents was discovered; 
that is, the greater the degree of LBD closure, the larger the measured currents. 
However, as more information relating LBD closure to channel activation began to 
surface, it became clear the relationship was not as direct as previously thought. The 
studies in this dissertation look at the single channel behavior of GluA3 receptors and 
supply new evidence that both full and partial agonists induce a similar mechanism of 
activation on AMPA receptors. These studies examine how subtle changes in the LBD 
can affect single channel properties. 
GluA3 channels have three conductance levels and the probability of opening to 
any of these levels is dependent on the agonist; that is, full agonists are more likely to 
open the channel to the largest conductance level than partial agonists. GluA3 
channels also display modal behaviors that are determined by the open probability and 
vary from very low to very high. A never before seen fast channel blocking effect is 
also reported. These modal behaviors are present at low agonist concentrations and 
 observed for all the agonists tested (glutamate, FW, ClW and NO2W). The agonists 
tested were all able to induce full LBD closures. The stability of the closures differed 
in the D655/S656 peptide conformation and the M712 orientation. D655/S656 flipped 
conformation allows H-bonding across the lobes to occur, stabilizing LBD closures.  
Bulkier substituents in the 5 position of the willardiine compounds reorients M712, 
which could alter the M4 transmembrane helix, thereby affecting channel gating.  
Based on these studies, although the mechanism of activation is similar for the 
agonists tested, it seems that subtle dynamic conformations of amino acids in the LBD 
caused by agonist binding can affect the agonist induced activation.   
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CHAPTER 1 
 
Introduction: The Progression of Ion Channel Research in the Quest to 
Understanding Ionotropic Glutamate Receptor Function 
 
 2 
1.1 Ion Channels 
One of the basic principles in biological systems is that cells communicate with 
each other through chemical and electrical means. The path to understanding cellular 
communication begins in 1663, when German physicist Otto von Guericke set forth 
the idea of electrical energy by creating the first electric generator of static electricity 
(1). Another two centuries had passed before Walther Nernst began testing how the 
diffusion of electrolytes in solution created potentials and developed the famous 
Nernst equation in 1888, that described the equilibrium potential of an ion as a 
function of the ratio of ions outside to inside the cell and the valence (1). Sidney 
Ringer was simultaneously running experiments on frog hearts with varying salt 
solutions of Na
+
, K
+
 and Ca
2+
, showing that specific ion concentrations of K
+
, Na
+
 and 
Ca
2+
 are needed to keep the heart beating (1). These advances in electrochemistry 
positioned researchers for future studies in cellular excitation and ultimately lead to 
the discovery of ion channels that governed cellular communication. 
Julius Bernstein was the first person to propose that cells are surrounded by a 
membrane that at rest is selectively permeable to K
+
 ions and during excitation there is 
an increase in permeability to other ions (1). During the period of 1935-1952, two 
separate groups, Cole and Curtis, and Hodgkin, Huxley and Katz, tested this theory by 
using the giant squid axon to study the properties of the resting cellular membrane and 
the propagated action potential (2, 3). Their studies revealed three different 
components to the action potential which we now know to be voltage-gated Na
+
 
channels, K
+
 channels, and various „leak‟ channels. The development of the patch 
clamp technique by Sakmann and Neher (1, 4) and advances in molecular genetics 
uncovered hundreds of ion channels that are involved in chemical and electrical 
signaling. The knowledge gained from these initial and subsequent studies on ion 
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channels have shaped our current understanding of how different cells types 
communicate with each other.   
Ion channels are now classified according to the channel‟s gating properties, such 
as voltage-gated ion channels, discovered by Hodgkin and Huxley (5), and ligand-
gated ion channels, first seen by Sakmann and Neher (4). Since the focus of this 
dissertation is on glutamate receptors, a ligand gated ion channel, there will be no 
further discussion of voltage gated channels.   
 
1.2 Ligand Gated Ion Channels 
Ligand gated ion channels regulate electrical changes in response to a specific 
binding of a chemical messenger. The first- and best-studied are the nicotinic 
acetylcholine receptors (nAchR) found in the neuromuscular junction of skeletal 
muscle in vertebrate. These receptors have been patch clamped, purified, cloned, and 
imaged (6-10). These receptors were found in extremely high abundance in electric 
fish electric organs which supplied a giant pool of nAchR‟s to study. Research on 
nAchR‟s first demonstrated how a chemical message was translated into an electrical 
signal. Muscle movement is controlled by the release of acetylcholine from 
prejunctional nerve terminals onto postjunctional muscle membranes (11, 12). This 
results in binding to and activation of nAchR‟s leading to depolarization of the muscle 
that activates voltage gated Na
+
 and Ca
2+
 channels, generating an action potential that 
propogates along the muscle fiber and leads to muscle contraction (12, 13).   
The in-depth characterization of acetylcholine receptors was subsequently 
translated to studies on other ligand-gated ion channels; in other words, the principles 
of ligand-gated ion channel activation learned from acetylcholine receptors were also 
used to understand other ligand-gated ion channels. From these studies, it was found 
that nAChR‟s are a part of a super family of pentameric, transmembrane ligand gated 
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ion channels that include 5-HT, glycine and GABA receptors (14). These pentameric 
channels function in similar ways; for example, only specific subunits can bind 
agonist, which lead to the discovery that receptors can bind two to five ligands, 
depending on their subunit composition (15).   
Glutamate receptors also were initially thought to be similar to acetylcholine 
receptors, which were later found to be untrue. Although both classes of ion channels 
share similar basic principles, such as ligand binding, activation, deactivation and 
desensitization, they also differ in how these basic functions are achieved. 
Acetylcholine receptors are pentameric channels in which the alpha subunit is 
necessary to bind an agonist (14).  Glutamate receptors are tetramers in which each 
subunit can bind an agonist. The membrane spanning region of nAchR‟s consists of 
four membrane spanning helices (16) whereas glutamate receptors consist of three 
membrane spanning regions and a reentrant loop (17). The ligand binding site on 
nAchR‟s is located in between two subunits (16) whereas each glutamate receptor 
subunit has its own ligand binding pocket. Although both receptor types are different, 
their shared basic properties allowed methods used to study nAchR to translate to 
uncovering glutamate receptor structure and function.   
 
1.3 The Glutamate Receptor Family 
From the first discovery of L-glutamate, it was difficult to believe this amino acid 
played any role as a neurotransmitter in the central nervous system (CNS). It wasn‟t 
until L-glutamate was shown in 1954 by Hayashi T. to have convulsant effects in the 
cerebral cortex (18), that researchers began to study this amino acid as a 
neurotransmitter. Since that time, with the discovery of different subtypes of glutamate 
receptors based on pharmacology it was realized that these receptors are prevalently 
abundant in the CNS and are major players in excitatory neurotransmission (18). 
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Molecular cloning identified the molecular species of each subtype (19-21), allowed 
the production of genetically modified animal models to study CNS diseases and 
disorders, as well as provided a foundation for structure-function studies. Another 
important aspect of these receptors was realized when it was recognized through that 
they play a role in learning and memory, specifically long term potentiation (LTP) 
(22) and long term depression (LTD) (23).  This and recent advances in uncovering 
the structural basis of the functioning of these receptors are opening up new avenues 
for potential drug discovery to treat neurological disorders and diseases. 
 
I. Classification 
There are three classes of functional ionotropic glutamate receptors (iGluR) 
comprised of six gene families (17) and named according to their selectivity for the 
full agonists: AMPA, Kainate and NMDA. A fourth class of receptors that are 
homologous to iGluR‟s are the delta receptors. Much molecular work has been 
undertaken to understand the structural basis of the functioning of these receptors.   
 
A. AMPA Receptors 
Ionotropic glutamate receptor of the AMPA class (GluA) binds a man-made 
compound called -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, or AMPA, 
with the highest affinity (17). GluA‟s mediate most of the fast synaptic 
neurotransmission in the central nervous system (CNS). There are four mammalian 
AMPA receptor genes that make up the AMPA class of receptor subunits, which 
consists of GluA1, GluA2, GluA3 and GluA4 (24, 25). The GluA receptor subunits 
can form both heteromeric and homomeric tetramers.   
AMPA receptors are widely expressed throughout the CNS in both neurons and 
glial cells, and are generally located at post synaptic sites of excitatory synapses (26).  
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There is significant variability in the expression of the four AMPA subunits in the 
brain.  The most abundant and widespread subunits are GluA1 and GluA2, and the 
fewer, more regionally expressed subunits are GluA3 and GluA4 (24). Similar to other 
ion channels, AMPA receptors have activation and desensitization kinetics that are 
dependent on subunit composition, RNA modifications, and other factors, such as 
polyamine block and assembly with transmembrane AMPAR regulatory proteins 
(TARP)  (17, 27, 28).   
AMPA receptors in the CNS can be either Ca
2+
 permeable or Ca
2+
 impermeable 
(29). Most AMPA receptors form heteromers that contain the GluA2 subunit, which 
play a role in many biophysical properties of the whole receptor, including Ca
2+
 
permeability, receptor kinetics, single-channel conductance, and block by polyamines 
(27, 30). ~95% of GluA2 subunits in the brain contain an arginine (R) in the pore loop 
due to pre-mRNA editing by site selective deamination of adenosine to inosine (31). 
This Q/R editing site is specific to the GluA2 subunit. GluA2 coassembly with other 
AMPA subunits greatly decreases Ca
2+
 permeability, abolishes polyamine block, and 
causes the channel to exhibit relatively low single channel conductance (30).   
All AMPA receptors have an extracellular 38 amino acid region preceding the 
transmembrane segment, M3, that can exist in either a flip or flop form. The flip form 
is predominantly expressed early in development, whereas flop form expression is 
increased in adult animals (32). This phenomenon arises from alternatively spliced 
mRNA (32). Flop forms desensitize to a greater degree and much more rapidly than 
the flip forms (32).   
Another site that undergoes RNA editing is the R/G editing site. In GluA2, GluA3, 
and GluA4, an adenosine located directly before the flip/flop splice region, also 
undergoes site selective deamination of adenosine to inosine, changing the amino acid 
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from arginine to glycine. This change increases the rate of desensitization and 
quickens the recovery from desensitization  (33). 
Functionally, AMPA receptors have rapid activation and deactivation kinetics (34-
37).  The single channel conductance of AMPA receptors consists of three or four 
sublevels and have been reported to range from 7 – 50 pS, which is dependent upon 
subunit composition (38-40). Receptors that co-assemble with an R-edited GluA2 
subunit exhibit a maximum single channel conductance of 10 pS (38). Homomeric 
GluA2 receptors have very low single channel conductance on the order of a few 
hundred femto-siemens (38). AMPA receptors are permeable to Na
+
 and K
+
, as well as 
Ca
2+
 (so long as the receptor does not contain an edited GluA2 subunit), with a 
reversal potential around 0 mV in vivo (17). Activation of AMPA receptors in 
synapses causes a rapid increase of inward currents in the postsynaptic cell that lasts 
for a few hundred microseconds (41).   
In neurons, AMPA receptors normally assemble with auxillary proteins called 
TARP‟s. TARP‟s interact with the C-terminal tails of AMPA receptors and are 
important in the cell surface expression of AMPA receptors in neurons (42-44).  
TARP‟s also modulate the kinetics of AMPA receptor gating which result in longer 
and larger currents into the cell. The main effects are a slowing of receptor activation, 
deactivation and desensitization (45, 46). There are currently four TARP‟s known to 
interact with AMPA receptors and result in different degrees of receptor kinetics (47).   
 
B. Kainate Receptors 
Ionotropic glutamate receptors of the kainate class (GluK) consists of five kainate 
receptor genes (25). The kainate receptors are involved in excitatory and inhibitory 
neurotransmission through activation of post- and pre-synaptic receptors.  Kainate 
receptors are comprised of GluK1, GluK2, GluK3, KA1 (or GluK4), and KA2 
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(GluK5) (24), with the latter two unable to form a functional channel without GluK1-3 
(48). Kainate receptors can form homo- and hetero- tetrameric channels and also 
contribute to fast excitatory transmission in the CNS (24). The single channel 
conductance of kainate receptors, depending on subunit combination and RNA 
editing, range from a few hundred fS to 25 pS (49).   
Kainate function in the CNS is similar to, yet different from, AMPA receptor 
function. Kainate receptors are found both pre and post synaptically. Kainate receptors 
on the presynaptic nerve terminal have been shown to affect excitation or inhibition of 
the postsynaptic cell by modulating presynaptic glutamatergic and/or GABA-ergic 
neurons (50, 51). Activation of kainate receptors also affects voltage gated ion 
channels through a noncanonical G protein signaling mechanism (52). Although 
kainate receptors are found in many areas of the CNS, in neurons the expression of 
these receptors seem to be clustered in specific areas rather than spread out (53, 54).     
GluK1-3 are known to undergo alternative splicing (55). These splice variants are 
found in the C-termini which may alter the physiological properties of the channel.  
Similar to AMPA receptors, kainate receptors also undergo Q/R editing in the 
reentrant pore loop on GluK2 and GluK3 subunits. Incorporation of these R-edited 
subunits causes the channel to be impermeable to Ca
2+
 (56), abolishes polyamine 
block (27), and also significantly lowers the single channel conductance to a few 
hundred femtosiemens (49).   Two additional editing sites, I/V and Y/C, also exist for 
kainate receptors.   
 
C. NMDA Receptors 
Ionotropic glutamate receptors of the NMDA class (GluN) are composed of seven 
genes (25). NMDA receptors are responsible for the slower activation and longer 
duration of excitatory synaptic neurotransmission.  NMDA receptors are coincidence 
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activators, needing to both overcome a voltage-dependent Mg
2+
 block and be activated 
by agonists (57). NMDA receptors are obligate tetrameric heteromers (58), needing 
two different agonists, glycine and glutamate, to activate. Activation of NMDA 
receptors can allow the influx of divalent cations into the cell, which is thought to play 
a role in synaptic plasticity. Two processes must occur in order for NMDA receptor 
activation and channel opening to occur, the first being fully bound with agonists and 
the second is overcoming a voltage-dependent Mg
2+ 
block. At resting membrane 
potentials, extracellular Mg
2+
 blocks NMDA channel activation.  Mg
2+
 inhibition is 
relieved only upon depolarization (59).  This important feature of NMDA receptor 
activity is the basis of long term potentiation in learning and memory (60).   
There are currently fourteen known variants of NMDA receptor subunits produced 
from alternative splicing and consisting of GluN1-3. There are eight different GluN1 
isoforms which binds glycine and -serine. There are four GluN2 gene products which 
bind glutamate and three GluN3 gene products which bind glycine (17). Splice 
variants for GluN2A-D are widely expressed in the CNS (61). GluN subunits differ in 
their functional properties and are also localized in different areas of the CNS (61). 
Various combinations of subunit assembly result in altered kinetics and sensitivity to 
divalent ions. For example, GluN2C and 2D have low sensitivity to Mg
2+
 block but 
still conducts Ca
2+
, which is thought to enhance long term potentiation processes (62).    
GluN1/N2A complexes have the shortest deactivation time constant on the order of 50 
ms, whereas GluN1/N2D complexes have the longest deactivation time constant 
ranging in seconds (63).   
Posttranslational modification of glutamate receptors has been extensively studied 
in NMDA receptors, although much still remains to be elucidated due to the numerous 
splice variants and subunit combinations. Examples of such modifications include 
phosphorylation, glycosylation, nitrosylation, and ubiquitinization.  Phosphorylation 
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of specific serine or tyrosine residues in the C-terminus by calmodulin can increase 
single channel conductance and also increase the insertion of NMDA receptors onto 
surface of the cell (64). Glycosylation occurs on the N-terminus and affects subunit 
assembly and trafficking (65). S-nitrosylation of cysteines can downregulate ion 
channel activity by decreasing Ca
2+
 influx (66).   
Location of each expressed subunit is dependent on the developmental stage and 
area of the brain. For example, in the forebrain GluN2B subunits are predominant in 
early development, but switches over to a higher expression of GluN2A as 
development progresses (67). The changes in expression might ultimately play a role 
in synapse formation and synapse maturation during development.   
 
D. Delta Receptors 
A fourth class of nonfunctional receptors, called the orphan ionotropic glutamate 
receptors, denoted Glu have been cloned by homology screening. These 
receptors share 40% sequence homology with AMPA / kainate receptors and 20-30% 
with NMDA receptors.  receptors are predicted to have similar structure to other 
iGluR‟s based on analysis of the transmembrane region, recent structures of the „LBD‟ 
and sequence similarities (68, 69). Glu subunits are insensitive to common iGluR 
agonists and currently, the endogenous ligand for Glu has not been found (70, 71). 
Glu 1 and 2 have not been found to co-express on the same neurons, suggesting they 
do not assemble together. However, they have been found to co-express with other 
iGluR‟s.  Although they have been shown to assemble with AMPA / kainate receptors 
in vitro, the same has not been proven in vivo (72).   
Much controversy surrounding whether these receptors actually form functional 
ion channels currently exists. Support for ion channel activity arose from mutations 
denoted lurcher and hotfoot which result in spontaneous channel opening that is 
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associated with neuronal cell death (73). This point mutation is located in a highly 
conserved transmembrane region (SYTANLAAF) of other iGluR‟s (73). Similar point 
mutations made on AMPA receptors result in a similar phenotype as the lurcher 
mutation in which agonist potency increases (74).   
Initial mouse knock-out studies of the 2 subunit reveal abnormal motor 
coordination and learning (75). Synaptogenesis in the cerebellum is also altered and 
parallel fiber synapses onto Purkinje cells are decreased. These synapses are actually 
important in LTD, which is abolished in 2 knockout mice (76). 1 subunits are found 
abundantly in the inner ear and knockout mice lacking 1 subunits show hearing 
impairment (77). Most of the recent findings suggest a metabotropic rather than 
ionotropic function (78).     
 
II. Glutamate Receptor Structure and Function 
Early work characterizing ionotropic glutamate receptors was slow due to the 
many subtypes, possible subunit combinations, RNA editing, and overall differences 
between the three main groups of ionotropic receptors. We now know that glutamate 
receptors can arrange as either tetrameric homomers or tetrameric heteromers, with 
NMDA receptors being obligate heteromeric channels (58). Pharmacologically, each 
group of iGluR‟s have different affinities for different compounds, and some ligand 
that have affinity for one group does not readily activate another group. For example, 
NMDA only activates NMDA receptors but not AMPA or kainate receptors, and 
kainate is a partial agonist at AMPA receptors but is a full agonist at kainate receptors 
(17).   
Correlating structure with function has been difficult because of the challenge in 
determining the structure of a membrane bound protein. Most of the structural 
information about glutamate receptors was determined using various methods.   
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Figure 1.1 
A one-dimensional topology of a single glutamate receptor subunit. A single 
glutamate receptor subunit consists of an N-terminal domain, a ligand binding domain 
(marked lobe 1 and lobe 2), a transmembrane domain and a C-terminal domain. Figure 
adapted from (86).   
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Research by various groups studying kainate (79) and AMPA (80) receptors resulted 
in uncovered the unexpected topology of the membrane spanning pore, which 
consisted of three transmembrane segments and a reentrant pore loop (79, 80), as well 
as solving the structure of the ligand binding domain bound to a variety of ligands (40, 
81-84).  Currently, the structures of the LBD of GluA2, 3, 4, GluK 1, 2, GluN1, 2A, 
3A and 3B, have been solved bound to various agonists and antagonists. Recent x-ray 
crystallography studies pursued by Sobolevsky, et al. (85), resulted in an extraordinary 
breakthrough – the solving of the structure of a homomeric GluA2 receptor bound to 
an antagonist. This almost full-length structure confirmed the results of many years of 
research on glutamate receptors. All glutamate receptor subunits have a similar 
structure (Figure 1.1): an amino-terminal domain, a clam shell-like ligand binding 
domain (LBD), a transmembrane domain with three transmembrane segments and a 
reentrant pore loop, and a variable length C-terminal domain (85, 86). The structural 
findings along with the results from many functional studies have yielded several 
mechanistic models to describe the activation, deactivation and desensitization of 
glutamate receptors. These studies will hopefully lead to rational drug design and aid 
in the development of therapies for many neurological diseases and disorders 
(discussed in section 1.5).   
 
A. Glutamate receptor mechanism of activation 
One of the long-standing questions in neurobiology is the mechanism of glutamate 
receptor activation. Recording electrophysiological activity from neurons uncovered 
the basis of cellular excitation by way of ionotropic glutamate receptors, but did not 
reveal how each specific subunit contributed to activation kinetics.  Functional studies 
on individually expressed subunits in cultured cells have yielded many properties that 
can be correlated with specific structural aspects of the protein.   
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The amino-terminal domain is a bilobate structure that is important for proper 
subunit assembly (87, 88) and can also bind modulators that affect channel function 
(89, 90). The LBD consists of two lobes that bind agonists necessary for channel 
activation (81). The transmembrane segments line the pore of the ion channel and are 
structurally similar to the pore region of voltage gated K
+
 channels, but are inverted 
and have an extra transmembrane segment (17). The reentrant loop is  also similar to 
the P-loop in K
+
 channels and controls ion selectivity (91). The M3 segment of the 
transmembrane region is connected to lobe 2 of the LBD and is thought to be the 
channel gate. Agonist binding in the LBD causes lobe 2 to move towards lobe 1. This 
in turn induces conformational changes in the M3 region that opens the channel.  The 
M3 segment is also analogous to the inner helix M2 segment in K
+
 channels (92, 93). 
The C-terminal domain varies in length depending on the subunit type and splice 
variants. This region can interact with numerous intracellular proteins that are 
involved in signal transduction and scaffolding (94).   
Isolation of the ligand binding domain (95, 96) provided much structural insight 
on how a ligand binds to an individual subunit (81, 97, 98). The best studied so far is 
the GluA2 receptor. Ligand binding to the LBD induces a „clamping‟ or closure on the 
ligand, eventually leading to conformational changes associated with channel opening 
(99-101). The agonist bound state is quite similar for all the iGluR‟s; the region in 
which the ligand docks onto the LBD is on lobe 1. All ligands that can bind to iGluR‟s 
have a chemical moiety that is similar to the -amino and -carboxyl groups of 
glutamate. The closed conformation shown from agonist bound structures of the 
GluA2 LBD is stabilized by many direct and water-mediated hydrogen bonds (84). An 
arginine residue that is conserved in all AMPA receptors (R485 in GluA2) is thought 
to be the initial docking site for the ligand and mutation of this residue abolishes 
channel activity (84, 102, 103).   
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Table 1.1 
The relationship between the degree of ligand binding domain closure and receptor 
function. The degree of lobe closures as measured by crystallography from (40, 81, 
84, 105).  Full agonists, such as glutamate and AMPA produce ~20˚ lobe closure and 
have maximal measured peak currents.  Partial agonists induce less than 20˚ LBD 
closures and have less than maximal currents.  All currents are normalized to the full 
agonist.     
 
 
 
 
Ligand 
Degree Lobe 
Closure 
Degree Lobe 
Closure with Zn
2+
 
Ipeak / I glu 
Glutamate / AMPA -- 20° 1 
DNQX 2.5° -- -- 
Kainate 12° -- 0.2 
Willardiine -- 16.6° 0.62 
Fluoro-Willardiine 15.3° -- 0.54 
Bromo-Willardiine 14.8° 17.5 0.37 
Iodo-Willardiine 10.8° 16.5 0.34 
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Structural studies on the GluA2 LBD of AMPA receptors provided evidence that 
the extent of lobe closure on an agonist is directly related to the efficacy measured 
with whole cell electrophysiology. GluA2 LBD bound to full agonists induced a cleft  
closure of ~20° and gave maximal whole cell electrophysiological responses (83).  
Partial agonists induced cleft closures ranging from 12 - 20° (83, 104, 105) and 
induced a whole cell electrophysiological response which corresponds to the extent of 
cleft closure (40); that is the less cleft closure, the smaller the measured response 
(Table 1.1). However, this relationship between lobe closure and efficacy may not be 
so simple based on more recent studies with specific mutations in the LBD, using 
other AMPA receptor subtypes and AMPA/kainate chimeras. For example, T686 
interacts across the LBD to form a hydrogen bond with E402 in the GluA2 receptor. 
Mutation of T686A increases the EC50 values for full agonists and also changes the 
degree of lobe closure for certain agonists (100, 106), which suggests residues 
involved in stabilizing the closed LBD conformation also play a role in channel 
activation. These studies weaken the correlation between channel activation and the 
extent of LBD closure (107, 108) and indicate other mechanisms are involved.  On 
another note, whole cell recordings can also be misleading because this technique 
depicts the average behavior of hundreds of active channels. To further complicate 
matters, each individual receptor is composed of four subunits that are equally able to 
bind agonist and contribute to activation. To put it simply, these initial correlations 
were a beginning to elucidating the function of glutamate receptors, but did not 
provide the best explanation for receptor activation.  To obtain a better understanding 
of the relationship between structure and function, single channel studies are 
necessary, allowing quantitative analysis of the underlying kinetic behavior.   
State models that describe the single channel activity of any ion channel can 
provide detailed kinetic information regarding receptor gating by way of transitions. 
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Each state represents a stable, measurable, protein conformation. NMDA receptors 
have been a model for single channel studies due to their large conductance and 
lengthy openings.  Activation of NMDA receptors, unlike non-NMDA (kainate and 
AMPA) receptors, requires all four subunits to be bound with agonist and causes full 
channel openings to ~40 pS (109, 110). NMDA receptors assemble with two glycine 
binding subunits and two glutamate binding subunits; two glycine molecules and two 
glutamate molecules are needed to activate the channel (111, 112). Quite a few 
thorough studies on the single channel activity of NMDA receptors have been 
undertaken within the past few decades and have lead to the generation of kinetic 
models of activation. Based on the duration of closed and open time distributions, a 
kinetic model composed of three closed states and two open states was generated (113, 
114). The combinations studied thus far also reveal modal gating behaviors which 
shift over time but are not agonist concentration-dependent (113). Partial agonists also 
induce similar modal gating behaviors but cause a decrease in the open probability of 
the channel (115). The few structures of NMDA LBD‟s bound to partial agonists 
reveal similar degrees of closure compared to full agonists (116). Based on these 
studies, it was been proposed that all four subunits need to rearrange into a high 
affinity conformation in order for gating to occur. Partial agonists are not as 
efficacious in achieving this rearrangement compared to full agonists (115). Another 
hypothesis has also been put forth suggesting that specific residues within the agonist 
binding pocket reorganize themselves to hold the two lobes together and the more 
efficacious the agonist, the stronger the interaction (116). Now that there is a model of 
activation for NMDA receptors, future studies using various mutations, 
pharmacological agents, and cellular factors, can clarify the effects these perturbations 
have on ion channel function.   
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Analogous studies can similarly be carried out with non-NMDA receptors to not 
only produce a better structure-function relationship, but also to begin elucidating the 
mechanism of a normally functioning receptor. However, AMPA and kainate 
receptors are quite different from of NMDA receptors, exhibiting smaller conductance 
levels and much shorter openings, making single channel data collection a difficult 
task. What data has been collected has lead to some initial characterization of single 
channel behavior. Non-NMDA receptors have multiple open conductance levels that 
correlate with the number of active (agonist-bound) subunits. At least two active 
subunits are necessary to observe the smallest conductance level, with each 
subsequent active subunit causing the channel to open to the next conductance level 
(38, 117). There are also studies that suggest there are actually four subconductance 
levels (39) observable from neuronal AMPA receptors. Kainate receptors also display 
subconductance levels but these behaviors have not been characterized the these 
receptors (49). The amplitudes of openings are also dependent on the subunit 
combinations, which has been more thoroughly studied with AMPA receptors than 
kainate receptors.  AMPA receptor assembly with an (R)-edited GluA2 subunit greatly 
decreases whole cell response and single channel conductance (17, 38). Although 
these studies provided some insight into channel activity, these studies ulitilized 
recordings from short-lived activation periods. Brief events only reveal activity of a 
single channel for that specific moment in time; they do not capture other possible 
activity schemes in that longer recordings can reveal.   
Longer single channel recordings on AMPA (and future studies on kainate 
receptors) using full agonists as well as with partial agonists can provide much more 
structure-function information. Another problem in the field regarding partial agonists 
is the fact that most studies on AMPA receptors have been conducted using kainate, 
which induce such small channel openings that it becomes difficult to resolve 
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openings from background noise. Kainate acting on AMPA receptors is also on the 
extreme end of the partial agonist spectrum, not only in the way its bound in the ligand 
binding pocket, (kainate sterically clashes with certain residues in the binding pocket 
(108)), but also because its maximal activation in whole cell recordings is only 20% of 
that of glutamate on GluA2 receptors (84). The willardiines are a group of partial 
agonists which differ in the 5 position substituent, yet show a graded level of whole 
cell activation that is greater than kainate (40, 118). These subtle differences and 
higher affinity for AMPA receptors make this group of partial agonists excellent 
candidates for detailed single channel studies. Single channel studies collected from 
homomeric, wild-type receptors using partial agonists with the full agonist as a 
control, can provide new insights into the gating mechanism as described in the 
studies in chapters 2-4.   
 
B. Mechanism of Desensitization 
Desensitization is a characteristic shared by many ligand gated ion channels to 
shut down channels that are in the continuous presence of activating factors.  AMPA 
and kainate receptors undergo rapid desensitization in the millisecond range (119).  
Structural and functional studies on AMPA/kainate subtypes have generated insight 
into the mechanism of desensitization.   
Initial crystallography studies on the GluA2 LBD revealed these isolated domains 
formed dimeric complexes (84). Most of the contacts are mediated by interactions 
between residues in lobe 1 of two LBD‟s (99). Specific point mutations in lobe 1 were 
shown in the intact receptor to alter desensitization, for example, the L/Y mutation 
(L483Y in GluA2) significantly reduced desensitization. Allosteric modulators which 
also interact within the lobe 1 interface, such as cyclothiazide (CTZ) also suppress 
desensitization. LBD structures of the L/Y mutant as well as structures of LBD‟s in 
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the presence of CTZ (99) also demonstrated the formation of dimers. NMR studies 
with a variety of allosteric modulators also show a similar interaction (120). The 
crystallographic structure of the almost full-length GluA2 receptor confirmed the 
formation of LBD dimers which then dimerizes with an adjacent pair of LBD‟s 
forming an asymmetric extracellular, symmetric transmembrane, tetrameric channel 
(85). Since stabilizing this dimer interface prevented desensitization and enabled long 
channel openings, it was hypothesized that destabilizing this interaction would induce 
a desensitized state. Crystallography and NMR studies (120, 121) of various allosteric 
modulators bound to this interface, which were then correlated with functional studies, 
supported the idea that formation of this dimer interaction prevents desensitization 
(122, 123). Recent LRET studies on an entire GluA2 receptor concluded agonist 
binding precedes dimer formation (124). The question of whether cooperation between 
the subunits is involved in only the desensitization process or also involved in the 
activation and deactivation process is currently unknown.   
Desensitization of NMDA receptors is much slower and occurs by several 
mechanisms, the first being similar to AMPA / kainate receptor desensitization in 
which the dimer interface collapses (125). Interestingly, the GluN1/GluN2A dimer 
interface contains a residue, Y535 in the GluN1 subunit which interacts with GluN2A 
in a similar fashion as allosteric modulators in GluA‟s (125).  The other mechanisms 
of desensitization of NMDA receptors involve Zn
2+
 binding to the amino terminal 
domain (126, 127), the glycine binding subunit (128), and Ca
2+
 entry into the cell 
(129).   
 
1.4 The Role of Glutamate Receptors in Synaptic Plasticity 
The first reports of mammalian excitatory neurotransmission by amino acids came 
from studies in the rat hippocampus. Since then, the molecular mechanisms of 
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synaptic plasticity involving glutamate receptors have come mainly from research on 
the hippocampal area in the brain. Animal models in which NMDA receptors in the 
hippocampus were blocked revealed an impairment of learning; subsequently similar 
studies carried out on other regions of the brain have corroborated the effects NMDA 
receptors had on learning. For example, blockade of NMDA receptors through 
pharmacological means inpaired fear conditioning; the animals in these experiments 
were unable to learn to avoid negative environmental stimuli (130). On the cellular 
level, scientists have long observed that brief, intense synaptic activation of neurons is 
usually followed by a long, slow activation, known as long term potentiation (LTP), 
that can persist for hours (131). The link between NMDA receptors and LTP was 
demonstrated when the NMDA receptor antagonist, APV, was shown to disrupt LTP 
without affecting synaptic neurotransmission (132). Since then, the current 
understanding of LTP is that it involves a number of coincidence events (133). NMDA 
receptors, during resting cell conditions, are normally blocked by Mg
2+
 ions due to 
negative membrane potential (59), with current flowing through theough these 
receptors only when the membrane has been depolarized. AMPA receptors, also 
expressed in the same regions of NMDA receptors, are activated by glutamate released 
into the synaptic cleft, and is the cause of the initial depolarization which relieves the 
Mg
2+
 block of NMDA receptors (57). Additional waves of released glutamate 
produces a summed postsynaptic depolarization from the now unblocked NMDA 
receptors and activate intracellular biochemical pathways involved in LTP, primarily 
via Ca
2+
 entry into the cell through these receptors (17, 57).   
The opening of NMDA channels allows the entry of Ca
2+
 into the cell, resulting in 
the activation of various Ca
2+
 signalling cascades.  Ca
2+
 has been shown to be a 
necessity in LTP induction because loading the cell with EDTA, a Ca
2+
 chelator 
prevents the occurrence of LTP (134). Synaptic plasticity by NMDA receptors can 
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result in either LTP or long term depression (LTD) and is determined by the amount of 
Ca
2+
 influx over time. High frequency stimulation over a short time course of a few 
seconds result in robust Ca
2+
 entry through NMDAR‟s and induce LTP whereas slow 
frequency stimulation over a much longer period of time which could last for many 
minutes result in smaller Ca
2+
 entry and induce LTD (135).   
Since then, more recent findings have also established other modes of synaptic 
strengthening and weakening.  An example is an increase in the membrane insertion of 
AMPA receptors during LTP induction (136). In a specific study on isolated 
hippocampal neurons, it was found that calmodulin activity induced by NMDA 
activation recruits Ca
2+
 permeable AMPA channels to dendritic spines (137). Another 
type of synaptic plasticity is the phenomenon of silent synapses, in which presynaptic 
activation does not have any affect on the postsynaptic cell (138). Recent evidence 
suggest these silent synapses are devoid of AMPA receptors (139) and it has been 
speculated based on postnatal development studies that synapses with weak activation 
lose surface expression of AMPA receptors leading to silent synapses (140). The study 
of the receptors that mediate synaptic plasticity can have many beneficial 
consequences, such as developing treatments for diseases such as Retts disease, in 
which glutamatergic neurons are affected (141). Aging brains also show a decline in 
AMPA receptor expression (142). Targeting these receptors to increase synapse 
formation could potentially reverse the effects of aging.   
 
1.5 Glutamate Receptor Involvement in CNS Diseases and Disorders 
The high prevalence and diverse function of ionotropic glutamate receptors in the 
CNS makes it unsurprising to find many CNS diseases and disorders to be linked to 
ionotropic glutamate receptor activity. Overactivation of ionotropic glutamate 
receptors can lead to excitotoxicity whereas underactivation can lead to overall CNS 
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depressed states. Evidence for the role of ionotropic glutamate receptors in 
excitotoxicity came from studies of NMDA and AMPA receptor antagonists, which 
were shown to have anti-convulsant effects (143, 144). Addiction to substances of 
abuse has also been shown to affect glutamatergic activity and in some cases, result in 
permanent changes. This section briefly covers the implications for the involvement of 
glutamate receptors in neurodegenerative diseases and disorders and the need for 
subunit specific agonists and antagonists to treat these problems.   
 
I. Excitotoxicity 
The role Ca
2+
 permeable ionotropic glutamate receptors play in neuronal cell death 
has been explored in many disorders, one of the most prominent being hypoxic 
induced ischemia. One hypothesis associated with neuronal excitotoxicity involves an 
overabundance of intracellular Ca
2+
. Excessive amounts of Ca
2+
 can trigger the 
activation of proteases, lipases, phosphatases and endonucleases which leads to the 
formation of oxidative radicals and cellular damage (145). Normally, the extracellular 
glutamate concentration is regulated by plasma membrane Na
+
/glutamate co-
transporters in which the gradient is supplied from the energy provided by a Na
+
/K
+
 
ATPase pump (146). A similar Ca
2+
 ATPase pump is also used to regulate the 
intracellular Ca
2+
 concentration. During periods of intracellular Ca
2+
 overload, excess 
ATPase activation rapidly expends the available ATP pool. Stress placed on the 
mitochondria to produce more ATP leads to the production of oxidative species which 
wreak havoc on cell (146). The inability to maintain a low extracellular glutamate 
concentration leads to activation of Ca
2+
 permeable glutamate channels, further 
exacerbating the problem.   
Ca
2+
 permeable AMPA channels are also permeable to Zn
2+
, which is normally co-
released with glutamate at some synaptic terminals.  Zn
2+
 effects are similar to Ca
2+
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effects, except Zn
2+
 is more harmful in that it induces prolonged production of 
oxidative species (147). Prolonged Zn
2+
 exposure leads to neuronal cell death (148).  
Zn
2+
 has been shown to increase the binding affinity of AMPA to AMPAR‟s, 
potentiate whole cell responses, and slow AMPAR desensitization (149). Similar 
potentiation effects were seen in rat CA3 pyramidal neurons (150). Not much is 
known about the direct effects of Zn
2+
 and Ca
2+
 on the single properties of AMPA or 
kainate receptors.   
In the case of excitotoxicity, a method of limiting neuronal cell death would be to 
create antagonists that block ionotropic glutamate receptor activity, particularly 
channels that are Ca
2+
 permeable. However, ionotropic glutamate receptors are 
prevalent in all areas of the CNS and antagonists would affect all brain areas. In this 
case, subtype selective antagonists that can target specific modes of function might 
reduce the side effects attributed to the current nonselective antagonists. Another 
avenue would be to produce a partial agonist that could potentially compete with 
glutamate binding, still enabling a somewhat normal function, while alleviating some 
of the excitotoxic events. In any case, a more thorough understanding of each specific 
glutamate receptor subtype can aid in drug development.   
 
II. Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is characterized by selective degeneration of 
motor neurons which leads to paralysis, and eventually, death (151). Clincal 
symptoms include muscle weakness, muscle atrophy and spasticity. 5-10% of ALS 
cases are caused by mutations in either the SOD1 (152) or ALS2 (153) gene; the rest 
of ALS cases have unknown causes. AMPA receptors have been implicated in this 
disease because AMPA antagonists are able to prevent death of neurons exposed to the 
cerebrospinal fluid of ALS patients (the cerebrospinal fluid of ALS patients have been 
 25 
shown to be toxic to neurons) (154). Edited GluA2 subunits (which decrease Ca
2+
 
permeability) were also found to be decreased in ALS patients (155).   
Pharmacological agents that selectively target Ca
2+
 permeable AMPA channels 
might alleviate ALS symptoms. However, as with the case of excitotoxicity, a more 
thorough understanding of each specific subtype will allow for more precise drug 
development.   
 
III. Alzheimer’s Disease 
Alzheimer‟s disease (AD) is the most common neurodegenerative disease of the 
elderly population and is marked by progressive memory loss (156). The hallmark of 
this disease is characterized by excessive amyloid beta plaque formation (A plaques) 
in the brain which leads to neuronal cell death (157). The specific cause of 
Alzheimer‟s has not been determined, although there are a few factors associated with 
the disease. The first is oxidative stress; brain tissue from AD patients and animal 
models of AD show an increase in the amount of oxidative species (158, 159). 
Acetylcholine and glutamate receptors are the two types of receptors thought to play 
the largest role in the progression of the disease. There is actually a decrease in certain 
nicotinic acetylcholine receptor subtypes (160). In vitro and mice studies have shown 
A plaques actually enhances glutamate neurotransmission and may contribute to 
neuroexcitoxicity (161, 162). Memantine, an NMDA antagonist, in clinical use 
actually reduces neuronal cell death (163). A possibility of future theurapeutics, which 
include glutamate receptor antagonists and nicotinic acetylcholine agonists, might 
provide better treatment for this horrible disease.   
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IV. Epilepsy 
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked 
seizures caused by excessive neuronal activity. Seizures can occur in any brain region 
and are characterized based on the whether or not the seizure spreads within the brain 
and whether the subject loses consciousness. Many ion channels have been linked to 
epilepsy, including glutamate and GABA channels. GABA channels provides 
inhibitory action in the CNS, whereas glutamate provides excitatory action (164).  
Therefore, it is easy to see why drugs targeted to glutamate and GABA receptors can 
be beneficial to patients who suffer from epilepsy. A problem with GABA agonists is 
that these drugs usually enhance the functioning of GABA channels, leading to 
excessive neuronal inhibition. Unwanted side effects include sedation and can also 
lead to tolerance (164).   Glutamate antagonists offer another avenue of drug 
treatment.   
Both NMDA and AMPA receptor antagonists have been shown to have anti-
convulsant effects (165) and AMPA antagonists are preferred over other anti-epileptic 
drugs due to the lack of tolerance development (166). However, due to the non-
specificity of these antagonists for AMPA receptors, unwanted side effects such as 
sedation, mild ataxia, and muscle relaxation, also occur with the anti-convulsant 
effects (167). In this case, subtype specific antagonists could provide partial blocking 
of neuronal excitation.   
 
 
1.6 Outline of Dissertation Research 
Research in the glutamate receptors field has made tremendous progress over the 
past few decades. Although much has been discovered, much information regarding 
the function of glutamate receptors, particularly AMPA channels, is lacking because 
of the unavailability of single channel data. Single channel data can be used to 
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generate state models, such as the case for NMDA receptors, and allow us to 
quantitate and characterize measurable protein conformational changes associated 
with each state (168). These characterizations can be used to make comparisons 
between structural and functional data.   
The studies described in this dissertation takes advantage of a specific technique, 
cell-attached single channel electrophysiological recordings, and uses the data 
collected from these recordings to determine how glutamate receptors function. 
Homomeric GluA3 channels are exposed to and left to equilibrate with either the full 
agonist glutamate, or a partial agonist, fluorowillardiine (FW), nitrowillardiine 
(NO2W), or chlorowillardiine (ClW). The data collected with glutamate not only 
serves as the initial single channel characterization, but it also serves as the control 
data.  Data collected from FW, NO2W, ClW function as a perturbation which allow us 
to distinguish small differences in behavior that is caused by small differences in the 
structure of the ligand binding domain. Single channel data is collected over several 
minutes, which allows most of the behavior to be captured. The data are then analyzed 
and state model fitted to the results.   
GluA3 channels exhibit three conductance levels which are conserved across all 
agonists tested. These channels also exhibit five modal behaviors, Very High, High, 
Medium, Low, Very Low, which correspond to open probabilities of: 80-100%, 60-
79%, 40-59%, 20-39%, <20%. These modes are also conserved across all agonists 
tested. The receptor spends the most time in the highest conductance level in the 
presence of glutamate and spends the least time in the highest conductance level for 
FW, NO2W, and ClW. The differences in the open probabilities for the willardiines 
are very small. Although these differences might seem small, they become very large 
when averaged together over the hundreds of ion channels present in a whole cell.   
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From structural data of the isolated LBD, it seems all agonists examined are able 
to induce full LBD closures, but the three willardiines are slightly more open than 
glutamate by 1-4°. From the single channel data and the available structural 
information, we propose channel activation is governed by three factors: agonist 
binding, degree of lobe closure and stability of lobe closure. Specifically, agonist 
efficacy can be correlated to the stability of the D655/S656 peptide conformation in 
the LBD; flipped conformations can form hydrogen bonds across the cleft to 
Y453/G453 which stabilizes LBD closure. Structures of FW and ClW also reveal a 
stable partially closed conformation mediated by waters in the D655/S656 peptide 
region which can explain the occurrence of an alternative kinetic behavior seen with 
ClW. The structures of FW, NO2W and ClW also reveal a rotameric change in M712, 
which normally points toward the ligand binding pocket in an extended state when 
glutamate is bound. These subtle differences in structure are related to the subtle 
effects on the single channel behavior. The studies in this dissertation address the 
anomaly in the current thinking which relates the degree of lobe closure to channel 
activation. These studies are meant to bridge the gap in the current research by 
providing functional information on the single channel level and will serve as a 
foundation for future single channel studies of glutamate receptors.   
 29 
REFERENCES 
 
1.  Hille, B., and B. Hille. 2001. Ion channels of excitable membranes. Sinauer, 
Sunderland, Mass. 
2.  Cole, K.S., and H.J. Curtis. 1939. Electric Impedance Of The Squid Giant Axon 
During Activity. J Gen Physiol. 22:649-670. 
3.  Hodgkin, A.L., A.F. Huxley, and B. Katz. 1952. Measurement of current-voltage 
relations in the membrane of the giant axon of Loligo. J Physiol. 116:424-448. 
4.  Sakmann, B., J. Patlak, and E. Neher. 1980. Single acetylcholine-activated 
channels show burst-kinetics in presence of desensitizing concentrations of 
agonist. Nature. 286:71-73. 
5.   Hodgkin, A.L., and A.F. Huxley. 1952. Currents carried by sodium and potassium 
ions through the membrane of the giant axon of Loligo. J Physiol. 116:449-472. 
6. Brisson, A., and P.N. Unwin. 1985. Quaternary structure of the acetylcholine 
receptor. Nature. 315:474-477. 
7.  Neher, E., and B. Sakmann. 1976. Single-channel currents recorded from 
membrane of denervated frog muscle fibres. Nature. 260:799-802. 
8.  Noda, M., H. Takahashi, T. Tanabe, M. Toyosato, S. Kikyotani, Y. Furutani, T. 
Hirose, H. Takashima, S. Inayama, T. Miyata, and S. Numa. 1983. Structural 
homology of Torpedo californica acetylcholine receptor subunits. Nature. 
302:528-532. 
9.   Mishina, M., T. Kurosaki, T. Tobimatsu, Y. Morimoto, M. Noda, T. Yamamoto, 
M. Terao, J. Lindstrom, T. Takahashi, M. Kuno, and et al. 1984. Expression of 
functional acetylcholine receptor from cloned cDNAs. Nature. 307:604-608. 
 30 
10. Weill, C.L., M.G. McNamee, and A. Karlin. 1974. Affinity-labeling of purified 
acetylcholine receptor from Torpedo californica. Biochem Biophys Res Commun. 
61:997-1003. 
11. Nachmansohn, D. 1966. Role of acetylcholine in neuromuscular transmission. Ann 
N Y Acad Sci. 135:136-149. 
12. Gage, P.W. 1976. Generation of end-plate potentials. Physiol Rev. 56:177-247. 
13. Ildefonse, M., V. Jacquemond, O. Rougier, J.F. Renaud, M. Fosset, and M. 
Lazdunski. 1985. Excitation contraction coupling in skeletal muscle: evidence for 
a role of slow Ca2+ channels using Ca2+ channel activators and inhibitors in the 
dihydropyridine series. Biochem Biophys Res Commun. 129:904-909. 
14. Corringer, P.J., N. Le Novere, and J.P. Changeux. 2000. Nicotinic receptors at the 
amino acid level. Annu Rev Pharmacol Toxicol. 40:431-458. 
15. Dougherty, D.A. 2008. Cys-loop neuroreceptors: structure to the rescue? Chem 
Rev. 108:1642-1653. 
16. Miyazawa, A., Y. Fujiyoshi, and N. Unwin. 2003. Structure and gating mechanism 
of the acetylcholine receptor pore. Nature. 423:949-955. 
17. Dingledine, R., K. Borges, D. Bowie, and S.F. Traynelis. 1999. The glutamate 
receptor ion channels. Pharmacol Rev. 51:7-61. 
18. Bowie, D. 2008. Ionotropic glutamate receptors & CNS disorders. CNS Neurol 
Disord Drug Targets. 7:129-143. 
19. Seeburg, P.H. 1993. The TiPS/TINS lecture: the molecular biology of mammalian 
glutamate receptor channels. Trends Pharmacol Sci. 14:297-303. 
20. Hollmann, M., and S. Heinemann. 1994. Cloned glutamate receptors. Annu Rev 
Neurosci. 17:31-108. 
21. Nakanishi, S., and M. Masu. 1994. Molecular diversity and functions of glutamate 
receptors. Annu Rev Biophys Biomol Struct. 23:319-348. 
 31 
22. Nicoll, R.A., J.A. Kauer, and R.C. Malenka. 1988. The current excitement in long-
term potentiation. Neuron. 1:97-103. 
23. Ito, M. 1989. Long-term depression. Annu Rev Neurosci. 12:85-102. 
24. Gereau, R.W., and G.T. Swanson. 2008. The glutamate receptors. Humana Press, 
Totowa, N.J. 
25. Buckingham, S.D., S. Kwak, A.K. Jones, S.E. Blackshaw, and D.B. Sattelle. 2008. 
Edited GluR2, a gatekeeper for motor neurone survival? Bioessays. 30:1185-1192. 
26. Bassani, S., P. Valnegri, F. Beretta, and M. Passafaro. 2009. The GLUR2 subunit 
of AMPA receptors: synaptic role. Neuroscience. 158:55-61. 
27. Bowie, D., and M.L. Mayer. 1995. Inward rectification of both AMPA and kainate 
subtype glutamate receptors generated by polyamine-mediated ion channel block. 
Neuron. 15:453-462. 
28. Tomita, S., H. Adesnik, M. Sekiguchi, W. Zhang, K. Wada, J.R. Howe, R.A. 
Nicoll, and D.S. Bredt. 2005. Stargazin modulates AMPA receptor gating and 
trafficking by distinct domains. Nature. 435:1052-1058. 
29. Geiger, J.R., T. Melcher, D.S. Koh, B. Sakmann, P.H. Seeburg, P. Jonas, and H. 
Monyer. 1995. Relative abundance of subunit mRNAs determines gating and 
Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat 
CNS. Neuron. 15:193-204. 
30. Hollmann, M., M. Hartley, and S. Heinemann. 1991. Ca2+ permeability of KA-
AMPA--gated glutamate receptor channels depends on subunit composition. 
Science. 252:851-853. 
31. Sommer, B., M. Kohler, R. Sprengel, and P.H. Seeburg. 1991. RNA editing in 
brain controls a determinant of ion flow in glutamate-gated channels. Cell. 67:11-
19. 
 32 
32. Sommer, B., K. Keinanen, T.A. Verdoorn, W. Wisden, N. Burnashev, A. Herb, M. 
Kohler, T. Takagi, B. Sakmann, and P.H. Seeburg. 1990. Flip and flop: a cell-
specific functional switch in glutamate-operated channels of the CNS. Science. 
249:1580-1585. 
33. Lomeli, H., J. Mosbacher, T. Melcher, T. Hoger, J.R. Geiger, T. Kuner, H. 
Monyer, M. Higuchi, A. Bach, and P.H. Seeburg. 1994. Control of kinetic 
properties of AMPA receptor channels by nuclear RNA editing. Science. 
266:1709-1713. 
34. Li, G., W. Pei, and L. Niu. 2003. Channel-opening kinetics of GluR2Q(flip) 
AMPA receptor: a laser-pulse photolysis study. Biochemistry. 42:12358-12366. 
35. Li, G., and L. Niu. 2004. How fast does the GluR1Qflip channel open? J Biol 
Chem. 279:3990-3997. 
36. Li, G., Z. Sheng, Z. Huang, and L. Niu. 2005. Kinetic mechanism of channel 
opening of the GluRDflip AMPA receptor. Biochemistry. 44:5835-5841. 
37. Pei, W., Z. Huang, and L. Niu. 2007. GluR3 flip and flop: differences in channel 
opening kinetics. Biochemistry. 46:2027-2036. 
38. Swanson, G.T., R.W.t. Gereau, T. Green, and S.F. Heinemann. 1997. 
Identification of amino acid residues that control functional behavior in GluR5 and 
GluR6 kainate receptors. Neuron. 19:913-926. 
39. Smith, T.C., L.Y. Wang, and J.R. Howe. 2000. Heterogeneous conductance levels 
of native AMPA receptors. J Neurosci. 20:2073-2085. 
40. Jin, R., T.G. Banke, M.L. Mayer, S.F. Traynelis, and E. Gouaux. 2003. Structural 
basis for partial agonist action at ionotropic glutamate receptors. Nat Neurosci. 
6:803-810. 
 33 
41. Otis, T.S., Y.C. Wu, and L.O. Trussell. 1996. Delayed clearance of transmitter and 
the role of glutamate transporters at synapses with multiple release sites. J 
Neurosci. 16:1634-1644. 
42. Chen, L., D.M. Chetkovich, R.S. Petralia, N.T. Sweeney, Y. Kawasaki, R.J. 
Wenthold, D.S. Bredt, and R.A. Nicoll. 2000. Stargazin regulates synaptic 
targeting of AMPA receptors by two distinct mechanisms. Nature. 408:936-943. 
43. Bats, C., L. Groc, and D. Choquet. 2007. The interaction between Stargazin and 
PSD-95 regulates AMPA receptor surface trafficking. Neuron. 53:719-734. 
44. Nicoll, R.A., S. Tomita, and D.S. Bredt. 2006. Auxiliary subunits assist AMPA-
type glutamate receptors. Science. 311:1253-1256. 
45. Priel, A., A. Kolleker, G. Ayalon, M. Gillor, P. Osten, and Y. Stern-Bach. 2005. 
Stargazin reduces desensitization and slows deactivation of the AMPA-type 
glutamate receptors. J Neurosci. 25:2682-2686. 
46. Milstein, A.D., W. Zhou, S. Karimzadegan, D.S. Bredt, and R.A. Nicoll. 2007. 
TARP subtypes differentially and dose-dependently control synaptic AMPA 
receptor gating. Neuron. 55:905-918. 
47. Korber, C., M. Werner, S. Kott, Z.L. Ma, and M. Hollmann. 2007. The 
transmembrane AMPA receptor regulatory protein gamma 4 is a more effective 
modulator of AMPA receptor function than stargazin (gamma 2). J Neurosci. 
27:8442-8447. 
48. Herb, A., N. Burnashev, P. Werner, B. Sakmann, W. Wisden, and P.H. Seeburg. 
1992. The KA-2 subunit of excitatory amino acid receptors shows widespread 
expression in brain and forms ion channels with distantly related subunits. Neuron. 
8:775-785. 
 34 
49. Swanson, G.T., D. Feldmeyer, M. Kaneda, and S.G. Cull-Candy. 1996. Effect of 
RNA editing and subunit co-assembly single-channel properties of recombinant 
kainate receptors. J Physiol. 492 (Pt 1):129-142. 
50. Malva, J.O., A.P. Carvalho, and C.M. Carvalho. 1994. Modulation of dopamine 
and noradrenaline release and of intracellular Ca2+ concentration by presynaptic 
glutamate receptors in hippocampus. Br J Pharmacol. 113:1439-1447. 
51. Engelman, H.S., and A.B. MacDermott. 2004. Presynaptic ionotropic receptors 
and control of transmitter release. Nat Rev Neurosci. 5:135-145. 
52. Rozas, J.L., A.V. Paternain, and J. Lerma. 2003. Noncanonical signaling by 
ionotropic kainate receptors. Neuron. 39:543-553. 
53.  Castillo, P.E., R.C. Malenka, and R.A. Nicoll. 1997. Kainate receptors mediate a 
slow postsynaptic current in hippocampal CA3 neurons. Nature. 388:182-186. 
54. Vignes, M., and G.L. Collingridge. 1997. The synaptic activation of kainate 
receptors. Nature. 388:179-182. 
55. Bettler, B., and C. Mulle. 1995. Review: neurotransmitter receptors. II. AMPA and 
kainate receptors. Neuropharmacology. 34:123-139. 
56. Egebjerg, J., and S.F. Heinemann. 1993. Ca2+ permeability of unedited and edited 
versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci U 
S A. 90:755-759. 
57. Seeburg, P.H., N. Burnashev, G. Kohr, T. Kuner, R. Sprengel, and H. Monyer. 
1995. The NMDA receptor channel: molecular design of a coincidence detector. 
Recent Prog Horm Res. 50:19-34. 
58. McIlhinney, R.A., E. Molnar, J.R. Atack, and P.J. Whiting. 1996. Cell surface 
expression of the human N-methyl-D-aspartate receptor subunit 1a requires the co-
expression of the NR2A subunit in transfected cells. Neuroscience. 70:989-997. 
 35 
59. Nowak, L., P. Bregestovski, P. Ascher, A. Herbet, and A. Prochiantz. 1984. 
Magnesium gates glutamate-activated channels in mouse central neurons. Nature. 
307:462-465. 
60. Martin, S.J., P.D. Grimwood, and R.G. Morris. 2000. Synaptic plasticity and 
memory: an evaluation of the hypothesis. Annu Rev Neurosci. 23:649-711. 
61. Laurie, D.J., and P.H. Seeburg. 1994. Regional and developmental heterogeneity 
in splicing of the rat brain NMDAR1 mRNA. J Neurosci. 14:3180-3194. 
62. Perez-Otano, I., and M.D. Ehlers. 2004. Learning from NMDA receptor 
trafficking: clues to the development and maturation of glutamatergic synapses. 
Neurosignals. 13:175-189. 
63. Cull-Candy, S., S. Brickley, and M. Farrant. 2001. NMDA receptor subunits: 
diversity, development and disease. Curr Opin Neurobiol. 11:327-335. 
64. Leonard, A.S., I.A. Lim, D.E. Hemsworth, M.C. Horne, and J.W. Hell. 1999. 
Calcium/calmodulin-dependent protein kinase II is associated with the N-methyl-
D-aspartate receptor. Proc Natl Acad Sci U S A. 96:3239-3244. 
65. Standley, S., and M. Baudry. 2000. The role of glycosylation in ionotropic 
glutamate receptor ligand binding, function, and trafficking. Cell Mol Life Sci. 
57:1508-1516. 
66. Kim, W.K., Y.B. Choi, P.V. Rayudu, P. Das, W. Asaad, D.R. Arnelle, J.S. 
Stamler, and S.A. Lipton. 1999. Attenuation of NMDA receptor activity and 
neurotoxicity by nitroxyl anion, NO. Neuron. 24:461-469. 
67.  Liu, X.B., K.D. Murray, and E.G. Jones. 2004. Switching of NMDA receptor 2A 
and 2B subunits at thalamic and cortical synapses during early postnatal 
development. J Neurosci. 24:8885-8895. 
 36 
68.  Yamazaki, M., K. Araki, A. Shibata, and M. Mishina. 1992. Molecular cloning of 
a cDNA encoding a novel member of the mouse glutamate receptor channel 
family. Biochem Biophys Res Commun. 183:886-892. 
69.  Naur, P., K.B. Hansen, A.S. Kristensen, S.M. Dravid, D.S. Pickering, L. Olsen, B. 
Vestergaard, J. Egebjerg, M. Gajhede, S.F. Traynelis, and J.S. Kastrup. 2007. 
Ionotropic glutamate-like receptor delta2 binds D-serine and glycine. Proc Natl 
Acad Sci U S A. 104:14116-14121. 
70. Lomeli, H., R. Sprengel, D.J. Laurie, G. Kohr, A. Herb, P.H. Seeburg, and W. 
Wisden. 1993. The rat delta-1 and delta-2 subunits extend the excitatory amino 
acid receptor family. FEBS Lett. 315:318-322. 
71. Mayat, E., R.S. Petralia, Y.X. Wang, and R.J. Wenthold. 1995. 
Immunoprecipitation, immunoblotting, and immunocytochemistry studies suggest 
that glutamate receptor delta subunits form novel postsynaptic receptor complexes. 
J Neurosci. 15:2533-2546. 
72. Kohda, K., Y. Kamiya, S. Matsuda, K. Kato, H. Umemori, and M. Yuzaki. 2003. 
Heteromer formation of delta2 glutamate receptors with AMPA or kainate 
receptors. Brain Res Mol Brain Res. 110:27-37. 
73. Zuo, J., P.L. De Jager, K.A. Takahashi, W. Jiang, D.J. Linden, and N. Heintz. 
1997. Neurodegeneration in Lurcher mice caused by mutation in delta2 glutamate 
receptor gene. Nature. 388:769-773. 
74. Taverna, F., Z.G. Xiong, L. Brandes, J.C. Roder, M.W. Salter, and J.F. 
MacDonald. 2000. The Lurcher mutation of an alpha-amino-3-hydroxy-5-methyl- 
4-isoxazolepropionic acid receptor subunit enhances potency of glutamate and 
converts an antagonist to an agonist. J Biol Chem. 275:8475-8479. 
75. Kashiwabuchi, N., K. Ikeda, K. Araki, T. Hirano, K. Shibuki, C. Takayama, Y. 
Inoue, T. Kutsuwada, T. Yagi, Y. Kang, and et al. 1995. Impairment of motor 
 37 
coordination, Purkinje cell synapse formation, and cerebellar long-term depression 
in GluR delta 2 mutant mice. Cell. 81:245-252. 
76. Hirano, T., K. Kasono, K. Araki, and M. Mishina. 1995. Suppression of LTD in 
cultured Purkinje cells deficient in the glutamate receptor delta 2 subunit. 
Neuroreport. 6:524-526. 
77. Gao, J., S.F. Maison, X. Wu, K. Hirose, S.M. Jones, I. Bayazitov, Y. Tian, G. 
Mittleman, D.B. Matthews, S.S. Zakharenko, M.C. Liberman, and J. Zuo. 2007. 
Orphan glutamate receptor delta1 subunit required for high-frequency hearing. 
Mol Cell Biol. 27:4500-4512. 
78. Schmid, S.M., and M. Hollmann. 2008. To gate or not to gate: are the delta 
subunits in the glutamate receptor family functional ion channels? Mol Neurobiol. 
37:126-141. 
79. Wo, Z.G., and R.E. Oswald. 1994. Transmembrane topology of two kainate 
receptor subunits revealed by N-glycosylation. Proc Natl Acad Sci U S A. 
91:7154-7158. 
80. Hollmann, M., C. Maron, and S. Heinemann. 1994. N-glycosylation site tagging 
suggests a three transmembrane domain topology for the glutamate receptor 
GluR1. Neuron. 13:1331-1343. 
81. Armstrong, N., Y. Sun, G.Q. Chen, and E. Gouaux. 1998. Structure of a 
glutamate-receptor ligand-binding core in complex with kainate. Nature. 395:913-
917. 
82. Hogner, A., J.S. Kastrup, R. Jin, T. Liljefors, M.L. Mayer, J. Egebjerg, I.K. 
Larsen, and E. Gouaux. 2002. Structural basis for AMPA receptor activation and 
ligand selectivity: crystal structures of five agonist complexes with the GluR2 
ligand-binding core. J Mol Biol. 322:93-109. 
 38 
83.  Jin, R., M. Horning, M.L. Mayer, and E. Gouaux. 2002. Mechanism of activation 
and selectivity in a ligand-gated ion channel: structural and functional studies of 
GluR2 and quisqualate. Biochemistry. 41:15635-15643. 
84. Armstrong, N., and E. Gouaux. 2000. Mechanisms for activation and antagonism 
of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand 
binding core. Neuron. 28:165-181. 
85. Sobolevsky, A.I., M.P. Rosconi, and E. Gouaux. 2009. X-ray structure, symmetry 
and mechanism of an AMPA-subtype glutamate receptor. Nature. 429:745-756. 
86. Oswald, R.E. 2004. Ionotropic glutamate receptor recognition and activation. Adv 
Protein Chem. 68:313-349. 
87. Leuschner, W.D., and W. Hoch. 1999. Subtype-specific assembly of alpha-amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits is mediated by 
their N-terminal domains. J Biol Chem. 274:16907-16916. 
88. Ayalon, G., and Y. Stern-Bach. 2001. Functional assembly of AMPA and kainate 
receptors is mediated by several discrete protein-protein interactions. Neuron. 
31:103-113. 
89. Herin, G.A., and E. Aizenman. 2004. Amino terminal domain regulation of 
NMDA receptor function. Eur J Pharmacol. 500:101-111. 
90. Ayalon, G., E. Segev, S. Elgavish, and Y. Stern-Bach. 2005. Two regions in the N-
terminal domain of ionotropic glutamate receptor 3 form the subunit 
oligomerization interfaces that control subtype-specific receptor assembly. J Biol 
Chem. 280:15053-15060. 
91. Kuner, T., C. Beck, B. Sakmann, and P.H. Seeburg. 2001. Channel-lining residues 
of the AMPA receptor M2 segment: structural environment of the Q/R site and 
identification of the selectivity filter. J Neurosci. 21:4162-4172. 
 39 
92. Jones, K.S., H.M. VanDongen, and A.M. VanDongen. 2002. The NMDA receptor 
M3 segment is a conserved transduction element coupling ligand binding to 
channel opening. J Neurosci. 22:2044-2053. 
93. Liu, Y., M. Holmgren, M.E. Jurman, and G. Yellen. 1997. Gated access to the pore 
of a voltage-dependent K+ channel. Neuron. 19:175-184. 
94. Soderling, T.R., and V.A. Derkach. 2000. Postsynaptic protein phosphorylation 
and LTP. Trends Neurosci. 23:75-80. 
95. Kuusinen, A., M. Arvola, and K. Keinanen. 1995. Molecular dissection of the 
agonist binding site of an AMPA receptor. Embo J. 14:6327-6332. 
96.  Keinanen, K., M. Arvola, A. Kuusinen, and M. Johnson. 1997. Ligand recognition 
in glutamate receptors: insights from mutagenesis of the soluble alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-binding domain of 
glutamate receptor type D (GluR-D). Biochem Soc Trans. 25:835-838. 
97. Chen, G.Q., and E. Gouaux. 1997. Overexpression of a glutamate receptor 
(GluR2) ligand binding domain in Escherichia coli: application of a novel protein 
folding screen. Proc Natl Acad Sci U S A. 94:13431-13436. 
98. Chen, G.Q., Y. Sun, R. Jin, and E. Gouaux. 1998. Probing the ligand binding 
domain of the GluR2 receptor by proteolysis and deletion mutagenesis defines 
domain boundaries and yields a crystallizable construct. Protein Sci. 7:2623-2630. 
99. Sun, Y., R. Olson, M. Horning, N. Armstrong, M. Mayer, and E. Gouaux. 2002. 
Mechanism of glutamate receptor desensitization. Nature. 417:245-253. 
100. Robert, A., N. Armstrong, J.E. Gouaux, and J.R. Howe. 2005. AMPA receptor 
binding cleft mutations that alter affinity, efficacy, and recovery from 
desensitization. J Neurosci. 25:3752-3762. 
 40 
101. Valentine, E.R., and A.G. Palmer, 3rd. 2005. Microsecond-to-millisecond 
conformational dynamics demarcate the GluR2 glutamate receptor bound to 
agonists glutamate, quisqualate, and AMPA. Biochemistry. 44:3410-3417. 
102. Kawamoto, S., S. Uchino, K.Q. Xin, S. Hattori, K. Hamajima, J. Fukushima, M. 
Mishina, and K. Okuda. 1997. Arginine-481 mutation abolishes ligand-binding of 
the AMPA-selective glutamate receptor channel alpha1-subunit. Brain Res Mol 
Brain Res. 47:339-344. 
103. Lampinen, M., O. Pentikainen, M.S. Johnson, and K. Keinanen. 1998. AMPA 
receptors and bacterial periplasmic amino acid-binding proteins share the ionic 
mechanism of ligand recognition. Embo J. 17:4704-4711. 
104. Maltsev, A.S., A.H. Ahmed, M.K. Fenwick, D.E. Jane, and R.E. Oswald. 
2008. Mechanism of partial agonism at the GluR2 AMPA receptor: Measurements 
of lobe orientation in solution. Biochemistry. 47:10600-10610. 
105. Jin, R., and E. Gouaux. 2003. Probing the function, conformational plasticity, 
and dimer-dimer contacts of the GluR2 ligand-binding core: studies of 5-
substituted willardiines and GluR2 S1S2 in the crystal. Biochemistry. 42:5201-
5213. 
106. Zhang, W., Y. Cho, E. Lolis, and J.R. Howe. 2008. Structural and single-
channel results indicate that the rates of ligand binding domain closing and 
opening directly impact AMPA receptor gating. J Neurosci. 28:932-943. 
107. Gill, A., A. Birdsey-Benson, B.L. Jones, L.P. Henderson, and D.R. Madden. 
2008. Correlating AMPA receptor activation and cleft closure across subunits: 
crystal structures of the GluR4 ligand-binding domain in complex with full and 
partial agonists. Biochemistry. 47:13831-13841. 
 41 
108.  Armstrong, N., M. Mayer, and E. Gouaux. 2003. Tuning activation of the 
AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced 
conformational changes. Proc Natl Acad Sci U S A. 100:5736-5741. 
109.  Stern, P., M. Cik, D. Colquhoun, and F.A. Stephenson. 1994. Single channel 
properties of cloned NMDA receptors in a human cell line: comparison with 
results from Xenopus oocytes. J Physiol. 476:391-397. 
110.  McLarnon, J.G., and K. Curry. 1990. Single channel properties of the N-
methyl-D-aspartate receptor channel using NMDA and NMDA agonists: on-cell 
recordings. Exp Brain Res. 82:82-88. 
111.  Kleckner, N.W., and R. Dingledine. 1988. Requirement for glycine in 
activation of NMDA-receptors expressed in Xenopus oocytes. Science. 241:835-
837. 
112.  Clements, J.D., and G.L. Westbrook. 1991. Activation kinetics reveal the 
number of glutamate and glycine binding sites on the N-methyl-D-aspartate 
receptor. Neuron. 7:605-613. 
113.  Popescu, G., and A. Auerbach. 2003. Modal gating of NMDA receptors and 
the shape of their synaptic response. Nat Neurosci. 6:476-483. 
114.  Auerbach, A., and Y. Zhou. 2005. Gating reaction mechanisms for NMDA 
receptor channels. J Neurosci. 25:7914-7923. 
115.  Kussius, C.L., and G.K. Popescu. 2009. Kinetic basis of partial agonism at 
NMDA receptors. Nat Neurosci. 12:1114-1120. 
116.  Inanobe, A., H. Furukawa, and E. Gouaux. 2005. Mechanism of partial 
agonist action at the NR1 subunit of NMDA receptors. Neuron. 47:71-84. 
117.  Rosenmund, C., Y. Stern-Bach, and C.F. Stevens. 1998. The tetrameric 
structure of a glutamate receptor channel. Science. 280:1596-1599. 
 42 
118.  Patneau, D.K., M.L. Mayer, D.E. Jane, and J.C. Watkins. 1992. Activation 
and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. 
J Neurosci. 12:595-606. 
119.  Robert, A., and J.R. Howe. 2003. How AMPA receptor desensitization 
depends on receptor occupancy. J Neurosci. 23:847-858. 
120.  Ptak, C.P., A.H. Ahmed, and R.E. Oswald. 2009. Probing the allosteric 
modulator binding site of GluR2 with thiazide derivatives. Biochemistry. 48:8594-
8602. 
121.  Ahmed, A.H., C.P. Ptak, and R.E. Oswald. 2010. Molecular mechanism of 
flop selectivity and subsite recognition for an AMPA receptor allosteric 
modulator: structures of GluA2 and GluA3 in complexes with PEPA. 
Biochemistry. 49:2843-2850. 
122.  Partin, K.M., M.W. Fleck, and M.L. Mayer. 1996. AMPA receptor flip/flop 
mutants affecting deactivation, desensitization, and modulation by cyclothiazide, 
aniracetam, and thiocyanate. J Neurosci. 16:6634-6647. 
123.  Yamada, K.A., and S.M. Rothman. 1992. Diazoxide blocks glutamate 
desensitization and prolongs excitatory postsynaptic currents in rat hippocampal 
neurons. J Physiol. 458:409-423. 
124.  Gonzalez, J., M. Du, K. Parameshwaran, V. Suppiramaniam, and V. 
Jayaraman. 2010. Role of dimer interface in activation and desensitization in 
AMPA receptors. Proc Natl Acad Sci U S A. 107:9891-9896. 
125.  Furukawa, H., S.K. Singh, R. Mancusso, and E. Gouaux. 2005. Subunit 
arrangement and function in NMDA receptors. Nature. 438:185-192. 
126.  Zheng, F., K. Erreger, C.M. Low, T. Banke, C.J. Lee, P.J. Conn, and S.F. 
Traynelis. 2001. Allosteric interaction between the amino terminal domain and the 
ligand binding domain of NR2A. Nat Neurosci. 4:894-901. 
 43 
127.  Erreger, K., and S.F. Traynelis. 2008. Zinc inhibition of rat NR1/NR2A N-
methyl-D-aspartate receptors. J Physiol. 586:763-778. 
128.  Mayer, M.L., L. Vyklicky, Jr., and J. Clements. 1989. Regulation of NMDA 
receptor desensitization in mouse hippocampal neurons by glycine. Nature. 
338:425-427. 
129.  Krupp, J.J., B. Vissel, C.G. Thomas, S.F. Heinemann, and G.L. Westbrook. 
1999. Interactions of calmodulin and alpha-actinin with the NR1 subunit modulate 
Ca2+-dependent inactivation of NMDA receptors. J Neurosci. 19:1165-1178. 
130.  Young, S.L., D.L. Bohenek, and M.S. Fanselow. 1994. NMDA processes 
mediate anterograde amnesia of contextual fear conditioning induced by 
hippocampal damage: immunization against amnesia by context preexposure. 
Behav Neurosci. 108:19-29. 
131.  Collingridge, G.L., J.T. Isaac, and Y.T. Wang. 2004. Receptor trafficking and 
synaptic plasticity. Nat Rev Neurosci. 5:952-962. 
132.  Collingridge, G.L., P.W. Gage, and B. Robertson. 1984. Inhibitory post-
synaptic currents in rat hippocampal CA1 neurones. J Physiol. 356:551-564. 
133.  Wigstrom, H., and B. Gustafsson. 1986. Postsynaptic control of hippocampal 
long-term potentiation. J Physiol (Paris). 81:228-236. 
134.  Lynch, G., J. Larson, S. Kelso, G. Barrionuevo, and F. Schottler. 1983. 
Intracellular injections of EGTA block induction of hippocampal long-term 
potentiation. Nature. 305:719-721. 
135.  Malenka, R.C., and M.F. Bear. 2004. LTP and LTD: an embarrassment of 
riches. Neuron. 44:5-21. 
136.  Hayashi, Y., S.H. Shi, J.A. Esteban, A. Piccini, J.C. Poncer, and R. Malinow. 
2000. Driving AMPA receptors into synapses by LTP and CaMKII: requirement 
for GluR1 and PDZ domain interaction. Science. 287:2262-2267. 
 44 
137.  Fortin, D.A., M.A. Davare, T. Srivastava, J.D. Brady, S. Nygaard, V.A. 
Derkach, and T.R. Soderling. 2010. Long-Term Potentiation-Dependent Spine 
Enlargement Requires Synaptic Ca2+-Permeable AMPA Receptors Recruited by 
CaM-Kinase I. J Neurosci. 30:11565-11575. 
138.  Isaac, J.T., R.A. Nicoll, and R.C. Malenka. 1995. Evidence for silent 
synapses: implications for the expression of LTP. Neuron. 15:427-434. 
139.  Takumi, Y., V. Ramirez-Leon, P. Laake, E. Rinvik, and O.P. Ottersen. 1999. 
Different modes of expression of AMPA and NMDA receptors in hippocampal 
synapses. Nat Neurosci. 2:618-624. 
140.  Petralia, R.S., J.A. Esteban, Y.X. Wang, J.G. Partridge, H.M. Zhao, R.J. 
Wenthold, and R. Malinow. 1999. Selective acquisition of AMPA receptors over 
postnatal development suggests a molecular basis for silent synapses. Nat 
Neurosci. 2:31-36. 
141.  Johnston, M.V., B. Mullaney, and M.E. Blue. 2003. Neurobiology of Rett 
syndrome. J Child Neurol. 18:688-692. 
142.  Magnusson, K.R., and C.W. Cotman. 1993. Age-related changes in excitatory 
amino acid receptors in two mouse strains. Neurobiol Aging. 14:197-206. 
143.  Palmer, G.C. 2001. Neuroprotection by NMDA receptor antagonists in a 
variety of neuropathologies. Curr Drug Targets. 2:241-271. 
144.  Kwak, S., and J.H. Weiss. 2006. Calcium-permeable AMPA channels in 
neurodegenerative disease and ischemia. Curr Opin Neurobiol. 16:281-287. 
145.  Sattler, R., and M. Tymianski. 2000. Molecular mechanisms of calcium-
dependent excitotoxicity. J Mol Med. 78:3-13. 
146.  Nicholls, D.G. 2008. Oxidative stress and energy crises in neuronal 
dysfunction. Ann N Y Acad Sci. 1147:53-60. 
 45 
147.  Sensi, S.L., H.Z. Yin, S.G. Carriedo, S.S. Rao, and J.H. Weiss. 1999. 
Preferential Zn2+ influx through Ca2+-permeable AMPA/kainate channels 
triggers prolonged mitochondrial superoxide production. Proc Natl Acad Sci U S 
A. 96:2414-2419. 
148.  Frederickson, C.J., J.Y. Koh, and A.I. Bush. 2005. The neurobiology of zinc 
in health and disease. Nat Rev Neurosci. 6:449-462. 
149.  Bresink, I., B. Ebert, C.G. Parsons, and E. Mutschler. 1996. Zinc changes 
AMPA receptor properties: results of binding studies and patch clamp recordings. 
Neuropharmacology. 35:503-509. 
150.  Lin, D.D., A.S. Cohen, and D.A. Coulter. 2001. Zinc-induced augmentation of 
excitatory synaptic currents and glutamate receptor responses in hippocampal CA3 
neurons. J Neurophysiol. 85:1185-1196. 
151.  Rowland, L.P., and N.A. Shneider. 2001. Amyotrophic lateral sclerosis. N 
Engl J Med. 344:1688-1700. 
152.  Rosen, D.R., T. Siddique, D. Patterson, D.A. Figlewicz, P. Sapp, A. Hentati, 
D. Donaldson, J. Goto, J.P. O'Regan, H.X. Deng, and et al. 1993. Mutations in 
Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral 
sclerosis. Nature. 362:59-62. 
153.  Hadano, S., Y. Yanagisawa, J. Skaug, K. Fichter, J. Nasir, D. Martindale, B.F. 
Koop, S.W. Scherer, D.W. Nicholson, G.A. Rouleau, J. Ikeda, and M.R. Hayden. 
2001. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, 
and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region 
at chromosome 2q33-q34: candidate genes for ALS2. Genomics. 71:200-213. 
154.  Couratier, P., J. Hugon, P. Sindou, J.M. Vallat, and M. Dumas. 1993. Cell 
culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being 
linked to glutamate AMPA/kainate receptors. Lancet. 341:265-268. 
 46 
155.  Kawahara, Y., K. Ito, H. Sun, H. Aizawa, I. Kanazawa, and S. Kwak. 2004. 
Glutamate receptors: RNA editing and death of motor neurons. Nature. 427:801. 
156.  Selkoe, D.J. 2002. Alzheimer's disease is a synaptic failure. Science. 298:789-
791. 
157.  Blennow, K., M.J. de Leon, and H. Zetterberg. 2006. Alzheimer's disease. 
Lancet. 368:387-403. 
158.  Smith, M.A., K. Hirai, K. Hsiao, M.A. Pappolla, P.L. Harris, S.L. Siedlak, M. 
Tabaton, and G. Perry. 1998. Amyloid-beta deposition in Alzheimer transgenic 
mice is associated with oxidative stress. J Neurochem. 70:2212-2215. 
159.  Smith, M.A., G. Perry, P.L. Richey, L.M. Sayre, V.E. Anderson, M.F. Beal, 
and N. Kowall. 1996. Oxidative damage in Alzheimer's. Nature. 382:120-121. 
160.  Guan, Z.Z., X. Zhang, R. Ravid, and A. Nordberg. 2000. Decreased protein 
levels of nicotinic receptor subunits in the hippocampus and temporal cortex of 
patients with Alzheimer's disease. J Neurochem. 74:237-243. 
161.  Smith, M.A., C.A. Rottkamp, A. Nunomura, A.K. Raina, and G. Perry. 2000. 
Oxidative stress in Alzheimer's disease. Biochim Biophys Acta. 1502:139-144. 
162.  Guo, Q., L. Sebastian, B.L. Sopher, M.W. Miller, C.B. Ware, G.M. Martin, 
and M.P. Mattson. 1999. Increased vulnerability of hippocampal neurons from 
presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles 
of superoxide production and caspase activation. J Neurochem. 72:1019-1029. 
163.  Reisberg, B., R. Doody, A. Stoffler, F. Schmitt, S. Ferris, and H.J. Mobius. 
2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 
348:1333-1341. 
164.  Moult, P.R. 2009. Neuronal glutamate and GABAA receptor function in 
health and disease. Biochem Soc Trans. 37:1317-1322. 
 47 
165.  Rogawski, M.A., and S.D. Donevan. 1999. AMPA receptors in epilepsy and 
as targets for antiepileptic drugs. Adv Neurol. 79:947-963. 
166.  De Sarro, G., E.D. Di Paola, P. Gareri, L. Gallelli, G. Scotto, and A. De Sarro. 
1999. Effects of some AMPA receptor antagonists on the development of 
tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur J 
Pharmacol. 368:149-159. 
167.  Franciosi, S. 2001. AMPA receptors: potential implications in development 
and disease. Cell Mol Life Sci. 58:921-930. 
168.  MacDonald, J.F., and L.M. Nowak. 1990. Mechanisms of blockade of 
excitatory amino acid receptor channels. Trends Pharmacol Sci. 11:167-172. 
48 
 
 
 
 
 
CHAPTER 2 
 
Characterizing Single Channel Behavior of GluA3 Receptors* 
 
 
 
 
 
 
 
 
 
 
* Reprinted from Biophysical Journal, Volume 99, Kinning Poon, Linda M. 
Nowak, and Robert E. Oswald, Characterizing Single Channel Behavior of 
GluA3 Receptors, 1437 - 1446, Copyright 2010, with permission from Elsevier. 
 49 
2.1 Abstract 
AMPA receptors play a major role in excitatory neurotransmission in the CNS and 
are involved in numerous neurological disorders. Agonists bind to each of four bilobed 
ligand binding domains (LBDs) of this tetrameric receptor, and upon binding, the 
lobes close to envelope the agonist, leading to channel activation. However, AMPA 
receptors exhibit complex activation kinetics, the mechanism of which has not yet 
been determined. We report here single channel studies of a homomeric AMPA 
receptor (GluA3) activated by the full agonist, glutamate, and a partial agonist, 
fluorowillardiine. Both agonists activate the channel to the same three open 
conductance levels but with different open probabilities in each level. The closed 
probability (Pc) varied within records, particularly at low agonist concentrations. By 
sorting discrete segments of the record according to Pc using the X-means algorithm, 
we defined five modes of activity. The kinetic behavior could then be analyzed for 
both agonists over a range of agonist concentrations with a relatively simple model 
(three closed states and two open states for each open conductance level). The 
structural mechanism underlying modal behavior is not clear, however, it occurs on a 
timescale consistent with hydrogen bonding across the lobe interface in the LBD. 
 
2.2 Introduction 
AMPA receptors, a subtype of ligand gated ionotropic glutamate receptors 
(iGluAs), not only mediate the majority of excitatory neurotransmission in the central 
nervous system (1-4) but also play a role in peripheral function (5, 6). Dysfunction of 
these receptors is associated with neurological diseases such as amyotropic lateral 
sclerosis, Huntington‟s disease and disorders such as epilepsy and ischaemic brain 
damage (7-9). The development of effective therapeutics is hampered by the 
widespread CNS distribution of AMPA receptors and a lack of clear understanding of 
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the role of specific subtypes in neuropathologies. Understanding functional 
characteristics of AMPA receptors can uncover differences between subunits and may 
allow for the design of selective pharmacological agents that target aberrant behavior 
without abolishing normal function. 
The four AMPA subunits, GluA1-4, can form functional homo- or hetero-
tetrameric channels (1, 10). Each subunit has a ligand binding domain (LBD) capable 
of binding one agonist molecule, a transmembrane domain responsible for channel 
gating, an extracellular N-terminal domain and an intracellular C-terminal domain (1, 
2, 11). Glutamate binding to the LBD leads to the opening of the ion channel and a 
positive inward current, consisting of Na
+
, K
+
, and, depending on subunit composition 
and RNA editing (12), Ca
2+
 (13-15). The rate of desensitization is determined in part 
by a short sequence in the LBD called the flip/flop region (16); the flop form 
desensitizes faster than the flip form (17, 18). In the case of the flip form, 
desensitization can be slowed with the addition of cyclothiazide (CTZ), an allosteric 
modulator that stabilizes dimerization between two LBDs. 
The structure of both the LBD (19) and the full length tetrameric GluA2 receptor 
(20) has been determined, and closure of the LBD upon agonist binding is thought to 
trigger the activation of the ion channel (19, 21-24). Functional studies of AMPA 
receptors on the macroscopic level have suggested a complex gating scheme (25, 26). 
However, macroscopic currents reveal average ion channel activation and deactivation 
from a large number of channels, sometimes masking details that can only be 
delineated with single channel recording. Previous single channel studies of various 
AMPA channels (23, 26-29) have been limited by heavy filtering of the data, channel 
rundown in the outside-out configuration, or recording of receptors from neuronal 
cells for which the subunit composition was not known. Earlier single channel studies 
on other ion channel subtypes, such as NMDA (30) and GABA (31) channels, have 
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revealed considerable insight into channel kinetics and modal behaviors that have yet 
to be characterized in detail for AMPA receptors. 
The single channel studies described here used homomeric GluA3 receptors in the 
cell-attached mode, simplifying our system while maintaining a physiological 
cytoplasmic milieu. The physiological agonist, glutamate, was used, as well as a 
partial agonist, fluorowillardiine (FW). The use of partial agonists has been extremely 
important in the comparison of functional data with the extensive structural and 
dynamic information on AMPA receptors (20, 23, 32, 33). We report the number of 
conductance levels, the minimum number of states in each conductance class, the open 
probability, the mean lifetimes of channel opening, modal behaviors based on open 
probability, and a model describing the activation mechanism. Glutamate and FW 
share a common mechanism of channel activation with the same open conductance 
levels but with different open probabilities in each level. In the presence of either 
agonist, concentration-dependent modal behaviors that range from a mostly inactive to 
a highly active channel were observed. 
 
2.3 Methods 
Cell culture 
Human embryonic kidney (HEK) 293 cells were stably transfected with GluA3i 
(G) (S.M. Holley & L.M. Nowak, unpublished). The receptor is the flip variant, and 
has a G in the R/G editing site. The cells were cultured in Dulbecco‟s Modified 
Eagle‟s Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin and 1 µg/mL blasticidin, pH 7.4. The addition of the antibiotic, 
blasticidin, in the culture media selects for the growth of cells that express GluA3 
channels. Cells are passaged every 3-4 days and used within 48 hours after passage. 
All cultures were maintained in a 37°C incubator with 5% CO2. 
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Acquisition of Single Channel Currents 
All experiments were performed at room temperature (~23°C). Pipettes were 
pulled from thick walled borosilicate glass with filament (Sutter Instrument Company, 
Novato, CA, USA) to a resistance of 15-20 M and firepolished. Solutions were 
buffered at pH 7.4 and filtered using a 2 µM sterile filtering system (Corning, Lowell, 
MA). The bath buffer was a 1X Dulbecco‟s phosphate saline buffer with either Ca2+ 
and Mg
2+
, or Mg
2+
 only (Invitrogen, Carlsbad, CA). The pipette solution contained (in 
mM): 150 NaCl, 10 Hepes/NaOH, 2 KCl.  Stock solutions of glutamate or 
fluorowillardiine (FW; Tocris Bioscience, Ellisville, MO) were made from the pipette 
solution and kept frozen in aliquots at -20°C until the day of the experiment. 
Cyclothiazide (CTZ; Tocris Bioscience, Ellisville, MO, or Ascent Scientific, 
Princeton, NJ) was dissolved in methanol, frozen as 50 mM stock solutions, and was 
added (100-150 µM) to all agonist containing pipette solutions. 
Single channel currents were amplified at a gain of 100 mV/pA with an EPC-7 
amplifier, low pass filtered to 10 kHz using an external 8-pole Bessel filter, and 
digitized at 20 kHz using pClamp 7 software (Molecular Devices, Sunnyvale, CA). 
Data were converted from abf to qdf format on QuB software (www.qub.buffalo.edu) 
for analysis. 
Single channel currents were recorded for 2 to 10 minutes in the cell-attached 
mode with pipette holding potentials of +80 to +120 mV. To determine single channel 
conductance, the current amplitude was measured in 20 mV increments, between -100 
mV and +120 mV. The single channel conductance was estimated as the slope of the 
current-voltage relationship. Open channel noise with an rmsd of approximately 0.2 
pA and a frequency of 1.3-2 kHz was occasionally observed using both FW and 
glutamate as agonists. This was likely due to a variable amount of rapid channel 
blocking, but was sufficiently small to have little effect on the analysis. 
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Analysis of Single Channel Data 
Number of conductance levels: The baseline was defined by choosing a segment of 
the record without channel activity using QuB. We initially tested the criteria to use 
for analysis, which included the number of open conductance levels by idealizing the 
data assuming up to four different conductance levels, filtering at frequencies ranging 
from 1 to 10 kHz, and altering the deadtime at a range from 50-200 s. The results 
from different combinations of criteria were then analyzed, and the criteria that 
provided the best fits to the amplitude histogram, dwell time histograms, and the 
largest log likelihood (LL) units were used for all subsequent analyses. In all cases, 
three open conductance levels provided the best fits to the data (Figure 2.1). The 
addition of a fourth open conductance level consistently exhibited a lower LL, despite 
the increase in free parameters (see Figure 2.1). Only records with one channel were 
chosen for further analysis. 
Idealization and modeling of data: The amplitudes for each of the open 
conductance levels were estimated using the Amps function from QuB (Baum-Welch 
algorithm (34)). Next, the file was idealized at a dead time of 150 s using the 
segmental-k-means (SKM) algorithm (35) to an initial simple linear model, 
C↔O1↔O2↔O3 (Figure 2.2A), consisting of one closed and three open classes 
starting with all rates set to 100 s
-1
. The data were analyzed with or without an 
additional 5 kHz filtering (effective filter of 4.5 kHz). With filtering greater than this 
(e.g., 2 kHz), baseline noise was often mistaken for small openings by QuB 
(Figure2.1). A dead time of 200 s was imposed with the patches that had additional 
filtering. Maximum interval likelihood (MIL) analysis (36) was applied on this initial 
model to determine the fit to the dwell time histograms. States were then added one at 
a time to each closed and open class, re-idealized, refitted using MIL, and retained if 
the fits to the histograms improved and/or if the LL units increased by >10 LL units. 
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Figure 2.1. 
Demonstration of three open conductance states: (A-C) Idealization using the SKM 
algorithm is shown for one segment of data (4.5 kHz filtration) assuming one (A), two 
(B), and three (C) open conductances. The LL for the analysis of the entire record was 
109868 for one conductance, 231758 for two conductance states, and 276996 for three 
conductance states. When the record was filtered to 2 kHz, four conductance states 
were detected (D); however, the additional state was a misidentification of the noise. 
This is illustrated using a portion of a record filtered at 4.5 kHz with no channel (F) 
where false events (arrows indicate several representative false events) appear with 2 
kHz filtering (E). The idealization is superimposed in red on the current record, with 
the baseline shown in green. 
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If the addition of a state increased the LL by 10, but the rates to the new state were 
either close to zero or unrealistically large, then the additional state was omitted. 
Because of the complex behavior of GluA3 channels, this method was applied in order 
to determine the least complex kinetic model. This process was repeated again with 
rates starting at 10 s
-1
 to confirm that the final model and final rates were not affected 
by the starting values. From earlier studies of glutamate receptors, it is thought that at 
least two bound agonists are required to open the channel (11). In this case, three 
closed states might reflect a channel that has 0, 1, and 2 subunits with open channel 
gates. The fourth and sometimes a fifth closed state would reflect a deactivated or 
desensitized state. Our final model (Figure 2.2B) consists of three closed states and 
two open states in each of the open conductance levels. Loops that additionally 
connected closed states to the intermediate or large conductance levels in the model 
were tested, but in most cases worsened the fit to the dwell time histograms and/or 
gave unrealistic rates, so loops were not considered in our final model. Based on the 
transition matrices, transitions between the closed and the intermediate or large 
conductance levels were infrequently observed. Therefore, the final model does not 
include these transitions. 
Segmentation of data: Inspection of the idealized traces indicated that most 
patches exhibited changes in activity over time, suggesting that the modal behavior 
observed for NMDA receptors (30) may also be a characteristic of AMPA receptors. 
Several different approaches were tested for sorting segments with different gating 
modes, including segmenting the data to 1 s segments or sorting based on mean open 
time (30). However, these approaches did not result in an improvement of LL within 
the segments. The patches that did contain activity changes had long closures between 
bursts. These long closures account for the fourth and sometimes fifth closed states, 
similar to what was found in previous studies (28). A critical time (tcrit), which  
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Figure 2.2 
(A) Initial kinetic model used as a starting point but found not to describe the data 
adequately. (B) Final kinetic model.  The notation for the equilibrium is as follows: 

KC21  kC2C1 kC1C2 , 

KO12a  kO1aO2a kO2aO1a , 

KO1ab  kO1aO1b kO1bO1a , etc. 
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describes the minimum closed duration between two bursts, was defined as described 
by Magleby and Pallotta (37).That is, tcrit was defined by solving: 

a1e
tcrit 1  a2 1 e
 tcrit 2  
Where a2 and 2 describe the shortest closed component between bursts and a1 and 1 
describe the longest closed component within a burst. This choice of tcrit equalizes the 
number of closed intervals in the two components that are misclassified. It was applied 
only to records with more than three closed components, and a2 and t2 refer to the 
longest of the three shortest closed time components in the distribution. The closed 
times equal to or longer than tcrit were discarded in long records to yield isolated 
segments of bursts. These newly separated clusters were re-idealized to one closed and 
three open conductance classes (Figure 2.2A) to determine the closed and open 
probabilities of each segment. The segments were then sorted into modes using the 
select function in QuB. The select function uses an X-means algorithm (38) to place 
each segment into the appropriate mode based on Pc (Pc was used instead of Po 
because of multiple conductance levels of the channel). The value of X is used to 
determine the number of modes by sorting the segments into similar clusters until the 
assignments stabilize. The modes were analyzed individually using the model 
described above (Figure 2.2B). Thus, the model in Figure 2.2B was applied to 
individual segments of data after removal of tcrit and sorted into modes using the X-
means algorithm. In a few records having only three closed states and one mode, the 
model in Figure 2.2B was applied to the entire record. The files that did exhibit modal 
behavior did not always contain all five modes, but often a combination of less than 
five modes. The dwell times of similar modes were averaged, but each mode was 
modeled separately. Table 2.1 summarizes each record analyzed, indicating which 
were segmented into modes and which were analyzed as a whole. Because the number  
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Table 2.1 
Summary of Single Channel Records.  Each record is shown as one row in the table. 
The concentration of agonist is given in the left column and the total length of the 
record in the second column. The total time in each of the modes is given in the next 
five columns, with the total time between bursts in the column on the far right. All 
times are in seconds and rounded to 10 ms. Records for which no entry is given in the 
interburst column had only three closed times and were analyzed without 
segmentation.   
[FW] 
µM 
Total 
length (s) 
VH (s) H (s) M (s) L (s) VL (s) 
Interburst 
(s) 
5 207.20  105.92 42.60 5.43  53.25 
 505.05  22.0  287.64  56.19 
10 68.81  63.96    4.85 
 209.21 140.51 22.74 9.64  3.67 32.65 
 190.60  80.05 67.92 10.49  32.14 
 566.26  176.88 89.15 11.67  288.56 
 301.61  53.57  104.78 42.64 100.62 
50 269.84  214.08    55.76 
 22.14 20.86     1.28 
 39.99 39.99      
 71.84 71.48     0.36 
 126.51 126.51      
 397.03 228.60   12.59 24.51 71.33 
 619.82 353.94 134.33 29.39 17.08 12.04 73.04 
200 127.17 127.17      
 404.47 404.47      
 654.23  27.96 42.49 38.28 21.83 523.67 
500 136.05 77.96    2.33 55.76 
 140.18 140.18      
 144.64 144.64      
 182.52 182.52      
 176.33 176.33      
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(Continued) 
 
 
[glu] 
µM 
Total 
length (s) 
VH (s) H (s) M (s) L (s) VL (s) 
Interburst 
(s) 
50 117.83   93.32   24.51 
75 268.66 29.39   9.18 14.23 215.86 
100 83.20 20.10 22.66 11.26 4.10  25.08 
 168.94     168.94  
 301.82   88.30  42.61 170.91 
 121.26    121.26   
 73.55    73.55   
 182.66   182.66    
200 448.29    297.06  151.23 
 64.08    64.08   
 211.23 35.25  58.06 30.55  87.37 
 433.61     168.47 265.14 
1000 180.52  36.58  10.28 24.11 109.55 
 165.07   165.07    
 46.14  46.14     
 69.12 69.12      
 392.96 164.08  9.54 14.16 13.11 192.07 
 31.97 31.97      
 19.94   19.94    
5000 49.78 49.78      
 63.20 63.20      
 134.08   105.06 22.69  6.33 
 203.54 203.54      
 80.02 80.02      
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of events in each group was necessarily less than the total number of events in the 
record, the LL was normalized to the number of events (LL/event) and each group was 
compared to the whole record. The final LL/event for each group ranged from 4.7-
5.20, which is higher than that for the record as a whole by 0.05-0.30 LL/event. Five 
distinct modes were observed. 
 
2.4 Results 
GluA3 channels open to three distinct conductance levels 
A continuous six-second segment of GluA3 single channel data recorded with 50 
µM FW is shown in Figure 2.3A. As described in Methods, the largest LL value was 
obtained with a model that contained three open conductance levels (Figures 2.2 and 
2.3), which is in agreement with most previous studies on GluA2 (23, 39), GluA4 
(39), GluA3 chimeras (11), and AMPA channels in granule cells (26, 27), although 
four levels have been reported (40). The different conductance levels are distinguished  
from multi-channel patches because patches containing two or more active channels 
had at least double the number of open levels, were rarely closed and exhibited an  
amplitude that was twice the largest conductance of the single channel patch. Also, in 
the presence of CTZ, the channel has a high Po (17), so that double openings are 
readily identified. 
Amplitude probability density functions for 50 µM FW and 5 mM glutamate 
(both concentrations are above the corresponding EC50 (17, 23, 41)) bound to a single 
GluA3 channel are shown in Figure 2.3B. In addition to a closed level, three open 
conductance levels with conductance estimates of 14 ± 0.6 (6), 26 ± 1.4 (3), and 35 ± 
1.8 (2) pS for FW and 14 ± 2.2 (3), 26 ± 1.3 (3), and 39 ± 0.8 (3) pS for glutamate (O1, 
small; O2, intermediate; O3, large, respectively; number in parenthesis is the number of 
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Figure 2.3. (A) A representative 6 s segment of a single channel record of GluA3 
activated by 50 µM FW. In this and all subsequent figures, the channel opens in a 
downward direction. (B) Amplitude histograms for an entire record obtained with 50 
µM FW at 100 mV (top) and another obtained with 5 mM glutamate at 80 mV 
(bottom). Above each histogram is a representative 500 ms segment of the single 
channel record with each of the three conductance levels indicated. The inset gives the 
percentage of each conductance level determined from a fit of four Gaussians to the 
amplitude histograms. For both the FW and glutamate records shown, the channel 
only exhibited M mode.  
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records used for the measurement; Figure 2.4), were observed for both FW and 
glutamate. However, the channel preferentially opens to the intermediate and large 
conductance levels when bound to glutamate, and to the small and intermediate 
conductance levels when bound to FW (Figure 2.3, inset). The presence of the same 
three conductance levels in both full and partial agonists is consistent with similar 
activation schemes. 
GluA3 single channel currents fit to a simple model 
The simplest model with the highest LL value determined from MIL analysis 
consists of two open states in each conductance class and three closed states (Figure 
2.2B). Dwell time histograms recorded with saturating concentrations of FW (50 µM) 
and glutamate (5 mM) are shown in Figure 2.5. The open histograms demonstrate the 
presence of two exponentials (consistent with the two open states used in the MIL 
modeling), similar to previous studies (28). Adding loops between states resulted in 
either distortion of the fit to the dwell time histogram or rate constants that were either 
unrealistically high or close to zero.  A state transition matrix from the two patches 
that describes the percent of transitions between states is given in Table 2.2. Based on 
transition matrices from all analyzed patches, the channel favors transitions between 
adjacent levels (stepwise opening and closing). These results are also in agreement 
with Zhang et al. (29) who reported transitions between adjacent levels for GluA2 WT 
and T686 mutant. At least three closed states are necessary to fit the data (Table 2.3). 
In some cases, depending upon the concentration of agonist, a fourth and fifth closed 
state can be detected. Previous studies on homomeric GluA2 and GluA4 channels 
detected four closed dwell times (29, 42). Patches acquired at high concentrations of 
agonist were uniform in activity. These patches usually had three, sometimes a fourth, 
closed state. At high concentrations when four closed states were observed, the long  
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Figure 2.4 
Demonstration of three open conductance states: Representative current-voltage 
relationship acquired from the application of 5 mM glutamate. GluA3 activity was 
acquired over a range of holding potentials. Current amplitudes for each open level 
were initially estimated with 500-1000 ms of data using Amps in QuB (Baum-Welch 
algorithm). The amplitudes for each conductance level were then reestimated during 
idealization (SKM algorithm; see Methods: Idealization and modeling of the data). 
The current amplitudes were plotted against the holding potential to determine the 
conductance from the slope of the plot. 
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Figure 2.5 
Dwell time histograms for the same records used to generate Figure 2.3B. The number 
in the upper left corner indicates the number of events. 
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Table 2.2 
State transition matrices showing the percentage of transitions between each 
conductance level. Transitions between adjacent states are far more frequent than 
transitions between nonadjacent states. This constrains the model shown in Figure 1 
such that transitions between closed states and O2, between closed states and O3, and 
between O1 and O3 are not included. 
 
 50 µM FW 5 mM glutamate 
 C O1 O2 O3   C O1 O2 O3 
C - 13.2 6.8 0.4  C - 13.6 4.7 0.7 
O1 13.4 - 18.5 1.6  O1 13.9 - 13.8 1.7 
O2 6.6 18.8 - 9.4  O2 4.4 13.7 - 15.5 
O3 0.5 1.4 9.5 -  O3 0.8 2.1 15.0 - 
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closures likely reflect a desensitized state for the following reasons:  (i) At high 
concentration of agonist, the receptor is saturated with agonist so long closures do not 
represent unbound receptor; (ii) Due to the cell-attached patch configuration, the 
agonist is at equilibrium with the binding sites; (iii) The recordings are relatively long, 
so it is expected that the channel would eventually desensitize, as cyclothiazide slows 
but does not abolish desensitization. At lower concentrations of agonist, four or five 
closed states were observed. Since lower concentrations may reflect a nonsaturated 
receptor, one of the closed times could represent deactivation.To investigate whether 
removal of these long closures caused an alteration in the measured parameters, we 
compared the dwell time constants of patches with and without the long closures. The 
shortest three dwell time constants for the closed state and the dwell time constants for 
the open states are similar before and after discarding the long closures. For records 
with four or five closed states, the critical time (tcrit; see Methods) was determined and 
closures longer than tcrit were discarded. 
 68 
Table 2.3 Fluorowillardiine 
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Table 2.3 (continued) Glutamate 
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Analysis of modal behavior 
Evidence for modal behavior as a function of concentration. The number of open 
states, as well as the final model, was consistent across all patches. Most patches 
acquired at lower concentrations of agonist exhibited fluctuation in activity over time. 
Analysis of patches at lower agonist concentrations as a whole did not yield fits that 
overlaid well to the dwell time histograms. Inspection of the records suggested that, 
over time, the channel operated in modes that changed abruptly from one to another, 
with the possibility that the rate constants differed in the various modes (Figures 2.6 
and 2.7). Although a number of methods were tested for sorting records into different 
modes, the most successful approach was based on Pc. Bursts were separated into 
segments based on the tcrit value (see Methods), with lower concentrations of agonist 
having the largest range of tcrit values between different files (1 mM Glu 79-182 ms, 
200 µM Glu 78-309 ms, 100 µM Glu 50-365 ms, 200 µM FW 73 ms, 50 µM FW 36-
87 ms, 10 µM FW 53-145 ms, 5 µM FW 53-348 ms). Bursts with similar activity 
(based on Pc) were clustered together and analyzed separately (Figure 2.6B). The 
closed channel probability (Pc), the open channel probability (Po) in each separate 
conductance class, as well as the length of time spent in each conductance class, 
varied among modes. 
Five modes were observed for the full and partial agonist (Very High (VH), High 
(H), Medium (M), Low (L) and Very Low (VL) modes), corresponding to Po (i.e., 1 - 
Pc) of approximately >90%, 70%, 50%, 30%, and <20%. Although up to five different 
modes were detected using the X-means algorithm, the frequency of observing these 
modes varied with the agonist and the agonist concentration and not all records 
contained all five modes (Table 2.1). Figure 2.6 shows three different patches acquired 
at 500, 50 and 10 µM FW and the modes exhibited in each patch. 
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Figure 2.6 
Representative segments of single channel records obtained with (A) 500 µM, (B) 50 
µM, and (C) 10 µM FW showing different modes of activity (VH, very high mode; H, 
high mode; M, medium mode; L, low mode). 
 72 
Figure 2.7 
(A) Po for segments of a single channel record with 50 µM FW. Closed times greater 
than tcrit were removed, and the horizontal lines indicate the length of the segment at a 
given Po (y-axis). The plotting symbol at the beginning and the end of a segment 
indicates the mode as defined in the legend. (B) The same segment as (A) but 
classified according to mode instead of Po. The inset is a modal transition matrix for 
the modes. 
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For each mode, the kinetic properties were similar regardless of the agonist 
concentration. In Figure 2.7A, the Po values (1 - Pc) for sequential segments of one 
record are shown (10 µM FW). The classification into modes is indicated by the 
plotting symbol in Figure 2.7A, and the mode for each segment is given in the 
corresponding plot in Figure 2.7B. The inset shows a modal transition matrix, 
demonstrating that the channel is more likely to remain in the same mode than to 
transition to a different mode. 
At very high concentrations of FW, the channel had a Po greater than 90% and 
mostly resided in the VH mode of activity throughout the record. At 500 µM FW, the 
average Po was 95% (n = 5) for all of the patches. At 200 µM FW, two out of three 
patches had a VH mode of activation and the third patch had a mixture of VH, H and 
M. As the agonist concentration was decreased, lower probability modes were more 
frequently observed. At 50 µM FW, the majority of the patches had a mixture of VH 
(n = 4), H (n = 2), and M (n = 1) modes. We also began to observe an L mode of 
activity at 50 µM FW, but with too few events to analyze. Most of the patches 
recorded with 10 µM FW displayed more than one mode of activation, which 
consisted of an assortment of all five modes, VH (n = 1), H (n = 5), M (n = 3), L (n = 
2) and VL (n = 3). The application of 5 µM FW for 2 out of 7 patches resulted in the 
activation of the channel to all but the VH mode. The other five patches displayed 
activation mainly to the lowest conductance level (see section on nonbinomial 
activation to a single conductance level). 
Modal behaviors follow a binomial distribution. Previous analyses of single 
channel events from GluA2 suggest that the channel opens to multiple levels and 
openings follow a binominal distribution (23). That is, once bound with a given 
number of agonist molecules (2 to 4), the channel can display openings to up to three 
levels. The four levels (closed plus three open) can be viewed as four trials (n) and the 
 74 
level of a particular opening is defined as the number of successes (k). The probability 
of success (p) can then vary between agonist, at different concentrations, and, in this 
case, in different modes. As shown in Table 2.4, p (also referred to an “efficacy 
factor” (23)), is consistent across modes and increases from VL to VH mode. 
Variation among modes. In VH mode, the open dwell times (o) in the open states 
of all conductance levels are longer, and decrease as the modal activity decreases. 
Generally, the VH mode has the longest o values whereas the VL mode has the 
shortest dwell times for all the conductance levels (Table 2.3). This is true both for 
channels activated by FW and by glutamate. With the exception of the longest closed 
dwell time (c), (which might have been affected from discarding long closures), the 
shortest c values were relatively similar between all the modes and concentrations. 
Following MIL modeling, equilibrium constants calculated from the rate constants (K 
= kf/kr) for the same modes were averaged across patches (Table 2.5). Overall, for the 
step that represents the transition from closed to open, the equilibrium constant (KC1O; 
see Figure 1 for the definition of the equilibrium constants) varies between modes, 
being greatest for the VH and lowest for the VL mode at all concentrations for both 
glutamate and FW (Table 2.5). KO12a and KO23a are slightly larger for bound glutamate 
than FW, indicating that the energy barrier for opening in the presence of glutamate is 
lower. The distribution in each conductance level is independent of agonist 
concentration and is dependent upon the mode. The distribution shifts toward the 
lower conductance states in the lower modes of activation. The O3 level is the least 
populated in all modes for FW relative to glutamate. 
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Table 2.4 
Efficacy Factors for Modes.  The efficacy factor (p) was calculated as described in 
Methods based on the conductance histograms for records separated into specific 
modes. The concentrations used ranged from 5 to 500 µM for FW and from 50 to 
5000 µM for glutamate. The efficacy factor is synonymous with the probability of 
success in a bionomial distribution. The higher the value, the more likely a gate will be 
open. 
 FW Glutamate 
VH 0.66 ± 0.02 0.73 ± 0.04 
H 0.60 ± 0.02 0.71 ± 0.05 
M 0.45 ± 0.05 0.59 ± 0.08 
L 0.26 ± 0.11 0.42 ± 0.05 
VL 0.24 ± 0.08 0.42 ± 0.11 
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Table 2.5 Fluorowillardiine 
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Table 2.5 (Continued) Glutamate 
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Transitions between modes. The long closures between bursts represented periods 
of channel inactivity that may be due to desensitization and/or deactivation. In  
order to determine if the channel entered modes randomly following a long closure or 
if specific transitions were observed, a modal transition matrix for each record was  
generated. These showed that the channel preferentially remains in the same mode 
following a long closure and when a transition to a different mode is observed, it is 
preferentially to an adjacent mode (Inset to Figure 2.7B). 
Nonbinomial activation to a single conductance level 
In a number of cases, the channel opened to an individual conductance level 
without transitions (or having few transitions) to other levels. In the presence of 200 
µM glutamate, six patches exhibited the largest conductance level without any 
transitions to the smallest and intermediate levels (Figure 2.8A). Four of these patches 
had a VH mode of activity (Po of 93.5% ± 0.03) and long mean lifetime of channel 
opening (25-145 ms). Because of this high activity and long duration openings, events 
(transitions between open and closed) were few in number and MIL analysis was 
limited. The remaining two patches had a mixture of H, M and VL modes or only L 
mode, despite exhibiting only the highest conductance level. 
In the case of FW, patches that exhibited mainly one conductance were largely in 
the lowest conductance level. This included 5 of 7 records with 5 µM FW (Figure 
2.8B), as well as, single records at 50, 200, and 500 µM. At 5 µM FW, 3 out of 5 
patches exhibited VH mode, while remaining in the lowest conductance state for 80% 
of the record. The remainder of these records showed other modes, but remained 
largely in the lowest conductance state. These records and those of glutamate cited 
above do not follow a binomial distribution and clearly represent an aspect of channel  
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Figure 2.8  
(A) Representative segment (5 s) of a record with 5 mM glutamate showing openings 
exclusively to the highest conductance level (O3) and (B) a representative segment (5 
s) with 5 µM FW showing openings exclusively to the lowest conductance level (O1). 
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gating that differs from that observed with the majority of the recordings from GluA3 
channels. 
 
2.5 Discussion 
While a great deal is known concerning the structure of AMPA receptors (20, 43), 
the details of channel activation are complex and less well characterized. The  
complexity arises at least in part from time-dependent changes in activity that varies 
with agonist concentration. Although an excess of high conductance openings at low 
glutamate concentrations in short records has been associated with two modes of 
activity (40), time-dependent changes in activity appear to be more complex and 
consist of a number of different modes that vary with agonist concentration. 
Homomeric GluA3 channels have three open conductance classes, which are 
shared by the full agonist, glutamate, and the partial agonist, FW. This is similar to 
what has previously been reported (11, 23, 29). We show here that at high 
concentrations, the channel can be modeled as three closed states and three 
conductance levels, each with two kinetically distinct open states. At lower 
concentrations, the channels can be modeled with a similar number of states, but the 
fit to the data is not as good as at high concentrations, and the probability of opening 
seems to vary within a given record. As has been described for GluN and GABA 
channels (30, 31), dividing the record into segments (in this case, grouping segments 
based on Pc using the X-means function in QuB) produced much higher LL/event 
values for dwell time fits. Using a range of FW and glutamate concentrations, we 
defined five modes of activity (see Figure 2.7). The distribution of openings was 
consistent within each mode regardless of concentration, and the probability of 
observing modes of higher activity increased with increasing agonist concentration. 
Modeling the openings as a binomial, the “efficacy factor” (23), p, is larger in higher 
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modes. Furthermore, analysis of the modal behavior suggested that the channel 
preferentially either remains in the same mode following a long closure or changes to 
an adjacent mode. 
The question then is what is the nature of the modal behavior? Our results clearly 
show that it is a graded process, with higher modes associated with higher agonist 
concentration and higher conductances. One possibility is that modal gating is tied to 
occupancy level. That is, the number of agonists bound and perhaps the distribution of 
bound LBDs within the tetramer may determine the mode, such that the lowest modes 
would have the lowest occupancy. Since the highest conductance is observed, albeit 
with low probability, even in VL mode, this model would suggest that the highest 
conductance level could be produced by tetramers that are only partially occupied by 
agonist. The structural basis of such a model is not obvious. Alternatively, the 
conductance levels could be set by the number of occupied subunits for which the 
LBD is in the closed lobe conformation. However, in its simplest form, this model 
does not explain modal gating. To account for modal gating, at least one additional 
factor would have to be controlling gating behavior. Although factors such as 
phosphorylation could play a role, at least two processes associated with the LBD 
could contribute to modal behavior. These include hydrogen bonding across the lobe 
interface and the binding of CTZ. 
Extensive studies of the GluA2 LBD (21, 23, 32, 33), supported by recent crystal 
structures of the GluA3 LBD (44), show that two H-bonds can form across the dimer 
interface, stabilizing the closed lobe form. However, the lobes can be closed in the 
absence of these H-bonds, in which a 180˚ flip of the peptide bond between D655 and 
S656 (GluA3 numbering) occurs (21). Generally, the conformation in which the H-
bonds can form is referred to as the "flipped form" and the 180˚ rotation of the peptide 
bond that cannot form H-bonds is the "unflipped form".  Intermediate forms have also 
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been observed (21). The flipped form of the peptide bond is a dynamic process that 
can occur both in the presence of FW and glutamate (32). Thus, the modes may be set 
by both the occupancy and by the H-bonding state. The VH mode could be generated 
by the occupancy of all four subunits with 3-4 H-bonded subunits; whereas, the lower 
modes would have progressively fewer H-bonds and a tendency toward lower 
occupation. Depending upon the time scale of the H-bonding, a receptor could be 
locked into a particular mode for at least a burst of channel openings. An important 
question is the timescale of the transition between the flipped and unflipped form of 
the peptide bond. This cannot be approached by crystallography. However, relaxation 
measurements by NMR suggest that at least for FW and glutamate, the process is 
longer than a few ms (33). H/D exchange studies can provide an estimate of the 
timescale of the opening rate for the H-bond, but only at high pH (EX1 limit; (45)). 
The rates measured at high pH are on the order of 10 Hz, which approach the 
timescale necessary to account for the duration of the modes. Although rigorous fitting 
to a model with transient H-bonds that lock the LBD would not be possible with our 
single channel data sets due to the relatively small number of transitions between 
modes, different modes can easily be simulated by an additional state with locked lobe 
(i.e., no off-rate). 
An additional factor that may contribute to modal behavior is the binding of CTZ. 
An intact dimer interface of the LBD is thought to be necessary for channel activation 
and the dissociation of the interface is associated with desensitization (13). The status 
of the dimer interface in the resting state has been ambiguous. A recent study by 
Gonzalez et al. (46) suggests that the dimer interface is not intact in the resting state 
but only forms with activation. This may mean that CTZ would bind preferentially to 
dimers, perhaps those with agonist in both LBDs. If this were true, it would be 
possible at low concentrations of agonist to obtain a mode with high levels of 
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activation to a low conductance state by occupation of both monomers within a dimer, 
with CTZ bound to the dimer interface. Conversely, occupying one monomer of each 
potential dimer would not necessarily bind CTZ and could lead to a mode with low 
levels of activation. 
An additional question relates to the nature of partial agonism and the transduction 
of the binding signal into gate opening. Clearly the closure of an LBD is associated 
with channel activation; however, it is not clear exactly how the LBD is coupled to 
channel gating. That is, an individual LBD bound to agonist is assumed to be able to 
activate a channel gate that is associated with an increase in channel conductance. 
Activation only occurs if the LBD has an intact dimer interface with the adjacent 
LBD. Even in the case of an intact dimer interface, individual subunit gating is 
unlikely to be directly coupled to occupancy of the binding site. This was recognized 
by Jin et al. (23) and, as noted above, the efficacy factor was introduced to quantitate 
the lower efficacy of partial agonists. Jin et al. (23) suggested that the efficacy factor 
is determined by the degree to which the lobes of the LDB were closed, in that partial 
agonists exhibit lower degrees of lobe closure than full agonists in many crystal 
structures. This was consistent with the data at the time, but the structural link to 
channel gating remained unclear. Zhang et al. (29) have suggested that channel 
activation is associated with the stability of the closed lobes, and Maltsev et al. (32) 
have suggested that partial agonists have a distribution of lobe closures ranging from 
perhaps fully closed to more open. Based on recent NMR and crystallographic 
evidence that a full lobe closing of GluA2 LBD can be observed under some 
conditions with partial agonists (e.g., iodowillardiine and kainate; Ahmed and Oswald, 
unpublished observations), we suggest that the efficacy relates to the probability of a 
full lobe closure, and that in a given mode or distribution of LBD occupancy, the 
conductance level is set by the number of LBD that are in the fully closed 
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conformation at any given time. The LBDs that have formed H-bonds as described 
above would be transiently locked (on the timescale of 100 ms) in this fully closed-
lobe conformation. FW is a relatively strong partial agonist and one might expect that 
full lobe closure is more likely than for a weaker partial agonist such as 
iodowillardiine or kainate. The occupancy in the conductance levels for FW are 
consistently lower than for the full agonist, glutamate, but the difference is not as 
dramatic as observed previously for iodowillardiine vs. glutamate (23). 
In addition to the modal behavior exhibited in the majority of records, occasionally 
openings to a single level (or largely a single level) were observed. In the case of 
glutamate, these openings were to the highest conductance levels, and with FW, the 
openings were largely to the lowest conductance level. In at least one case, the activity 
changed from the typical three conductance levels to a single conductance within one 
record. These channels have the same conductance levels as GluA3 and have not been 
observed in the absence of agonist, and thus appear to be a distinct functional state of 
GluA3. 
NMDA receptors, unlike AMPA receptors, require all four subunits to be bound to 
agonist (two of which are glycine-specific) for activation (47). Unlike the 
concentration dependence of modal behavior for GluA3, no such correlation exists for 
NMDA channels (30). Nevertheless, AMPA receptor activation shares some 
commonalities with NMDA receptor gating. Modeling of both channels requires three 
closed states, with one leading into an open level, and two exponentials are needed to 
fit to the open level (30, 48). Partial agonism at NMDA channels result in a decrease 
in open channel probability of a single conductance level (49); whereas, for AMPA 
channels, partial agonism is associated with a decrease in open probability in the 
largest conductance levels. Thus, although NMDA receptors open to only a single 
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conductance level, considerable similarities between the two classes of glutamate 
receptors are evident. 
The single channel results obtained with GluA3 suggest that the kinetic model of 
activation is simple, but that the channel can exist in different modes depending, at 
least in part, on agonist occupation. All recordings were done in the presence of 
cyclothiazide, which dramatically decreases the rate of desensitization. Nevertheless, 
one might expect that the modal behavior may still have relevance to normal channel 
activation at the synapse. The half-time of desensitization of GluA3 is several 
milliseconds (13, 50), so that for a given EPSP, the mode would not necessarily 
change for any given channel. However, the EPSP is made up of synchronous 
activation of thousands of channels, probably activating in a distribution of modes. 
The development of compounds that could favor high or low modes could be of 
therapeutic value for neurological disorders such as Alzheimer‟s disease (drugs 
favoring high modes) or epilepsy (drugs favoring low modes). 
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CHAPTER 3 
 
Structural and Functional Mechanism for Modal Activation of GluA3 Receptors  
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3.1 Abstract 
AMPA receptors are the major excitatory neurotransmitter receptors in the CNS 
and are involved in numerous neurological disorders. An agonist-binding site is found 
in each of four subunits. Binding consists of three steps: docking of agonist to the 
bilobed ligand binding domain (LBD), closure of the LBD, and an increase in the 
stability of the closed lobe conformation through interlobe hydrogen bonding. We 
report single channel currents recorded with GluA3 channels in the presence of 
nitrowillardiine (NO2W) and chlorowillardiine (ClW), in conjunction with crystal 
structures of GluA2 and GluA3 LBDs bound to fluorowillardiine (FW), ClW, and 
NO2W. The GluA3 channel, when bound to NO2W or ClW, opens to three 
conductance levels with comparable open probabilities and displays modal behaviors, 
similar to that obtained with glutamate and FW as agonists (Poon et al., 2010). At low 
agonist concentrations, ClW displayed an alternative kinetic behavior, consisting of 
high open probability (high mode of activation) to the lower conductance states. The 
structure of ClW bound to GluA3 LBD exhibits a unique partially open hydrogen 
bonding structure that may be associated with an alternative kinetic gating. NO2W 
exhibits long open times in the very high modes of activation. The structure of NO2W 
bound to GluA2 LBD exhibits fully closed lobes with additional interlobe interactions 
mediated by the nitro group of NO2W. These results suggest that differences in GluA3 
receptor activation by full and partial agonists are not simply just coupled to the 
degree of LBD closure but may be associated with multiple small differences within 
the LBD. 
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3.2 Introduction 
AMPA receptors are a class of ionotropic glutamate receptors involved in 
excitatory neurotransmission in the CNS and include four different types of subunits, 
GluA1-4. A single subunit consists of an N-terminal domain, a ligand binding domain 
(LBD), a transmembrane domain, and a C-terminal domain. Four subunits associate to 
form a functional heteromeric or homomeric receptor in which each subunit can bind 
an agonist and contribute to channel activation (1).  
Characterization of AMPA receptor structure and function has led to initial models 
of channel activation. Specifically, the closure of the LBD upon agonist binding is 
directly correlated to activation of the gating mechanism within the transmembrane 
segments (2, 3). Early studies correlated the degree of LBD closure in crystal 
structures to the amplitude of whole cell currents at saturating agonist concentrations. 
Full agonists exhibited the most closure and partial agonists exhibited partial closures 
(3). However, dynamic studies using NMR and crystal structures of mutant GluA2 
LBDs have suggested that closed lobe stability may also determine agonist efficacy. 
Agonist binding to the LBD consists of at least three steps: (1) agonist binding to Lobe 
1, (2) closure of the lobes and contacts with Lobe 2, and (3) interlobe contacts 
(including H-bonds) to stabilize the closed lobe form (2, 5, 6). The current speculation 
is that lobe closure is required for channel gating, but the degree of lobe closure that 
can trigger gating is not clear (that is, does gating require a full closure?). In addition, 
the role of auxiliary interlobe contacts has not been completely resolved. We recently 
suggested (8) that the H-bonding associated with the flip of the D655/S656 peptide 
bond determine the modal behavior observed in homomeric GluA3 channels activated 
by FW and glutamate. 
 94 
Our previous studies found that both glutamate and FW activated the GluA3 
channel to similar three conductance levels (8). The studies described here involve a 
larger spectrum of functional activity using two other partial agonists in the willardiine 
family of compounds, nitrowillardiine (NO2W) and chlorowillardiine (ClW). We have 
also obtained crystal structures of FW and ClW bound to the LBD of GluA3 as well as 
NO2W and ClW bound to the LBD of GluA2. Although overall, the structures are 
quite similar to the large number of published AMPA LBD structures, several details 
may be related to the functional properties elicited by NO2W and ClW. The structural 
details that vary upon binding of different ligands are the orientation of the two lobes 
(e.g., lobe closure and twist), the orientation of the peptide bond between D655 and 
S656, and the orientation of the sidechain of M712. These differences may affect the 
single channel properties of GluA3 receptors when bound to the willardiine 
compounds, specifically the probability the channel enters each conductance level and 
the modal behaviors.   
 
3.3 Methods 
Cell culture 
Human embryonic kidney (HEK) 293 cells were stably transfected with GluA3i 
(G) (S.M. Holley & L.M. Nowak, manuscript in preparation). The receptor is the flip 
variant, and has a G in the R/G editing site. The cells were cultured in Dulbecco‟s 
Modified Eagle‟s Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% 
penicillin-streptomycin and 1 µg/mL blasticidin, pH 7.4. The addition of the 
antibiotic, blasticidin, in the culture media selects for the growth of cells that express 
GluA3 channels. Cells are passaged every 3-4 days and used within 48 hours after 
passage. All cultures were maintained in a 37°C incubator with 5% CO2. 
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Acquisition of Single Channel Currents 
All experiments were performed at room temperature (~23°C). Pipettes were 
pulled from thick walled borosilicate glass with filament (Sutter Instrument Company, 
Novato, CA, USA) to a resistance of 15-20  and firepolished. Solutions were 
buffered at pH 7.4 and filtered using a 2 μM sterile filtering system (Corning, Lowell, 
MA). The bath buffer was a 1X Dulbecco‟s phosphate saline buffer with Mg2+ only 
(Invitrogen, Carlsbad, CA). The pipette solution contained (in mM): 150 NaCl, 10 
Hepes/NaOH, 2 KCl. Stock solutions of nitrowillardiine or chlorowillardiine (NO2W; 
ClW; Tocris Bioscience, Ellisville, MO, or Ascent Scientific, Princeton, NJ) were 
made from the pipette solution and kept frozen in aliquots at -20°C until the day of the 
experiment. Cyclothiazide (CTZ; Tocris Bioscience, Ellisville, MO, or Ascent 
Scientific, Princeton, NJ) was dissolved in methanol, frozen as 50 mM stock solutions, 
and was added (100-150 μM) to all agonist containing pipette solutions.  
Single channel currents were amplified at a gain of 100 mV/pA with an EPC-7 
amplifier, low pass filtered to 10 kHz using an external 8-pole Bessel filter, and 
digitized at 20 kHz using pClamp 7 software (Molecular Devices, Sunnyvale, CA). 
Single channel currents were recorded for 2 to 10 minutes in the cell-attached mode 
with pipette holding potentials of +80 to +120 mV. Data were converted from abf to 
qdf format on QuB software (www.qub.buffalo.edu) for analysis. 
Analysis of Single Channel Data 
All data were initially idealized at a dead time of 150 s using the segmental-k-
means (SKM) algorithm (9) to an initial simple linear model, C↔O1↔O2↔O3 
(Figure 3.1A), consisting of one closed and three open classes starting with all rates 
set to 100 s
-1
. The data were analyzed with or without an additional 5 kHz filtering 
(effective filter of 4.5 kHz). A dead time of 200 µs was imposed on patches that had 
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additional filtering. Maximum interval likelihood (MIL) analysis (10) was applied on 
this initial model to determine the fit to the dwell time histograms. States were then 
added one at a time to each closed and open class, re-idealized, refitted using MIL, 
and retained if the fits to the histograms improved and/or if the LL units increased by 
>10 LL units. If the addition of a state increased the LL by 10, but the rates to the new 
state were either close to zero or unrealistically large, then the additional state was 
omitted. This process was repeated again with rates starting at 10 s
-1
 to confirm that 
the final model and final rates were not affected by the starting values. Similar to our 
previous findings, our final model consists of three closed states and two open states in 
each of the open conductance levels. Loops that additionally connected closed states to 
the intermediate or large conductance levels in the model were tested, but in most 
cases worsened the fit to the dwell time histograms and/or gave unrealistic rates, so 
loops were not considered in our final model. Based on the transition matrices (not 
shown), transitions between the closed and the intermediate or large conductance 
levels were infrequently observed. Therefore, the final model does not include these 
transitions. Data were further segmented into modes based on the closed probability. 
Patches with long closures were modeled to four or five closed states. The critical time 
(tcrit), which describes the minimum closed duration between two bursts, was used to 
discard long closures. The newly separated clusters were re-idealized to one closed 
and three open conductance classes to determine the closed and open probabilities of 
each segment. The segments were then sorted into modes using an X means algorithm 
in QuB (11). The sorted modes were analyzed individually using the model described 
above. In a few records having only three closed states and one mode, the model in 
Figure 3.1B was applied to the entire record. The dwell times of similar modes were 
averaged, but each mode was modeled separately. Table 3.1 summarizes each record 
analyzed, indicating which were segmented into modes and which were analyzed as a  
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Figure 3.1 
(A) Initial kinetic model used as a starting point but found not to describe the data 
adequately. (B) Final kinetic model.  The notation for the equilibrium is as follows: 

KC21  kC2C1 kC1C2 , 

KO12a  kO1aO2a kO2aO1a , 

KO1ab  kO1aO1b kO1bO1a , etc. 
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Table 3.1 
Summary of Single Channel Records 
Each record is shown as one row in the table. The concentration of agonist is given in 
the left column and the total length of the record in the second column. The total time 
in each of the modes is given in the next five columns, with the total time between 
bursts in the column on the far right. All times are in seconds and rounded to 10 ms. 
Records for which no entry is given in the interburst column had only three closed 
times and were analyzed without segmentation. 
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(Continued)  
[NO2W] 
M 
Total 
Length 
(s) 
VH (s) H (s) M (s) L (s) VL (s) 
Interburst 
(s) 
1000 166.866 52.625 84.0582 12.0505 
 
2.1706 13.646 
 
246.072 
     
19.781 
500 578.91 
 
69.21 59.80 31.14 
 
390.12 
 
249.64 96.30 
    
109.64 
 
179.33 
 
161.09 
   
14.20 
 
286.83 
 
88.86 91.76 4.68 
 
101.53 
 
335.99 
 
85.54 66.14 32.71 16.17 135.44 
 
190.74 190.74 
     
 
180.82 180.82 
     
100 126.03 126.03 
     
 
279.21 163.14 41.89 32.45 9.55 6.15 26.04 
 
61.94 
 
61.94 
    
 
31.52 30.81 
    
0.71 
 
139.66 
 
139.66 
    
 
94.94 
  
94.94 
   
 
84.88 83.31 
    
1.56 
 
352.86 124.95 96.60 
 
3.91 
 
127.40 
 
71.20 
 
69.87 
    
 
162.27 162.27 
     
50 98.53 
 
98.53 
    
 
45.60 
   
27.64 
 
17.96 
 
33.25 
 
33.25 
    
 
244.59 
 
244.59 
    
 
335.77 
 
335.77 
    
 
622.42 134.74 93.00 17.11 12.30 19.35 342.55 
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(Continued) 
 
[ClW] 
M 
Total 
Length (s) 
VH (s) H (s) M (s) L (s) VL (s) 
Interburst 
(s) 
1000 73.92 73.92 
     
 
40.46 40.46 
     
 
233.43 91.14 57.00 55.56 
 
9.14 18.32 
500 181.72 
 
110.82 16.29 
  
54.10 
 
149.12 149.12 
     
 
140.34 
 
140.34 
    
 
233.93 214.54 12.45 
   
6.81 
 
127.88 127.88 
     
 
85.44 85.44 
     
 
319.83 319.83 
     
 
115.30 115.30 
     
100 771.80 
 
512.52 146.04 39.47 20.22 53.49 
 
615.78 
  
153.29 215.48 74.45 172.56 
 
356.40 143.65 93.96 
 
11.83 35.93 68.06 
 
172.16 
 
167.81 
   
4.35 
 
122.69 110.84 
  
6.94 
 
4.90 
50 366.77 
    
335.14 31.64 
 
157.64 
    
150.07 
 
 
60.43 
 
60.43 
    
 
360.90 
 
224.04 
 
32.64 34.00 
 
 
643.51 
 
224.57 
 
102.40 28.42 271.53 
 
217.07 217.07 
     
 
540.87 540.87 
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whole. Because the number of events in each group was necessarily less than the total 
number of events in the record, the LL was normalized to the number of events 
(LL/event) and each group was compared to the whole record. Five distinct modes 
were observed. For a more detailed description of the single channel analysis methods, 
refer to (8). 
Protein Preparation and Purification 
GluA2 S1S2 consists of residues N392 - K506 and P632 - S775 of the full rat 
GluA2o subunit (12), a „GA‟ segment at the N-terminus, and a „GT‟ linker connecting 
K506 and P632 (12). A similar construct of GluA3 S1S2 was prepared as described 
previously (13). pET-22b(+) plasmids were transformed in E. coli strain Origami B 
(DE3) cells and were grown at 37˚C to OD600 of 0.9 to 1.0 in LB medium 
supplemented with the antibiotics (ampicillin and kanamycin). The cultures were 
cooled to 20˚C for 20 min. and isopropyl--D-thiogalactoside (IPTG) was added to a 
final concentration of 0.5 mM. Cultures were allowed to grow at 20˚C for 20 h. The 
cells were then pelleted and the S1S2 protein purified using a Ni-NTA column, 
followed by a sizing column (Superose 12, XK 26/100), and finally an HT-SP-ion 
exchange-Sepharose column (Amersham Pharmacia).  Glutamate (1 mM) was 
maintained in all buffers throughout purification. After the last column, the protein 
was concentrated and stored in 20 mM sodium acetate, 1 mM sodium azide, and 10 
mM glutamate at pH 5.5.  
Crystallography  
For crystallization trials, the ligand was exchanged by successive dilution and 
concentration, and the protein was subsequently concentrated to 0.2 - 0.5 mM using a 
Centricon 10 centrifugal filter (Millipore, Bedford, MA). Crystals were grown at 4˚C 
 102 
using the hanging drop technique, and the drops contained a 1:1 (v/v) ratio of protein 
solution to reservoir solution. The reservoir solution contained 14-15% PEG 8K, 0.1 
M sodium cacodylate, 0.1-0.15 M zinc acetate, and 0.25 M ammonium sulfate, pH 6.5. 
The final concentrations of agonists were: FW, 2 mM; NO2W, 2 mM; and ClW, 2 
mM. 
Data were collected at the Cornell High Energy Synchrotron Source beam line A1 
using a Quantum-210 Area Detector Systems charge-coupled device detector. Data 
sets were indexed and scaled with HKL-2000 (14). Structures were solved with 
molecular replacement using Phenix (15). Refinement was performed with Phenix 
(15), and Coot 0.6.1 (16) was used for model building. 
 
3.4 Results  
Structures of GluA2 and GluA3 bound to FW, NO2W and ClW 
Lobe closure variability: The GluA3 and GluA2 LBD structures when bound to 
various agonists are quite similar, with small differences (Figure 3.2A). FW bound 
GluA3 (2.5 Å resolution) is 2.6˚ degree more open relative to glutamate (3DP6, B 
protomer, glutamate bound to GluA3, (17)). The structure of the GluA2 LBD bound to 
FW has been reported previously (18) and is overall very similar to the GluA3 LBD 
structure reported here. The FW bound GluA2 structure is 4˚ more open relative to 
glutamate.  
Despite the fact that the nitro substituent of NO2W is larger than the fluorine on 
FW, two of the three copies in the asymmetric unit for NO2W bound to GluA2 LBD 
(1.78 Å resolution) are more closed than observed for FW bound to either GluA2 or 
GluA3 LBD. In fact, defined by the distribution of lobe orientations of GluA2 bound 
to glutamate (0.53˚ and 1.75˚ relative to the most closed copy; 3DP6, C and A 
protomers, respectively), two of the three copies of NO2W are fully closed. The most  
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Figure 3.2 (continued) D655/S656 peptide conformation. (A) GluA2 LBD bound to 
NO2W. (B) FW bound to GluA3 LBD. The D655/S656 is in the flipped conformation; 
however, an additional water is mediating a hydrogen bonding network to the 
backbone carbonyls of D655 and S656, the backbone amides of G453 and Y452, and 
the sidechain hydroxyl of S656. (C) ClW bound to GluA3 LBD. The D655/S656 is in 
the flipped conformation; however, an acetate molecule is present which forms an 
interlobe H-bond with the backbone carbonyls of D655 and K451, as well as three 
water molecules which joins the carbonyl of S656 to the amides of both Y452 and 
G453. (D) ClW bound to GluA2 LBD. The D655/S656 is in the unflipped 
conformation. (E) NO2W bound to GluA2 LBD.  The D655/S656 is in the appropriate 
position to form hydrogen bonds to G453 and Y452. (F) NO2W bound to GluA2 LBD.  
The D655/S656 is in the unflipped conformation. For both ClW and NO2W, the 
sidechain of D655 (D651 GluA2 equivalent) forms a salt bridge with K660 (K656 
GluA2 equivalent). (All residues in the figure are numbered according to its respective 
subunit; all residues in legend are GluA3 numbering unless specified.) 
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striking aspect of the NO2W structure is the variation observed. The range of lobe 
opening relative to the most closed glutamate-bound structure is more than 3˚ (0.68˚, 
1.5˚, and 3.9˚; average 2.0˚ ± 1.7˚).  
The structures of ClW bound to the LBDs of GluA2 and GluA3 were determined 
to 1.7 and 2.0, Å, respectively. Despite the somewhat smaller size of the chloride 
moiety, the average lobe opening relative to the most closed glutamate-bound form of  
GluA3 for ClW bound to GluA2 LBD (4.1˚, 2.4˚, 2.2˚; average 2.9˚ ± 1.0˚) is larger 
than NO2W bound to GluA2 LBD, but the distributions overlap. The lobe opening for 
GluA3 LBD bound to ClW (3.7˚; one copy per asymmetric unit) is within the range 
observed for GluA2.   
D655/S656 peptide conformation: The flipped conformation of the D655/S656 (all 
subsequent residues are given in GluA3 numbering), which is typically seen in full 
agonist structures, allows the formation of two H-bonds across the lobe interface: the 
carbonyl of S656 (Lobe 2) forms an H-bond with the amide of G453 (Lobe 1) and the 
carbonyl of D655 forms a water-mediated H-bond with the amide of Y452. This 
conformation has been correlated to modal behaviors; that is, the formation of these 
hydrogen bonds allows the channel to stably open for long periods of time, resulting in 
very high modes of activation in full ligand bound receptors (8). The FW bound 
GluA3 LBD structure reveals the D655/S656 peptide bond is in the flipped 
conformation (Figure 3.2B). Although this conformation has not been 
crystallographically observed for the GluA2 LBD bound to FW, residual dipolar 
coupling measurements using NMR spectroscopy (19) suggested that FW-bound 
GluA2 can also assume a flipped conformation for the D655/S656 peptide bond. In the 
case of FW bound to GluA3, the lobes are slightly more separated than glutamate so 
that the water-mediated D655-Y452 H-bond is maintained but the direct H-bond 
between S656 and G453 cannot be formed. Instead, an additional water molecule sits 
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in the pocket forming an H-bonding network that includes the backbone carbonyls of 
D655 and S656, the backbone amides of G453 and Y452, and the sidechain hydroxyl 
of S656 (Figure 3.2B). This may result in additional stability in this partially open 
form of the LBD.  
The GluA3 LBD structure bound to ClW exhibits several interesting features 
(Figure 3.2C, D). Unlike other structures that are not fully closed but similar to the 
FW GluA3 LBD structure, the D655/S656 peptide bond is in the flipped 
conformation. The question then is whether the H-bonds typical of the flipped 
conformation are formed. The carbonyl of D655 probably does not participate in H-
bond with the amide of Y452, although the water molecule is in the appropriate 
position. However, an acetate molecule is present in the cleft that forms an interlobe 
H-bond with the backbone carbonyls of D655 and K451 (Figure 3.2C). Also, the 
carbonyl of S656 is not sufficiently close to the amide of G453 to make a direct H-
bond. However, an H-bonding network involving three water molecules joins the 
carbonyl of S656 to the amides of both Y452 and G453 (Figure 3.2C). This seems to 
suggest that a semi-stable partially open, flipped conformation exists. In contrast, all 
three structures of GluA2 LBD bound to ClW are in the unflipped conformation; 
however, in two of the three structures, the three water molecules are in similar 
positions (Figure 3.2D). The sidechain of S656 (S652 in GluA2) is rotated to form a 
water-mediated H-bond with G453. In all three copies, both the backbone carbonyl 
and the sidechain of D655 interact with K660 (Figure 3.2D). 
NO2W bound to GluA2 differs in each copy. In the most closed copy, the 
D655/S656 peptide bond is in the flipped conformation (Figure 3.2E). For the other 
two, the bond is not flipped, and two conformations of the sidechain of D655 are 
apparent (Figure 3.2F). The sidechain of D655 can form a salt bridge with the 
sidechain of K660. This is seen in the conformer with the flipped peptide bond, but  
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Figure 3.3 
The nitro group of NO2W bound to GluA2 contributes to stability by making 
additional H-bonds to T686 and Y450 (GluA2 numbering; T690 and Y452 GluA3 
equivalent). 
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only one of the two conformations of the D655 sidechain can form this salt bridge in 
the two unflipped structures. In the case of the unflipped structure, the sidechain of 
K660 can interact with both the sidechain and backbone carbonyl of D655 (Figure 
3.2F). However, in the flipped form, the carbonyl of D655 forms an interlobe H-bond 
with Y452, so that only the D655 sidechain is available for this interaction. In 
addition, the nitro group of NO2W contributes interactions that may stabilize the 
closed lobe conformation; NO2W can H-bond with the sidechain of T690 and the 
sidechain hydroxyl of Y452 (Figure 3.3).  
Although these structures capture either the flip or unflipped conformations, it is 
very likely that both of these states are visited in solution. Based on the structures 
reported here, it seems the flip conformation of the D655/S656 peptides can exist in 
partially closed LBD structures and is stabilized by water molecules occupying the 
partially open space. NMR results (20) suggest the GluA2 LBD exhibits an 
equilibrium between the flipped and unflipped conformations, which means either 
form could be crystallized. The differences in this flip region between GluA2 and 
GluA3 are unlikely to be functional differences but rather both conformations are most 
likely present in both subtypes.  
Met 712 sidechain conformation: M712 has been seen to adopt different 
conformations depending on the agonist that is bound (2, 18, 21). In glutamate bound 
and FW bound GluA2 and GluA3 structures, M712 is in an extended conformation. 
For NO2W, comparison of the structure with that of the FW-bound and glutamate-
bound GluA2 and GluA3 structures indicates that the larger size of NO2W is 
accommodated by a change in the rotameric state of M712 at the  carbon and the 
exclusion of one water molecule (relative to the glutamate bound form) from the 
binding pocket (Figure 3.4A). This places the sidechain in a position that is  
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Figure 3.4 
Conformation of the sidechain of M712. The sidechain of M712 is in an extended 
state when bound to FW.  There is a rotomeric change at the  carbon when bound to 
NO2W.  The rotameric change is most dramatic with ClW bound. 
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intermediate between the glutamate-bound form and the form reported previously for 
BrW and IW (18)).  
The rotamer of the sidechain of M712 in the ClW bound GluA3 LBD structure is 
similar to willardiine partial agonists such as BrW and IW. However, in the structure 
of GluA2 bound to ClW, two of the protomers have a conformation of M712 similar 
to that of the NO2W structure and one has density corresponding to both the NO2W 
conformation and that similar to the conformation seen with ClW bound to GluA3. In 
the case of GluA3 ClW, the rotation of the sidechain allows an additional water 
molecule to enter the binding pocket to interact with the sidechain hydroxyls of Y407 
and Y736 (Figure 3.4B).   
Single Channel Behavior of GluA3 Activated by NO2W and ClW 
NO2W and ClW activate GluA3 channels in the same manner as glutamate and 
FW: The willardiine family of partial agonists shares the same structure but differ in 
the substituent in the 5-position and produces a graded level of whole-cell activation 
based on the size and electronegativity of the substituent. The electronegativity seems 
to affect ligand potency while the size seems to affect efficacy (22). The trend for 
efficacy of the willardiine compounds in whole cell studies is FW > NO2W > ClW 
(22). Interestingly, our single channel studies show the willardiine compounds can all 
activate the homomeric GluA3 receptor to three similar conductance levels. Figure 
3.5A is a 500 ms representative trace of 100 µM NO2W. Figure 3.5B and C are 
amplitude histograms of 500 M NO2W and 500 M ClW activating in a Very High 
mode. Similar to our previous findings with glutamate and FW (8), NO2W and ClW 
activate GluA3 channels to three open conductance levels with conductances of: 15.6 
± 0.74, 28.8 ± 1.59, 40.4 ± 1.39 pS NO2W (n=3); 14.5 ± 0.99, 22 ± 4, 38 ± 3 pS ClW  
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Figure 3.5 
GluA3 channels have three conductance levels. (A) A 500 ms representative segment 
of a GluA3 channel activated by 100 M NO2W opens to three different conductance 
levels. (B, C) Amplitude histograms for an entire record obtained with 500 M NO2W 
at 100 mV (B) and 500 M ClW at 80 mV (C). For both the NO2W and ClW records 
shown, the channel exhibited VH mode. 
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Figure 3.6 
Dwell time histogram for the same records used to generate Figure 5 B and C. 
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(n=2) (refer to (8) for example of IV curve). The population in each conductance level 
is very similar for both agonists. The channel is activated largely to the small and 
intermediate conductance levels by NO2W and ClW (PC, PO1, PO2, PO3, for these two 
patches are: 9%, 38%, 34%, 20%, for NO2W and 11%, 29%, 36%, 24% for ClW).  
The data also fit well to the simple model created from studies with glutamate and 
FW. Figure 3.6 shows dwell time histograms for the 500 M NO2W and ClW data. 
The closed histogram consists of three exponentials and the open histograms consist of 
two exponentials, consistent with our previous findings with glutamate and FW. Based 
on state transition matrices (Table 3.2), the channel when bound to NO2W and ClW 
preferentially transitions between adjacent conductance levels. These results suggest 
the mechanism of activation is the same for both glutamate and the willardiines.   
The probability in each conductance level for each agonist was averaged for the 
VH mode (see (8) and next section for a description of modal behaviors) to obtain a 
more global comparison of the occupancy in each conductance level for glutamate, 
FW, NO2W and ClW (Table 3.3). All three willardiines have very similar open 
probabilities in all conductance levels with small subtle differences. FW and glutamate 
populate the highest conductance level to a greater extent than ClW and NO2W, with 
glutamate being greater than all the willardiines. NO2W and ClW both spend a similar 
percentage of time in the largest conductance level. The population in the intermediate 
conductance level is higher for FW than NO2W. The rank order of the population of 
the largest conductance level is: ClW  NO2W  FW < glutamate. The slightly higher 
efficacy of FW compared to NO2W seems to be caused by a higher open probability in 
O2. These findings correlate well with the efficacy measured in whole cell recordings 
and also suggests the difference in lowered efficacy of partial agonists in whole cell  
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Table 3.2 
State transition matrices showing the percentage of transitions between each 
conductance level. Transitions between adjacent states are far more frequent than 
transitions between nonadjacent states. This constrains the model shown in Figure 3.1 
such that transitions between closed states and O2, between closed states and O3, and 
between O1 and O3 are not included.  
 
500 M 
ClW 
C O1 O2 O3  
500 M 
NO2W 
C O1 O2 O3 
C  8.95 1.13 0.04  C  7.99 0.41 0.01 
O1 8.70  25.20 0.53  O1 8.22  25.14 1.24 
O2 1.37 24.81  14.36  O2 0.19 25.64  14.96 
O3 0.05 0.66 14.21   O3 0.00 0.97 15.23  
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Table 3.3 
The averaged probability of the GluA3 channel visiting each conductance level in the 
VH mode for glutamate, FW, NO2W and ClW (n=3 for each agonist).  
 
  
5 mM 
glutamate 
200 M 
FW 
500 M 
NO2W 
500 M 
ClW 
PC  6% ± 3 9% ± 1 12 ± 3% 13 ± 2% 
PO1  6% ± 3 22% ± 5 37 ± 5% 31 ± 3% 
PO2  51% ± 6 47% ± 2 33 ± 4% 42 ± 3% 
PO3  36% ± 12 22% ± 7 17 ± 2% 14 ± 4% 
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Table 3.4  
Efficacy Factors for Modes 
The efficacy factor (p) was calculated as described in (Poon et al, 2010) based on 
conductance histograms for records separated into modes. The concentrations used 
range from 50 to 1000 M of ClW and NO2W. The efficacy factor is synonymous 
with the probability of success in a binomial distribution. The higher the value, the 
more likely a gate will be open. 
 
  ClW NO2W 
VH 0.63 ± 0.02 0.64 ± 0.02 
H 
0.55 ± 0.02 
(0.30 ± 0.02) 
0.55 ± 0.01 
M 0.43 ± 0.002 0.29 ± 0.03 
L 0.25 ± 0.03 0.19 ± 0.004 
VL 0.24 ± 0.07 0.08 ± 0.01 
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Figure 3.7 
Representative 500 ms segments of single channel records showing modal behaviors 
for 50 M ClW (VL), 100 M ClW (L, M, H), 500 M ClW (VH), and 50 M NO2W 
(VL, L), 100 M NO2W (M, H), 500 M NO2W (VH). The traces are additionally 
filtered at 1 kHz for viewing purposes.   
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studies is attributed to the differences in open probability in each of the conductance 
levels.   
NO2W and ClW induce modal behaviors: Modal gating of AMPA receptors has 
been previously described in detail for GluA3 bound to FW or glutamate and has been 
correlated to hydrogen bonding of the peptide flip conformation of D655 and S656 to 
Y452 and G453 (8). We tested if modal gating could also be observed for the lower 
efficacy partial agonists, NO2W and ClW. The single channel data acquired with 
NO2W and ClW were analyzed as described previously for glutamate and FW (8). 
Patches with long closures were segmented according to the tcrit (values ranging from: 
1000 M, 79 ms; 500 M, 82 -226 ms; 100 M, 49-170 ms; 50 M, 50-280 ms for 
ClW; 1000 M, 78ms; 500 M, 127-295 ms; 100 M, 81-180 ms; 50 M, 131-169 ms 
for NO2W) and sorted into the closest PC distribution using the X means method (11). 
These sorted segments were then reanalyzed using the model in Figure 3.1B. Like 
glutamate and FW, NO2W and ClW also exhibited five modes of behavior (Figure 
3.7). The five modes are represented by PO (where PO = 1 – PC) of: 80-100%, 60-79%, 
40-59%, 20-39%, and <20%, (which correspond to Very High (VH), High (H), 
Medium (M), Low (L) and Very Low (VL) modes). Patches were also recorded in 
which a specific mode of activity was retained throughout the record, independent of 
agonist concentration. The kinetic data acquired from these patches were averaged 
with other similar PO modes of behavior. The values for each patch and mode are 
given in Table 3.1. Interestingly, the LBD structures reported here show both flipped 
and unflipped conformations of the D655/S656 peptide region and either conformation 
can be visited in solution for NO2W and ClW (19). The modal behaviors reported here 
for NO2W and ClW were similar to those reported for FW and thus may also be 
correlated to the H-bonding of this flip region.   
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ClW and NO2W, similar to FW and glutamate, also follow a binomial distribution, 
which is referred to as an „efficacy factor‟ (Table 3.4).  The efficacy factors remain 
constant for a given mode regardless of concentration, and are similar for ClW and 
NO2W. The exceptions are the M, L and VL modes for NO2W.  This is likely due to 
the small sampling size of those modes for NO2W; in comparison to ClW, most of the 
M, L and VL activity for NO2W are short in duration (Table 3.1). The efficacy 
compared to FW and glutamate (0.66 ± 0.02, 0.60 ± 0.02, 0.45 ± 0.05, 0.26 ± 0.1 0.24 
± 0.08 for FW; 0.73 ± 0.04, 0.71 ± 0.05, 0.59 ± 0.08, 0.42 ± 0.05, 0.42 ± 0.11 for 
glutamate; VH, H, M, L, VL respectively) is lower for ClW and NO2W. This also 
follows the trend for efficacy in whole cell mode.  
The equilibrium constants also show differences among modes. The Keq for both 
ClW and NO2W favor channel opening to the smallest conductance level in all modes 
with the exception of L and VL modes (Table 3.6). Interestingly, at the VH mode, the 
Keq for ClW is actually greater than one from the smallest to the intermediate 
conductance level. This is in contrast to NO2W, in which the majority of the Keq from 
O1 to O2 are less than one (Keq is a forward equilibrium constant so that a value greater 
than one indicates a relatively greater population of O2 than O1). For both agonists, the 
forward Keq dramatically decreases when the channel transitions from O2 to O3. As the 
modal behavior descends in activity, the Keq also decreases.   
ClW exhibits an alternative kinetic behaviors at lower concentrations of agonist: 
ClW activity generally follows the same modal pattern as glutamate; however, an 
anomaly was detected at lower concentrations of agonist. Table 3.5 highlights the PO 
of ClW acquired at 50 M ClW activating in H mode. In the H mode, ClW seems to 
exhibit two populations of activity; one with a high Po in the largest conductance level  
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Table 3.5 
Patches which exhibited an alternative kinetic behaviors when bound with either ClW, 
FW or NO2W in the High mode of activation. The sub-modes are in italics or bold.   
 
M ClW  C PO1  PO2  PO3  
100 31% 32% 26% 11% 
  27% 32% 28% 13% 
  32% 55% 13% 0.17% 
50 24% 28% 35% 13% 
  26% 36% 28% 10% 
  33% 47% 19% 0.96% 
  37% 49% 14% 0.39% 
  35% 49% 16% 0.67% 
 M FW  C PO1  PO2  PO3  
10 29% 25% 29% 17% 
  30% 23% 30% 17% 
  31% 28% 29% 12% 
  36% 40% 19% 5% 
  27% 49% 21% 3% 
 M NO2W  C PO1  PO2  PO3  
100 26% 36% 27% 12% 
  22% 34% 32% 12% 
  20% 34% 34% 12% 
  31% 31% 27% 11% 
  24% 25% 37% 14% 
  31% 37% 26% 6% 
50 23% 38% 28% 12% 
  34% 30% 25% 10% 
  32% 39% 22% 7% 
  38% 32% 24% 6% 
  27% 39% 26% 8% 
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Table 3.6 NO2W 
Equilibrium constants as defined in Figure 1 were calculated using NO2W and ClW as 
the agonist. All constants are unitless. 
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(continued) ClW 
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and another with a very low PO in the largest conductance level. The possibility that 
other agonists also displayed this alternative kinetic behavior led to the decision to 
reanalyze the PO‟s for glutamate, FW and NO2W in the VH and H modes at lower 
concentrations. Interestingly, FW and NO2W also presented this type of alternative 
kinetic behavior, but to a much smaller, less observable degree (Table 3.5). The 
alternative kinetic behavior was not present with glutamate. Two efficacy factors are 
given for ClW in H mode, arising from the two behaviors seen at lower concentration 
of agonist and having a lower efficacy. 
NO2W and FW have long dwell times: Similar to previous glutamate and FW 
results, the dwell times in the open states of all conductance levels measured with 
NO2W and ClW are longer in the VH modes and shorten with a decrease in modal 
activity (Table 3.7). The longest dwell time (the second time constant, O1,2,3b)) in each 
of the conductance levels in the VH mode for NO2W is much longer than those 
observed for glutamate and ClW. O1,2,3b for NO2W ranges from 10-30 ms for all three 
conductance levels. O1,2,3b for ClW range from 2-12ms. Comparing this with previous 
findings (8); O1,2,3b for glutamate, similar to ClW, ranges from 2-6 ms, whereas FW 
ranges from 5-28 ms. The order of O1,2,3b in increasing length is: NO2W > FW > ClW 
> glutamate. 
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Table 3.7  
Exponential fits to the dwell time histograms for different concentrations of NO2W 
and ClW separated by modes. The dwell times are averaged. The open probability 
(PO) is 1 – PC.  values are in ms.  
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(continued) 
NO2W 
 126 
(continued) 
 ClW 
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3.5 Discussion 
Efficacy of partial agonists 
The original hypothesis concerning the mechanism of partial agonism was that 
efficacy correlates with the degree of lobe closure (3). While this was consistent with 
the original data, more recent work has supported a model in which the stability of full 
lobe closure determines efficacy (4, 5), such that partial closures more likely represent 
intermediate states of low energy in the crystal. The evidence supporting the stability 
argument includes a demonstration that at least some partial agonists can exist in a 
wide range of lobe orientations (19) that are in equilibrium (13, 23, 20) and that even 
the lowest efficacy agonists can access a fully closed state (Ahmed, Wang, Chuang & 
Oswald, manuscript in preparation). The crystal structures presented here show that 
FW, ClW and NO2W–bound LBD can access a range of lobe orientations, one of 
which was essentially fully closed. Furthermore, all structures show multiple side 
chain orientations near the lobe interface, suggesting that the LBD is not held in a 
fixed conformation but is in equilibrium between distinct states. This suggests the 
differences in conductance level population are less likely to be affected by the extent 
of lobe closure but rather other structural and dynamic differences within the LBD. 
The question is how often these states are visited for each agonist. The fact that GluA2 
can be crystallized in the fully closed state when bound to NO2W, may suggest that 
this state is of low energy. However, if this is the case, then why is the efficacy of FW, 
albeit to a small degree, greater than NO2W yet the single channel open probabilities 
are very similar? There are three potential structural differences between the bound 
form of FW and that of NO2W. These include (1) the orientation of M712, (2) the 
additional interactions with Lobe 2 by virtue of the nitro group in NO2W, and (3) 
possible differences in H-bonding across the lobe interface.  
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Considering first the orientation of M712, the rotameric state for this sidechain in 
both the ClW and NO2W structures of GluA2 differs from previous structures of full 
and partial agonists (3). The M712 sidechain rotates slightly around the  carbon and 
by about 60˚ around the  carbon relative to the FW-bound structure, providing space 
for the nitro moiety in NO2W. Although the functional significance of this change in 
rotameric state is difficult to assess, M712 is part of Helix I, which undergoes a 
bending motion when bound to weak partial agonists, such as IW (24). At the other 
end of Helix I, a disulfide bond connects Helix I to the C-terminal portion of the LBD, 
which in the intact protein is beginning of the linker to the M4 helix. The M4 helix of 
one subunit is actually associated with the ion channel gating region of an adjacent 
subunit (26) and this slight change in M712 could alter gating kinetics. In fact, 
mutations in the M4 segment in NMDA receptors alters function (25).  
With RDC measurement using NMR spectroscopy, Maltsev et al. (2008) estimated 
the proportion of the flipped conformation of the D655/S656 peptide bond varies with 
agonist as follows: 0.54, 0.44, 0.46, 0.45, 0.28, and 0.29 for HW, FW, ClW, BrW, IW, 
and NO2W, respectively. This would suggest that the D655/S656 bond would be in a 
position to form H-bonds more often for FW and ClW than NO2W; however, as 
demonstrated by the GluA3 structures bound to FW and ClW, the flipped peptide 
bond does not always correspond to a fully closed lobe. It is possible that the 
additional contacts made by NO2W in Lobe 2 (H-bonding to E705 and Y452) could 
stabilize lobe closure and compensate for the lower propensity to form a flipped 
conformation. Preliminary ITC studies (Romero B., unpublished results) do show that 
the binding of NO2W is driven by enthalphy to a larger extent than FW and ClW, 
possibly suggesting the importance of additional contacts in the bound state. 
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Modal gating and the peptide flip conformation 
Like glutamate and FW, activation of the channel by NO2W and ClW exhibits five 
distinct modes of activation (VL, L, M, H, and VH). We previously postulated (8) that 
modal behavior could arise from locking a specified number of LBD’s closed as a 
result of the flip of the D655/S656 peptide bond. This flipping results in the formation 
of two H-bonds between the carbonyl of S656 (Lobe 2) and the amide of G453 (Lobe 
1), and between the carbonyl of D655 and the amide of Y452 through a water 
molecule. This H-bonding pattern is seen in one of three protomers of the structure of 
NO2W bound to GluA2 LBD, similar to that reported for glutamate bound to the same 
construct (2). FW and ClW bound to GluA3 LBD show a variation on this H-bonding 
pattern. In both cases, the peptide bond is flipped in the context of lobes that are 
slightly open (about 3˚ relative to the glutamate structure that is the most closed), 
making the H-bonds difficult to form. However, additional water molecules enter the 
cleft (and, in one case, an acetate molecule) and mediate the H-bonds between the two 
lobes. These hybrid H-bonded conformations have not been previously reported for 
partial agonists and may result in subtle functional effects. One possibility is the sub-
modes observed with ClW and to a lesser extent FW and NO2W. If one assumes that 
the modes are set by the occupancy and H-bonding state as we suggested previously 
(8), the existence of this hybrid H-bonding state increases the number of possibilities. 
The fully closed, previously reported H-bonding pattern exists on the timescale of 
approximately 100 ms (23), suggesting that this stabilization is on the same timescale 
as modal gating. If the hybrid H-bonding states have the same stability as the fully 
closed pattern but actually are a conformation that does not permit channel activation, 
then the H and VH modes that are observed with extremely low probability for the 
largest conductance state may arise from a fully occupied tetramer with two to three 
subunits in the standard H-bonding conformation and one or two in the hybrid 
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conformation. In fact, ClW has three water molecules tethering this hybrid 
conformation whereas FW has only one water molecule and the single channel results 
show ClW has the greatest effect on inducing the alternative kinetic behavior than 
FW, with NO2W being the least affected.  
Dwell time variation between agonists 
In the VH mode, NO2W exhibits relatively long channel lifetimes in the large 
conductance state and the overall efficacy is slightly better than ClW. The size of the 
nitro group is larger than the chloro substituent, but the lobes are, on average, more 
closed for NO2W and ClW.  The fraction of bound NO2W in the flipped conformation 
calculated from RDC measurements suggest NO2W was 0.29 (similar to that of 
relatively low efficacy partial agonist, iodowillardiine); whereas, the fraction for ClW 
and FW was 0.46 and 0.44, respectively (19). However, the additional contacts of 
NO2W to the sidechains of T690 and Y452 may help stabilize the fully closed state 
and may contribute to longer openings in each of the conductance levels. These 
interactions are not present in the other willardiine partial agonists and may 
compensate for the decreased population of the flipped conformation. 
3.6 Conclusions 
The structures of the willardiines bound to GluA2 and GluA3 LBD suggest full 
lobe closures are possible for partial agonists. Crystal structures of kainate bound to 
the LBD of a kainate receptor reveal 3° less closure than glutamate and yet kainate is a 
full agonist at kainate receptors (27), further implying crystal structures are only 
representative of a specific conformation that is in a low energy state and other 
conformations are possible. Partial agonists at NMDA receptors exhibit full lobe 
closures (28). Although NMDA receptors have very different activation kinetics (slow 
activation, long openings) compared to AMPA receptors, the mechanism leading to a 
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gating event may be conserved for all subtypes of glutamate receptors. Taken together 
with our results, these findings imply that agonist-induced activation of AMPA 
channels is not necessarily dependent on any specific attribute in the LBD but rather 
on the ‘push and pull’ of various factors, such as, agonist affinity, lobe closure, and 
interdomain contacts.   
In summary, although the differences in single channel activity between FW, ClW 
and NO2W are small, these small differences can multiply into large whole cell 
differences and have an impact on neuronal function. ClW and NO2W show similar 
conductance levels, mechanism of activation, and modal behaviors as glutamate and 
FW. The small disparities in single function can be compared to specific structural 
dissimilarities and provide new insights into the range of channel activation.  
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CHAPTER 4 
 
Flicker Gating Mode of Single Channel GluA3 Receptors 
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4.1 Abstract 
Single channel studies on ion channels have revealed a plethora of information on 
their possible in vivo mechanisms of function, including modal gating behaviors, 
mechanisms of allosteric modulation, and single channel block. Systemic 
characterization has only recently begun for AMPA receptors. AMPA receptor-
channel block has never been characterized on the single channel level. We report here 
a flicker mode of activity that corresponds to a fast open channel block by an intrinsic 
HEK 293 cell factor and is independent of the agonist or agonist concentration. We 
also show that the block is voltage-dependent, with increasing negative membrane 
potentials reducing the level of block. Development of drugs that mimick this behavior 
could potentially prove useful in treating various CNS diseases and disorders. 
 
4.2 Introduction 
AMPA receptors are a class of ionotropic glutamate receptors that play a major 
role in excitatory neurotransmission in the CNS. AMPA receptors form functional 
homo- or hetero-tetrameric channels (1). Upon binding of agonist, AMPA channels 
open and flux Na
+
, K
+
 and Ca
2+
. Assembly with an R-edited GluA2 subunit affects 
AMPA channel including weak permeability to Ca
2+
, decreases in the channel 
conductance and resistance to intracellular polyamine block (1, 2). The majority of 
neurons in the CNS contain AMPA receptors which co-assemble with GluA2 subunits 
(1, 2). However, there are populations of neurons that do not assemble with GluA2 
and are Ca
2+
 permeable. These Ca
2+
 permeable AMPA channels are susceptible to ion 
channel block that is reminiscent of block on other ion channels that have been 
characterized in whole cell studies (3).   
Blockade of ion channels, including K
+
 channels, Ca
2+
 channels, and NMDA 
channels is not a new concept (4, 5). There are many types of channel block induced 
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by a variety of different factors, such as toxins or extracellular ions. One particular 
type of block, open channel block, is caused by a charged species that enters the pore 
of the ion channel. There are three types of open channel blockers, slow, intermediate 
and fast, in which each affect activation in distinct ways (6). Slow open channel 
blockers have a slow dissociation rate leading to long blocking periods that result in a 
mostly closed state throughout the record.  Intermediate channel blockers generate 
periods of rapid channel opening and closing seen as flickers (6). Fast open channel 
blockers have fast rates of association and dissociation; they tend to decrease the 
apparent amplitude of opening and also cause a flickering effect (5, 6).  Although 
these types of block have been reported on the single channel level for other ion 
channel subtypes, they have not been seen at a single channel level in AMPA 
receptors.   
Recent studies on GluA3 homomeric channels have revealed modal gating 
behavior which ranged from very low to very high open probability that is dependent 
on the concentration of the agonist. However, single channel blocking behavior has 
not been recorded for any AMPA receptor. The studies highlighted here have captured 
a flicker mode of activity for GluA3 receptors that reflect a fast open channel block.  
The activity was seen only when using AMPA receptor agonists. This section 
characterizes the block and provides some possible factors that could be associated 
with this activity.   
 
4.3 Methods 
Cell Culture 
Human embryonic kidney (HEK) 293 cells were stably transfected with r/m 
GluA3i (G). The cells were cultured in Dulbecco‟s Modified Eagle‟s Medium 
(DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 
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1g/mL blasticidin, pH 7.4. The addition of the antibiotic, blasticidin, in the culture 
media selects for the growth of cells that express GluA3 channels. Cells are passaged 
every 3-4 days and used within 36-48 hours. All cultures were kept in a 37°C 
incubator with 5% CO2.  
Acquisition of Single Channel Data  
All experiments were performed at room temperature (~23°C). Pipettes were 
pulled from thick-walled borosilicate glass with filament (Sutter Instrument Company, 
Novato, CA, USA) to a resistance of 15-20  and firepolished. All solutions were 
buffered at pH 7.4 and filtered using a 2 M sterile filtering system (Corning, Lowell, 
MA). The bath buffer is 1X Dulbecco‟s phosphate saline buffer (DPBS) with either 
Ca
2+
 and Mg
2+
, or Mg
2+
 only (Invitrogen, Carlsbad, CA). The pipette solution 
contained: 150 mM NaCl, 10 mM Hepes / NaOH, 2 mM KCl. Stock solutions of 
glutamate, fluorowillardiine (FW), chlorowillardiine (ClW) and nitrowillardiine 
(NO2W) (Tocris Bioscience, Ellisville, MO or Ascent Scientific, Princeton, NJ) were 
made from the pipette solution and kept frozen in aliquots at -20°C until the day of the 
experiment. Cyclothiazide (CTZ; Tocris Bioscience, Ellisville, MO, or Ascent 
Scientific, Princeton, NJ) was solubilized in methanol and frozen as 50 mM stock 
solutions and was added (100-150 µM) to all agonist containing pipette solutions. 
Single channel currents were acquired in the cell-attached configuration. Single 
channel currents were amplified at a gain of 100 mV/pA with an EPC-7 amplifier, low 
pass filtered to 10 kHz using an external 8-pole Bessel filter, and digitized at 20 kHz 
using pClamp 7 software (Molecular Devices, Sunnyvale, CA) and stored directly on a 
PC hard drive. Data were converted from abf to qdf format on QuB software 
(www.qub.buffalo.edu) for analysis. Single channel currents were recorded from 30 
 140 
seconds to 2 minutes at holding potentials ranging from 80 to 130 mV. The single 
channel conductance was estimated from the slope of the current-voltage relationship.   
Analysis of Single Channel Data 
The data were analyzed in steps: first, the baseline was set; next, the amplitude of 
the open level was estimated using AMP function from QuB (Baum-Welch algorithm 
(7)). Visual inspection of the data revealed more than one open conductance level, but 
the kinetics of channel openings and closures were so rapid that these levels could not 
be resolved (Figure 4.1A). Instead, the data was then idealized using the segmental-k-
means (SKM) algorithm (8) to an initial model of one closed state and one open 
conductance state using a dead time of 150 s (Figure 4.1B). Patches with lower to 
signal-to-noise ratio were additionally filtered at 5 kHz (effective filter of 4.5 kHz) 
and idealized using a dead time of 200 s. Maximum interval likelihood (MIL) (9) 
analysis was applied to this initial model to determine the fit to the dwell time 
histograms. Additional closed and open states were added one at a time, re-idealized, 
re-fitted using MIL, and kept if the addition of the state increased by >10 units. If the 
addition of the state increased the LL by 10 but yielded rates that were close to zero or 
unrealistically large, then the additional state was omitted. The results of all the 
patches that exhibited the flicker mode are in Table 1.   
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Figure 4.1 
A 50 ms representative trace of GluA3 with 200 M glutamate at a holding potential 
of 100 mV.  (A) The red box highlights subconductance levels within the flicker mode 
that were too brief to be resolved. (B) The same trace as A, with idealization to one 
closed and one open state overlaid in red.   
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Table 4.1  
A summary of all the patches acquired in flicker mode  The * denotes a patch 
acquired without the addition of cyclothiazide. The highlighted data are the anomalies.   
 
Glutamate 
 
Cell # 
Vhold 
(mV) 
Conc 
(M) PC PO 
Closed 
Lifetime 
(ms) 
Open 
Lifetime 
(ms) 
Closed 
Amp 
(pA) 
Open 
Amp 
(pA) 
1 100 50 0.48 0.52 0.21 0.23 0.51 6.07 
  110 50 0.43 0.57 0.18 0.24 0.49 6.42 
2 100 50 0.79 0.21 0.68 0.18 0.19 3.24 
3 100 50 0.53 0.47 0.31 0.28 0.16 4.05 
4 100 50 0.78 0.22 1.26 0.36 0.06 1.89 
5 100 50 0.52 0.48 0.27 0.25 0.35 5.34 
6 100 50 0.48 0.52 0.30 0.32 0.22 4.29 
7 80 50 0.78 0.22 1.20 0.33 0.02 2.98 
8 100 100 0.54 0.46 0.26 0.22 0.22 5.39 
9 100 200 0.42 0.58 0.23 0.31 0.43 5.47 
  110 200 0.33 0.67 0.17 0.34 0.64 6.10 
  90 200 0.42 0.58 0.29 0.40 0.37 5.00 
10 90 200 0.59 0.41 0.55 0.38 0.12 3.10 
11 100 200 0.59 0.41 0.39 0.27 0.14 4.28 
12 100 200 0.63 0.37 0.43 0.26 0.04 4.40 
13 90 200 0.67 0.33 0.72 0.35 0.30 2.96 
  100 200 0.79 0.21 0.83 0.22 0.42 2.87 
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(continued) 
 
FW 
 
Cell # 
Vhold 
(mV) 
Conc 
(M) PC PO 
Closed 
Lifetime 
(ms) 
Open 
Lifetime 
(ms) 
Closed 
Amp 
(pA) 
Open 
Amp 
(pA) 
1 100 5 0.41 0.59 0.34 0.48 0.77 6.27 
  100 5 0.74 0.26 1.88 0.67 0.43 2.72 
2* 70 5 0.44 0.56 1.08 1.36 0.19 1.78 
  80 5 0.45 0.55 0.98 1.20 0.34 2.30 
  100 5 0.65 0.35 1.68 0.90 0.22 1.81 
  110 5 0.59 0.41 1.06 0.73 0.21 2.41 
  120 5 0.68 0.32 1.27 0.60 0.20 2.95 
3 20 5 0.86 0.14 2.07 0.35 0.05 1.92 
  50 5 0.77 0.23 0.79 0.23 0.13 3.06 
  60 5 0.73 0.27 0.59 0.22 0.17 3.44 
  80 5 0.64 0.36 0.33 0.19 0.09 4.21 
  100 5 0.54 0.46 0.23 0.19 0.18 5.05 
4 100 5 0.75 0.25 1.63 0.55 0.04 1.32 
5 100 10 0.43 0.57 0.45 0.59 0.23 4.12 
6 100 10 0.42 0.58 0.24 0.33 0.42 5.84 
  110 10 0.39 0.61 0.20 0.31 0.46 6.10 
7 100 10 0.53 0.47 0.33 0.29 0.26 4.50 
  110 10 0.46 0.54 0.29 0.35 0.29 4.95 
8 100 50 0.48 0.52 0.37 0.39 0.48 4.95 
  100 50 0.57 0.43 0.46 0.34 0.14 4.39 
9 100 50 0.73 0.27 0.62 0.23 0.08 2.90 
  110 50 0.67 0.33 0.49 0.24 0.21 3.15 
  120 50 0.62 0.38 0.40 0.25 0.25 3.39 
10 80 50 0.63 0.37 0.53 0.31 0.17 2.74 
  90 50 0.66 0.34 0.48 0.24 0.23 3.51 
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(continued) 
NO2W 
 
Cell # 
Vhold 
(mV) 
Conc 
(M) PC PO 
Closed 
Lifetime 
(ms) 
Open 
Lifetime 
(ms) 
Closed 
Amp 
(pA) 
Open 
Amp 
(pA) 
1 100 500 0.55 0.45 0.43 0.35 0.57 4.79 
2 90 500 0.64 0.36 0.41 0.23 0.27 4.41 
  100 500 0.58 0.42 0.32 0.24 0.32 4.83 
  110 500 0.54 0.46 0.28 0.24 0.24 5.20 
  120 500 0.48 0.52 0.23 0.24 0.45 5.80 
  130 500 0.43 0.57 0.19 0.24 0.58 6.29 
3 90 500 0.66 0.34 0.95 0.49 0.16 3.76 
  100 500 0.66 0.34 0.86 0.45 0.27 5.77 
  110 500 0.58 0.42 0.58 0.42 0.24 3.55 
4 80 500 0.53 0.47 0.51 0.46 0.27 6.10 
5 80 100 0.66 0.34 1.05 0.53 0.31 5.80 
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(continued)  
ClW 
 
Cell # 
Vhold 
(mV) 
Conc 
(M) PC PO 
Closed 
Lifetime 
(ms) 
Open 
Lifetime 
(ms) 
Closed 
Amp 
(pA) 
Open 
Amp 
(pA) 
1 100 50 0.61 0.39 0.31 0.19 0.32 4.91 
2 100 50 0.41 0.59 0.28 0.40 0.79 5.46 
  90 50 0.36 0.64 0.20 0.36 0.57 6.07 
3 90 50 0.54 0.46 0.60 0.50 0.21 3.79 
  100 50 0.48 0.52 0.39 0.42 0.20 4.33 
  90 50 0.43 0.57 0.32 0.43 0.31 4.70 
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4.4 Results 
Conductance levels vary in flicker mode.   
The initial guess as to the cause of the flicker mode was based on the probability 
of capturing an endogenous HEK 293 channel and not a GluA3 channel in the patch.  
The possibility that it was a Ca
2+
 activated channel prompted the removal of all Ca
2+
 
from the extracellular bath: the flicker activity was still observed. However, the 
evidence that this activity belonged to a GluA3 channel was strengthened when the 
flicker mode could not be replicated when patching in the absence of agonist. This 
behavior was only seen when agonists of GluA3 channels, specifically glutamate, FW, 
ClW, or NO2W, were present in the pipette. This behavior is reminiscent of 
intermediate and fast channel block on other ion channels, such as ion mediated K
+
 
channel block (4) and Mg
2+
 block of NMDA channels (5).   
All data were idealized to one closed and one open state (Figure 4.1B). Most of the 
patches exhibiting flicker activity rapidly closed and opened but did not contain long 
closures. A small number of patches did exhibit long closures between bursts and were 
could be fit with two or more closed states (Figure 4.2). These closures did not make 
up a large percentage of the overall activity. For example, in Table 4.2, a 5 M FW 
patch had a long closure with a dwell time of 405 ms which only represented 0.04% of 
the area of the exponential. The flicker mode was observed with every agonist tested 
and at all concentrations (50, 100 200 M glutamate, 5, 10 50 M FW, 100, 500 M 
NO2W, 50 M ClW; Figure 4.3). Table 4.1 is a summary of all the patches acquired 
with flicker mode.   
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Figure 4.2 
A 1 s representative trace of 500 M NO2W at a holding potential of 90 mV. The red 
box highlights longer closures in between flicker bursts.  The yellow line represents 
the baseline. 
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Figure 4.3 
50 ms representative traces of flicker activity in the presence of (A) glutamate, (B) 
FW, (C) ClW and (D) NO2W. The flicker activity ranges from more block to less 
block with no observable dependence on agonist or agonist concentration.   
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A few patches were recorded over a range of holding potentials and plotted as a 
current-voltage relationship to estimate the conductance, which ranged from 25 pS to 
55 pS (Figure 4.4). Visual inspection of the data revealed a different degree of flicker 
activity which ranged from longer closings to shorter closings that showed no 
dependency of the agonist and agonist concentration (Figure 4.3). The patches with 
more dramatic flicker activity also seemed to have a decrease in channel conductance.  
Based on these results, it appears the flicker mode of activity does not arise from a 
difference in the agonist used, but rather from an unknown mechanism of channel 
block. This suggests the difference in conductance is possibly caused by the 
concentration of the blocker or by differences in membrane potential which are 
unknown in cell-attached patch recording.   
To test whether the addition of cyclothiazide (CTZ) to the pipette buffer 
contributed to this blocking activity, a test patch with 5 M FW was acquired in the 
absence of CTZ (Figure 4.5) and not surprisingly, the same flicker activity was 
observed. To further test whether this blocking effect arose from intracellular factors 
intrinsic to HEK 293 cells, patches with this flicker activity were pulled from the cell.  
The flicker mode disappeared once the patch was isolated from the cell (data not 
recorded). This confirmed our suspicion that the blocking activity was caused by 
intrinsic factor(s) present in the HEK 293 cell itself and not from the recording 
conditions.   
Flicker mode is voltage dependent.   
The activity of the channel in the flicker gating mode seemed to be affected by 
voltage changes (Table 4.2), in which increasing the holding potential (which 
corresponds to more negative membrane potentials) altered the kinetics of the flicker.  
The open probability (PO) of the channel generally increased as the holding potential 
was increased whereas the closed probability (PC) decreased. The mean lifetime of the  
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Figure 4.4 
Current-Voltage relationship for glutamate, FW, ClW, and NO2W at varying 
concentrations. The amplitude at each holding potential was determined by idealizing 
the data to one closed and one open conductance level. The conductance for each of 
the agonists are: 24.5 pS 50 M FW; 54.9 pS 200 M Glutamate; 45.6 pS 50 M 
ClW; 47.5 pS 500 M NO2W; 39.04 pS 5 M FW.   
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Figure 4.5 
GluA3 flicker activity was acquired with 5 M FW in the absence of CTZ. 
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Table 4.2 
Flicker activity is voltage dependent. The kinetic values of a few patches acquired 
with 200 M glutamate, 5 M FW, and 500 M NO2W.   
 
Agonist 
(M) 
Vhold 
(mV) 
PC 
(%) 
PO 
(%) 
Open 
(pA) 
C1 
(ms) 
Area 
C2 
(ms) 
Area 

(ms)
Area 
200 
Glutamate 
90 42 58 5 0.47 1 
  
0.78 1 
 
100 42 58 5.47 0.45 1 
  
0.78 1 
 
110 33 67 6.1 0.33 1 
  
1.17 1 
5 FW 20 86 14 1.92 2.81 1 
  
0.32 1 
 
50 77 23 3.06 1.59 1.00 405 0.0004 0.31 1 
 
60 73 27 3.44 1.41 1 
  
0.31 1 
 
80 64 36 4.21 0.99 1 
  
0.38 1 
 
100 54 46 5.05 0.71 1 
  
0.53 1 
50 FW 100 73 27 2.9 1.26 1 
  
0.29 1 
 
110 67 33 3.15 1.00 1 
  
0.32 1 
 
120 62 38 3.39 0.83 1 
  
0.38 1 
50 ClW 90 54 46 3.79 0.73 1.00 246 0.0004 0.67 1 
 
100 48 52 4.33 0.61 1 
  
0.70 1 
 
110 43 57 4.7 0.50 1 
  
0.79 1 
500 
NO2W 
90 64 36 4.41 0.95 1.00 90 0.0001 0.39 1 
 
100 58 42 4.83 0.72 1.00 70 0.0006 0.48 1 
 
110 54 46 5.2 0.60 1.00 132 0.0007 0.57 1 
 
120 48 52 5.8 0.51 1.00 108 0.0007 0.69 1 
 
130 43 57 6.29 0.44 1.00 52 0.0009 0.85 1 
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Table 4.3 
Kinetic behavior of flicker mode.   
The model corresponding to the rates is: C2↔C1↔O. 
 
Agonist 
Vhold 
(mV) 
KC-O (s
-1
) KO-C (s
-1
) 
 Closed 
(ms) 
 Open 
(ms) 
200 M 
Glutamate 
90 2866 1975 0.47 0.78 
 
100 2972 2002 0.45 0.78 
 
110 3777 1502 0.33 1.17 
5 M FW 20 592 3386 2.81 0.32 
 
50 1111 3784 1.59 0.31 
 
60 1270 3878 1.41 0.31 
 
80 1671 3376 0.99 0.38 
 
100 2071 2552 0.71 0.53 
50 M FW 100 1522 4343 1.26 0.29 
 
110 1837 4085 1.00 0.32 
 
120 2055 3555 0.83 0.38 
50 M ClW 90 1848 1956 0.73 0.67 
 
100 2222 1995 0.61 0.70 
 
110 2646 1885 0.50 0.79 
500 M NO2W 90 1729 3311 0.95 0.39 
 
100 2137 2885 0.72 0.48 
 
110 2437 2532 0.60 0.57 
 
120 2744 2180 0.51 0.69 
 
130 2965 1830 0.44 0.85 
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open state was relatively the same at all holding potentials. However, the mean closed 
lifetime decreased with increasing holding potential. This indicates the length of 
closures shortened and contributed to the overall reduction in PC. The forward rate 
from CO also increased while the backward rate OC is decreased with increasing 
holding potentials (Table 4.3). This suggests that increasing the driving force of 
inward currents decreases the intensity of channel block. However, a complete loss of 
the block has never been observed with increasing membrane potentials.   
There were also patches which deviated from this behavior (Table 4.1, highlighted 
in yellow). Although the holding potential was increased, the activity seemed to 
fluctuate; the PC would increase or decrease regardless of holding potential. This was 
also the same with respect to PO, amplitudes, mean closed lifetimes and mean open 
lifetimes (Table 4.1 highlighted in yellow). However, these patches also contained 
long closures in between bursts, which could signify an activity change in the channel 
causing nonlinear results.   
 
4.5 Discussion  
Although different modes of activity for AMPA receptors have been established 
on the single channel level, this is the first study which has demonstrated an open 
channel block. The cause of the block, however, still remains a mystery. A few 
potential causes of the block have been explored and ruled out. We have determined 
the block is not caused by any exogenous factors that were introduced to the recording 
system and did not notice a dependence on the agonist or the concentration of the 
agonist. The blocking effect is also somewhat alleviated with increasing membrane 
potential, though the block is never fully eliminated unless the patch is excised from 
the membrane. The degree of flicker activity also ranged from highly blocked, which 
revealed itself as a decrease in amplitude and an increase in the duration of closures, to 
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a lesser degree of block, which exhibited larger amplitude openings and shorter closed 
durations. From these results, we propose that the block is caused by a factor present 
in the HEK 293 cells and that the extent of blockage is dependent on the concentration 
of this unidentified factor. Although the data did not reveal an agonist concentration 
dependence on block, this possibility is still unclear and needs to be resolved in future 
studies.   
The question now is what this factor that is causing the channel block? One 
possibility is a divalent cation.  K
+
 channels have a similar transmembrane topology 
but flipped 180˚ in the cell membrane.  K+ channels, like AMPA receptors, also form 
tetramers. Studies on various K
+
 channels have demonstrated channel blockade by 
various divalent cations, such as Mg
2+
, Zn
2+
 and Ni
2+
 (10-12). This same mechanism 
could possibly explain AMPA channel block. However, when extracellular Ca
2+
 was 
removed the block was still observed. The only divalent cation present in our 
recording buffer is Mg
2+
, and possibly intracellular Ca
2+
. Although these two ions are 
possibilities, our receptor subtype actually allows the influx of these two divalent ions. 
Not only that, but normal intracellular divalent ions, other than extremely high 
concentrations of Zn
2+
 (13), have not yet been shown to have an inhibitory effect in 
whole cell studies, so it is unlikely the flicker activity is caused by an ion block of the 
channel. Polyamines, on the other hand, are abundant in cells and have been shown to 
induce AMPA channel block on the whole cell level. Polyamines have blocking 
effects on all ionotropic glutamate receptors (3, 14). Polyamine block on NMDA 
receptors has also been shown in single channels and have been shown to have a 
voltage dependent block that is relieved by large negative potentials (14). The block 
by polyamines of NMDA channels is reminiscent of the block that is reported here for 
GluA3 channels. One method to test if polyamines were affecting GluA3 channels is 
to collect data in the inside-out patch configuration, in which the intracellular portion 
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of the receptor can be exposed directly to added polyamines. However, inside-out 
patches were not very stable in our system and thus not suitable for testing this 
hypothesis.   
Ion channel block has been speculated to play a physiological role in regulating 
channel activity in neuronal cells. Polyamine block of Ca
2+
 permeable AMPA 
channels has been shown to contribute to short term synaptic plasticity in local circuits 
(15).  During high-frequency stimulation, relief of polyamine block seems to inhibit 
neuronal depression (15). Identifying a pharmacological agent that mimics this block 
in neuronal cells might be of use in disorders such as epilepsy, in which the neuronal 
excitatory threshold is lower, and diseases such as amyotrophic lateral sclerosis, in 
which the expression of Ca
2+
 AMPA channels is increased (16, 17). There are 
currently several drugs that act as open channel blockers on other ion channels and are 
used for a range of purposes, such as local anesthetics, which block Na
+
 channels and 
a drug used to treat Alzheimer‟s disease, memantine that blocks NMDA channels.  
Future studies to understand the block and source of the block on the channel may 
open a new avenue for pharmacological manipulation of AMPA receptor function in 
patients with CNS related diseases and disorders.   
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CHAPTER 5 
 
Conclusions  
 160 
I. Summary of findings 
Research on ionotropic glutamate receptors, specifically AMPA receptors, has 
come a long way since the first discovery that glutamate was an excitatory 
neurotransmitter. We currently know the structure of the full length GluA2 receptor, 
without the C-terminus, bound to an antagonist (1). Many mutational, structural, and 
spectroscopic studies have been pieced together to formulate a better picture of how 
these receptors function. From these prior studies combined with the studies discussed 
here, we are now beginning to understand how each individual subunit contributes to 
the activation of an entire receptor.   
Using homomeric GluA3 receptors as a model for AMPA receptor function we 
can elucidate structure function relationships that can extend to other AMPA subtypes 
and other classes of glutamate receptors. Small differences in single channel activity 
when averaged over hundreds of channels can yield very large differences in whole 
cell function.  More importantly, the behaviors that are reported here can only be 
determined from single channel studies. Previous single channel studies were lacking 
for many reasons, but the most important is the inability to separate modes. AMPA 
receptors are very fast activators, switching between VL to VH modes on millisecond 
time scales. If these behaviors were not separated, then the underlying behavior could 
never be resolved. The studies outlined here have revealed many fundamental aspects 
to GluA3 receptor function; the first is that GluA3 channels exhibit different modes of 
activity (Chapter 2). These modal behaviors are dependent on the concentration of 
agonist; the lower the concentration, the more likely the receptor will activate in a low 
mode. These channels also display an unknown mechanism of fast open channel 
block. This flicker-mode is described in Chapter 4 and it appears to be due to a 
voltage-dependent block of the open channels from the cytoplasmic side, possibly by 
polyamines. The second observation is that all the agonists tested can induce the 
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channel to open to the same three conductance levels with differences in the open 
probability in each conductance level. At very high modes, the full agonist, glutamate, 
preferentially opens the channel to the intermediate and large conductance levels. The 
partial agonists, in comparison, follow in order of their efficacy; that is, when 
comparisons are made in the same mode, the less efficacious the agonist, the less 
likely the channel visits the largest conductance level (Chapter 3). Based on the single 
channel data collected in these studies, activation of AMPA receptors, although 
complex, seems to be conserved within the groups of agonists tested.   
The willardiines have the ability to induce lobe closures that is similar in 
magnitude to glutamate induced closures, yet in whole cell studies the willardiines 
reveal maximal currents that are less than glutamate (2, 3). Another interesting fact is 
that the willardiine family itself shows a graded whole cell response (3). This 
observable fact has always in itself questioned the correlation between the degree of 
lobe closure and agonist efficacy. Structural data on the LBD and the availability of 
the single channel data have allowed us to make direct correlations between structure 
and function. The single channel results show that low concentrations of agonist can 
induce the channel to activate to very high modes, similar to high concentrations of 
agonist. However, low concentrations of agonists imply a non-saturated receptor.  
What method is being employed by the receptor to induce these VH modes of activity 
with low concentrations of agonist? We proposed that stably closed LBD‟s trap 
agonists into the binding pocket, allowing for extended periods of activation that is 
associated with very high modes of activation. However, this brings up many new 
questions, the first being, what is the cause of these stable closures? From NMR 
studies, we have correlated stable closures with the flipping of D655 and S656 in lobe 
2 of the LBD to enable the formation of hydrogen bonds across the cleft (4). The 
timescale of the residues flipping into the proper conformation for H-bonding is on a 
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similar timescale to mode changes in single channel activity (4). The question of 
whether these are the only residues involved or if other residues in the ligand binding 
pocket play a role in stabilizing lobe closure is still uncertain and needs to be studied 
further.   
 Our studies also highlight the differences between a full agonist, glutamate, 
and the partial agonists, FW, NO2W, and ClW. The single channel data reveals the 
efficiency of the agonists to produce full channel openings to decrease in the same 
order of efficacy of the agonists; glutamate > FW > NO2W > ClW (2, 3). From the 
structures of the LBD‟s bound to these agonists, the lobe closures for the willardiines 
ranged from less closed to more closed, with ClW being slightly more open than 
NO2W and FW. The less closed structures have water molecules surrounding the 
peptide flip region and the more closed structures do not. Interestingly, the affinity of 
the willardiine compounds for AMPA receptors is much higher than glutamate. This 
suggests the willardiines can readily bind to the LBD. We speculate these partial 
closures do not provide enough energy to actually induce channel opening until the 
LBD‟s fully close. Indeed, when the channel does activate, the length of time spent 
open in the presence of the willardiines were always longer than with glutamate, 
suggesting the high affinity of the willardiines for the receptor is important in the 
function. Within the willardiine family itself, these burst lengths also seemed to 
correlate with the efficacy of the agonist; FW and NO2W cause longer burst duration 
than ClW, and glutamate has the shortest. Interestingly, ClW being the least 
efficacious of the three willardiines tested, and also displaying the more open LBD 
conformation, also shows an alternative kinetic  gating behaviors at low 
concentrations of agonist.  That is, at VH or H modes of activation, ClW can either 
have a high open probability or a very low open probability in the largest conductance 
level that does not affect the overall channel open probability (the addition of the open 
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probability of all three conductance levels remains the same). These results suggest 
four factors play a role in channel activation: affinity of the ligand for the receptor, the 
ability to induce lobe closure, the stability of the closure, and the actual degree of lobe 
closure. The affinity of the ligand for the receptor determines the length of time an 
agonist can dock into the LBD; the higher the affinity, the higher the probability long 
bursting behaviors will be observed. Once the agonist is docked, the LBD can either 
begin to close, or stay open. If the closure is full, then the channel will open; if the 
closure is less than full, then the channel will not open. Upon lobe closure, if hydrogen 
bonds form between the two lobes then the closure becomes more stable and will 
result in VH modes of activation.  Obviously, this correlation between the structural 
and functional studies cannot be proven unless the full length receptor is crystallized 
in the channel‟s active form, or more evidence is collected.   
In order to further obtain evidence for this mechanism, mutational studies which 
disrupt or strengthen any of these factors could be employed. Indeed, mutation of 
T686 which H-bonds to E402 (in GluA2) has been characterized and shown to cause a 
change in activation with a shift to a lower probability of the channel opening to the 
largest conductance level in the presence of full agonists (5). However, that study did 
not examine the open channel behavior in detail. The next step would be to kinetically 
characterize the open channel activity and search whether these mutants also display 
modal gating behaviors. Structural and functional studies with partial agonists on that 
specific mutation can yield results which either support or refute our hypothesis. 
Future single channel studies with mutations on other residues hypothesized to 
stabilize lobe closure can also further add proof to our correlation, such as T690, or 
E404 which H-bonds to Y450 in GluA2. If the initial hypothesis is correct, perturbing 
these residues to destabilize LBD closure should result in a decrease in very high 
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gating modes in single channel studies and a decrease in the open probability of the 
largest conductance level in each mode.    
Another question to address is how exactly LBD closure result in gating events in 
the transmembrane region. Currently, it is speculated that Lobe 2 of the LBD connects 
to transmembrane segment 3 (TM3) by a linker that is located between lobe 2 and 
TM3. Upon closure of the LBD, lobe 2 moves toward lobe 1, causing a separation of 
the linker which has been hypothesized to provide the energy for opening the gate of 
the channel (6). Until the structure of the full length receptor bound to an agonist is 
solved, this question will most likely remain speculated, but mostly unanswered. 
 
II. Future Directions 
Although the studies outlined here have systematically characterized the single 
channel behavior of wild type GluA3 channels using the neurotransmitter glutamate 
and 5-substituted willardiines, future studies on this subtype, and other glutamate 
receptors, remains to be undertaken. The first would be to determine the effects of the 
other willardiine compounds, IW and HW. IW is the weakest of the willardiines (3), 
with an efficacy that almost matches the low efficacy of kainate. Structures of IW 
bound to the LBD have closures ranging from 10 – 16 ° (2, 7). IW has already been 
shown in GluA2 receptors to exhibit three conductance levels (2), but modeling for 
modal behaviors has not been done. HW is a strange partial agonist; it can induce a 
level of desensitization that is as rapid as a full agonist, but does not cause large 
currents on the whole cell level (3). Structurally, HW can induce a lobe closure that is 
equivalent to FW. Kainate is also an interesting partial agonist to test because of the 
more open LBD conformation and low level of whole cell currents. If all the partial 
agonists have the ability to open the channel to the largest conductance level and the 
main difference would be in the probability of the channel opening to the largest 
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conductance level, then it would seem the hypothesis we put forth is more accurate at 
describing channel function.   
From there, mutations in the LBD, which have been studied on the whole cell 
level, can be studied on the single channel level. One such residue to mutate would be 
the residue equivalent to L650 in GluA2 receptors, which is conserved in all AMPA 
receptors (8). This residue juts into the binding pocket and is thought to sterically 
clash with the isopropenyl group of the partial agonist, kainate. Mutation of this 
residue to a threonine in GluA2 actually increases the potency of kainate and also 
causes a shift in the EC50 to the left (8). However, a functional consequence for the 
full agonists was a rightward shift in the EC50. AMPA had the most dramatic results 
with a large decrease in potency (8). In studies such as this one, it is difficult to tell 
what component of function is affected; does the channel still display three 
conductance levels or is the population of channel openings shifted so that the largest 
conductance level is sparsely visited? Single channel studies on these mutations will 
not only address this question, but provide more insight on how specific interactions in 
the LBD affect channel activation.   
A point mutation in the delta receptor, which has been replicated in AMPA 
receptors, result in a channel that has a lower activation threshold (9). How these 
channels function on the single channel level has never been addressed.  Studies on the 
point mutation in AMPA channels can yield some insight to the gating behavior by 
determining the kinetics of channel activation. A few questions to tackle is whether 
modal behaviors still exist, if the conductance levels are still observed and at what 
populations, and would there be a difference in function between full and partial 
agonists, as well as antagonists?   
 More experiments also need to be conducted to determine the cause of the 
flicker mode in GluA3 channels. The most obvious to test would be polyamines, 
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which have been shown to block Ca
2+
 permeable AMPA channels (10, 11). These 
experiments would have to be performed in excised patches in order to control the 
polyamine concentration. Even if polyamines are not the cause of the flicker mode, 
polyamine block on single channel function has not been characterized in AMPA 
receptors and would be reflective of in vivo behavior.   
A question which arose from these studies regards the data in which the channel 
was able to open to a specific conductance level for the entire record. This behavior 
has been characterized but an explanation has not been determined. There is a 
possibility this behavior is induced by phosphorylation but the current data to support 
this is lacking. Phosphorylation of the C-terminus is thought to induce higher levels of 
activity (12). This alteration in function has not been characterized on the single 
channel level. Future studies which either eliminate or induce C-terminal 
phosphorylation should be conducted to determine how single channel function is 
affected. Even if phosphorylation is not the cause of this specific behavior, 
nonetheless studying the effects of phosphorylation has many benefits to 
understanding the role it plays in channel function in neuronal cells, where 
phosphorylation of glutamate receptors readily occurs.   
Transmembrane AMPA receptor regulatory proteins, or TARP‟s, also play a huge 
role in AMPA receptor function in neurons. TARP‟s have been found to traffic with 
AMPA receptors and increase channel activation (13). Determining the single channel 
difference in a receptor that expresses with TARP‟s would be more reflective of 
AMPA receptor function in neurons.   
A question that has been brought up but difficult to answer is how cooperativity, if 
any, affects channel activation. This is a difficult question to address for many 
reasons. Based on the full structure of GluA2 bound to an antagonist, it seems AMPA 
channels form dimers which then interact with another dimer pair to form a tetramer.  
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These interactions are further complicated by how the dimer interactions form in the 
N-terminal domain. The N-terminal domain dimerizes with the adjacent subunit 
different from the LBD dimer (subunit 1 LBD dimerizes with subunit 2 LBD, subunit 
2 N-terminal domain dimerizes with subunit 3 N-terminal domain). This results in an 
asymmetric extracellular portion that also consists of interactions across dimer pairs 
(1). Dimerization of the LBD has been shown to occur after an agonist has bound and 
strengthening dimer contacts causes a decrease in the desensitization (14). Whether 
cooperativity arises from desensitization or channel activation is not yet clear. If the 
closure of one LBD can lead to the formation of dimer interface, with or without 
agonist in its dimer partner, then this might explain the single channel data in which 
the channel opened to only one level for long periods of time. LRET could also be 
used to study this (14), but determining which subunit in the tetramer had an agonist 
bound and which did not would be difficult to determine.   
Future studies addressing any of these questions can lead to fundamental insight 
on glutamate receptor function and elucidate the role these receptors play in neurons.  
These studies can also provide a logical basis for the creation of better 
pharmacological agents to target specific properties of neurodegenerative diseases.  
Although much is known, there is much more still to be uncovered. One truth is for 
certain, and that is research in this field has most certainly not been exhausted. 
 
 
 
 
 
 
 
 168 
REFERENCES 
 
1.  Sobolevsky, A.I., M.P. Rosconi, and E. Gouaux. 2009. X-ray structure, symmetry 
and mechanism of an AMPA-subtype glutamate receptor. Nature. 429:745-756. 
2.  Jin, R., T.G. Banke, M.L. Mayer, S.F. Traynelis, and E. Gouaux. 2003. Structural 
basis for partial agonist action at ionotropic glutamate receptors. Nat Neurosci. 
6:803-810. 
3.  Patneau, D.K., M.L. Mayer, D.E. Jane, and J.C. Watkins. 1992. Activation and 
desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J 
Neurosci. 12:595-606. 
4.  Fenwick, M.K., and R.E. Oswald. 2010. On the mechanisms of alpha-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor binding to 
glutamate and kainate. J Biol Chem. 285:12334-12343. 
5.  Zhang, W., Y. Cho, E. Lolis, and J.R. Howe. 2008. Structural and single-channel 
results indicate that the rates of ligand binding domain closing and opening 
directly impact AMPA receptor gating. J Neurosci. 28:932-943. 
6.  Armstrong, N., and E. Gouaux. 2000. Mechanisms for activation and antagonism 
of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand 
binding core. Neuron. 28:165-181. 
7.  Jin, R., and E. Gouaux. 2003. Probing the function, conformational plasticity, and 
dimer-dimer contacts of the GluR2 ligand-binding core: studies of 5-substituted 
willardiines and GluR2 S1S2 in the crystal. Biochemistry. 42:5201-5213. 
8.  Armstrong, N., M. Mayer, and E. Gouaux. 2003. Tuning activation of the AMPA-
sensitive GluR2 ion channel by genetic adjustment of agonist-induced 
conformational changes. Proc Natl Acad Sci U S A. 100:5736-5741. 
 
 169 
9.  Taverna, F., Z.G. Xiong, L. Brandes, J.C. Roder, M.W. Salter, and J.F. 
MacDonald. 2000. The Lurcher mutation of an alpha-amino-3-hydroxy-5-methyl- 
4-isoxazolepropionic acid receptor subunit enhances potency of glutamate and 
converts an antagonist to an agonist. J Biol Chem. 275:8475-8479. 
10.  Rozov, A., and N. Burnashev. 1999. Polyamine-dependent facilitation of 
postsynaptic AMPA receptors counteracts paired-pulse depression. Nature. 
401:594-598. 
11.  Dingledine, R., K. Borges, D. Bowie, and S.F. Traynelis. 1999. The glutamate 
receptor ion channels. Pharmacol Rev. 51:7-61. 
12.  Barria, A., V. Derkach, and T. Soderling. 1997. Identification of the 
Ca
2+
/calmodulin-dependent protein kinase II regulatory phosphorylation site in the 
alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptor. 
J Biol Chem. 272:32727-32730. 
13.  Nicoll, R.A., S. Tomita, and D.S. Bredt. 2006. Auxiliary subunits assist AMPA-
type glutamate receptors. Science. 311:1253-1256. 
14.  Gonzalez, J., M. Du, K. Parameshwaran, V. Suppiramaniam, and V. Jayaraman. 
2010. Role of dimer interface in activation and desensitization in AMPA receptors. 
Proc Natl Acad Sci U S A. 107:9891-9896. 
 
 
170 
 
 
 
 
 
 
APPENDIX 
 
 
Distinct Modulations of Human Capsaicin Receptor by Protons and Magnesium 
through Different Domains* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This  research was originally published in The Journal of Biological Chemistry.   
Shu Wang, Kinning Poon, Robert E. Oswald, Huai-hu Chuang.  Distinct 
Modulations of Human Capsaicin Receptor by Protons and Magnesium through 
Different Domains.  JBC. 2010; 258: 11547-11556.  © the American Society for 
Biochemistry and Molecular Biology. 
 171 
Abstract 
The capsaicin receptor (TRPV1) is a nonselective cation channel that integrates 
multiple painful stimuli, including capsaicin, protons, and heat. Protons facilitate the 
capsaicin- and heat induced currents by decreasing thermal threshold or increasing 
agonist potency for TRPV1 activation (Tominaga, M., Caterina, M. J., Malmberg, A. 
B., Rosen, T. A., Gilbert, H., Skinner, K., Raumann, B. E., Basbaum, A. I., and Julius, 
D. (1998) Neuron 21, 531–543). In the presence of saturating capsaicin, rat TRPV1 
(rTRPV1) reaches full activation, with no further stimulation by protons. 
HumanTRPV1 (hTRPV1), a species ortholog with high homology to rTRPV1, is 
potentiated by extracellular protons and magnesium, even at saturating capsaicin. We 
investigated the structural basis for protons and magnesium modulation of fully 
capsaicin-bound human receptors. By analysis of chimeric channels between hTRPV1 
and rTRPV1, we found that transmembrane domain 1–4 (TM1–4) of TRPV1 
determines whether protons can further open the fully capsaicin-bound receptors. 
Mutational analysis identified a titratable glutamate residue (Glu-536) in the linker 
between TM3 and TM4 critical for further stimulation of fully liganded hTRPV1. In 
contrast, hTRPV1 TM5–6 is required for magnesium augmentation of capsaicin 
efficacy. Our results demonstrate that capsaicin efficacy of hTRPV1 correlates with 
the extracellular ion milieu and unravel the relevant structural basis of modulation by 
protons and magnesium. 
 
Introduction 
The capsaicin receptor (transient receptor potential vanilloid 1 (TRPV1)), a 
transduction channel gated by multiple noxious stimuli, plays a central role in signal 
integration in pain-sensing neurons (2, 3). Noxious heat (>42 °C), acid, and capsaicin, 
a pungent natural product from chili peppers, all activate TRPV1 to elicit burning pain 
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(1, 4). Functional synergism among modalities allows TRPV1 to summate different 
types of subthreshold stimuli and produce a robust response (1, 5, 6). The extent of 
TRPV1 activation by one or a combination of stimuli determines the intensity of 
evoked pain (7–12).   
Many mammalian TRPV1 agonists exhibit weak receptor activation, even if they 
may bind the receptor comparably to capsaicin (13, 14). Acidic pH potentiates 
responses evoked by a low concentration of capsaicin in human and rat TRPV1 alike 
(1, 15). In contrast, extracellular acidification can enhance only the human receptor 
currents when capsaicin is applied at a concentration higher than 10 M (15). Thus, 
capsaicin functions as a partial agonist for hTRPV1 but a full agonist for the rat 
receptor. An elevation of temperature or local acidity can in principle augment the 
efficacies of partial agonists, transforming them from weakly or non-pain-producing 
ligands into noxious chemicals (16, 17). Thus, pain sensation arising from TRPV1 
activation by chemical agonists in humans could conceivably be different from that in 
rodents, the model species frequently used in biomedical research.   
Besides its involvement in pain sensation, TRPV1 displays a low level of activity 
at normal body temperature (18). Constitutive activity of TRPV1 is essential for 
regulation of body temperature, evidenced by high fever as a perilous side effect of 
many TRPV1 blockers during clinical trials for their efficacy in management or 
prophylaxis of pain (19). Modulators of TRPV1 basal activity and their sites of action 
are largely unknown; far less known is the variation of basal activities among species 
in which TRPV1 has been characterized. TRPV1 is a homotetrameric ion channel (20, 
21). Hydropathy analysis predicts each subunit to be a six-pass transmembrane 
polypeptide (4).  Earlier work suggests that capsaicin binds to the region between the 
second and the third transmembrane helices to gate TRPV1 (22). The region between 
the fifth and the sixth transmembrane segments, including a putative pore loop, forms 
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the ion permeation pathway (23). Several negatively charged amino acid residues in 
the pore have been shown to be important for sensitization or activation of TRPV1 by 
cations, particularly protons and magnesium (11, 24). Because of its therapeutic 
implication, a better understanding of how hTRPV1 opens in response to the 
extracellular ionic milieu is important. Notably, both protons and magnesium enhance 
the efficacy of capsaicin as an agonist for hTRPV1. Given its overall similar 
topological structure and a high percentage of identity (86%) at the amino acid 
sequence level to rTRPV1, we identified the structural determinants that allow these 
two ions to specifically sensitize the human receptor. We found that the stimulatory 
effects of protons and magnesium on fully liganded hTRPV1 require different modular 
domains. The first four transmembrane segments (TM1–4) of TRPV1 dictate whether 
the activity of a fully capsaicin-bound receptor can be further enhanced by protons, 
and a glutamate residue (Glu-536) in the linker between TM3 and TM4 of hTRPV1 is 
critical in the modulation by protons. TM5–6 of TRPV1 determines the species 
difference in magnesium modulation of both saturating capsaicin-induced currents and 
ligand-independent basal currents. A concerted action of the capsaicin-binding domain 
and the permeation pathway converges at the final stage of hTRPV1 opening.  
 
Materials and Methods 
Molecular Biology 
Chimeric channels between human and rat TRPV1 were constructed by 
overlapped extension PCR of the sequence fragments to be transferred with Pfu 
polymerase (Stratagene, CA), followed by restriction digestion and ligations into the 
expression vectors containing wild type cDNAs. Thanks to a high level of sequence 
homology between the hTRPV1 and rTRPV1, we could select common 
oligonucleotide primer sets of identical sequences for PCR. We first amplified TM1-4 
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and TM5-6 fragments using wild type TRPV1 as templates. For TM1-4, we used a 
pair of oligonucleotides with the following sequences: 5‟-
CAGGACAAGTGGGACAGATT-3‟ and 5‟-TAGATGCCCATCTGCTGGAA-3‟. 
For TM5-6, the oligonucleotides have the following sequences: 5‟-
TTCCAGCAGATGGGCATCTA-3‟ and 5‟-CAGGATGATGAAGACAGCCTTG-3‟. 
The first PCR fragments were extended using external primers outside the domains to 
be swapped and the wild type recipient receptor plasmid as the templates. The 
common primer for the N-terminal region has the following sequence: 5‟-
AGGCTCTATGATCGCAGGAG-3‟, and the C-terminal common primer has the 
sequence 5‟-GCAACTAGAAGGCACAGTCG-3‟ that anneals to the sequence within 
the vector plasmid. The extended PCR products were digested with BstEII and AflII, 
gel-purified, and subcloned into the gapped plasmid vectors containing the cDNA of 
the recipient receptor. Single point mutations were created by QuikChange 
mutagenesis following the manufacturer‟s protocol (Stratagene, CA). The sequences 
of mutagenic primers for the sense strand are as follows: H533Q, 5-
CTGTACTTCAGCCAGCTCAAGGAGTATGT-3; E536Q, 5‟-
ACTTCAGCCACCTCAAGCAGTATGTGGCTTCCAT-3‟; H533Q/E536Q, 5‟- 
CTGTACTTCAGCCAGCTCAAGCAGTATGTGGC-3‟.  All mutants were 
confirmed by Sanger‟s dideoxy DNAsequencing.   
 
Cell Culture and Transfection 
HEK293T cells were grown in minimal essential medium plus 10% newborn calf 
serum with penicillin/streptomycin, incubated at 37 °C in 5% CO2, and transfected 
using Lipofectamine according to the manufacturer‟s protocols (Invitrogen). Cells 
were transiently transfected with 300 ng of plasmid DNA encoding TRPV1 receptor 
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and 100 ng of reporter plasmid encoding enhanced green fluorescent protein. 
Electrophysiological recordings were performed 2 days after transfection.  
 
Electrophysiology 
Outside-out patch clamp and conventional whole-cell recording methods were 
used. Pipettes were fabricated from borosilicate glass (World Precision Instruments) 
and fire-polished to a resistance of ~2 megohms. For the outside-out patch clamp 
experiment, the intracellular pipette solution and standard extracellular bath solution 
were symmetrical and contained 150mM NaCl, 10mM HEPES, 1mM EGTA, pH 
adjusted to 7.4 or 6.4 with NaOH.  For the magnesium potentiation experiments, a 2 M 
MgCl2 stock solution was used as the source of Mg
2+
.  It was added into the external 
solution to achieve a final concentration of 5 mM Mg
2+
. For whole-cell recordings, we 
used a cesium solution containing 150 mM CsCl, 10 mM HEPES, 1 mM EGTA. 
Capsaicin was dissolved in DMSO to make a 0.1 mM stock solution, and diluted into 
the recording solution at 100 M concentration before  the experiment (0.1% final 
DMSO). Exchange of external solutions was performed using a gravity-driven 
perfusion system with manually controlled solenoid valves (ValvebankTM, Automate 
Scientific Inc.). Voltage clamp experiments were performed at -60 mV holding 
potential with 320-ms voltage ramps from -120 to 80 mV at 1 Hz. Macroscopic 
currents were recorded using an Axopatch 200B amplifier (Molecular Devices) and 
filtered at 2 kHz and digitized at 1 kHz (ITC-18; Instrutech Corp.). Single channel 
recordings were performed in the outside- out patch clamp configuration. The holding 
potential was -60 mV. Data were sampled at 5 kHz and low-pass filtered at 2 kHz. 
Data were acquired and analyzed using Pulse-Pulsefit software(HEKA, Pfalz, 
Germany), QuB (Program PRE, QUB Suite, Drs. A. Auerbach, F. Qin, and F. Sachs, 
SUNY, Buffalo, NY), and Origin 8.0 (OriginLab Corp., Northampton, MA). A series 
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of voltage steps for a 150 ms duration was used to induce steady-state currents. 
Because the tail currents were too small to be measured accurately, the conductance 
(G) was derived from the steady-state currents at the ends of the voltage steps using 
the equation: G = I/(V - Vrev), where Vrev is reversal potential (equal to zero in our 
experiments because we used symmetric solutions). The normalized conductance 
(G/Gmax) was plotted against the membrane potentials and was fitted with the 
following equation: G/Gmax = (Gmin/Gmax - 1)/(1+exp(V - V1⁄2)/K) + 1, where V1⁄2 is the 
potential for half-maximal activation, and K is the slope factor. The dose response 
curve was fitted with Hill equation: I/Imax = 1/(1 + (EC50/C)
n
).  I/Imax is the 
normalized current at -60 mV; EC50 is the half-maximal effective concentration of 
capsaicin, and n is the Hill coefficient. Data were presented as means ± S.E., and 
statistical significance was evaluated using unpaired Student‟s t test. A probability 
level of less than 0.05 was considered significant. 
 
RESULTS 
Protons Increase the Efficacy of Capsaicin as a Human TRPV1 Agonist 
Extracellular acidosis has been shown to markedly sensitize rTRPV1 by increasing 
the apparent affinity but not the maximal activation by capsaicin (1). In contrast, the 
ability of capsaicin to activate hTRPV1 at saturating concentrations depends on 
extracellular pH. Protons have been shown to permeate capsaicin-activated TRPV1 
channels and reduce intracellular pH (25). To better control both extracellular and 
intracellular pH values, we adopted the excised outside-out patch configuration to 
study the effect of protons on hTRPV1. Application of 100 M capsaicin induced a 
robust strongly outwardly rectifying current typical of hTRPV1 activation, which was 
further enhanced when the extracellular pH was reduced from 7.4 to 6.4 (Fig. A.1, A  
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FIGURE A.1 
Protons increase the capsaicin efficacy of hTRPV1 but not that of rTRPV1. A, 
protons increase the 100 M capsaicin (CAP)-induced currents of hTRPV1. Left, the 
capsaicin currents at -60 mV; right, current-voltage relationships at time points 
indicated by numbers in the left panel. B, protons block the 100 M capsaicin-induced 
currents of rTRPV1. C, comparison of the proton effect on the current amplitudes of 
hTRPV1 and rTRPV1 at -60 mV.  CAP pH 7.4 and CAP pH 6.4 represent the 
amplitudes of 100 M capsaicin (CAP)-induced currents at different pH values. 
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TABLE A.1 
Proton and magnesium effects on the 100 M capsaicin-induced currents of the 
wild type and chimeric TRPV1s.  The proton effect was analyzed at -60 mV. The 
magnesium effect was analyzed at -110 mV. CAP, capsaicin. 
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and C, and Table A.1). Further extracellular acidification only led to inhibition of 100 
M capsaicin-evoked rTRPV1 currents (Fig. A.1, B and C, and Table A.1). Similar 
results were also observed for these two receptors activated with 30 M capsaicin 
(data not shown). 
Acid potentiation of hTRPV1 was observed within the entire range of the voltage 
ramp (from -120 to +80 mV). Nevertheless, the potentiation effect is more pronounced 
at -60 mV (2.74 ± 0.23-fold, n = 7) compared with +80 mV (1.53 ± 0.03-fold, n = 7). 
Because channel numbers, single channel currents, and channel open probability 
jointly determine the amplitude of macroscopic currents, we asked which factor 
primarily contributes to the potentiation of hTRPV1 by protons. When we recorded 
hTRPV1 in the outside-out configuration at -60 mV with 100 M capsaicin, protons 
decreased the single channel current of hTRPV1 from 2.62 ± 0.10 (pH 7.4, n = 3) to 
1.35 ± 0.15 pA (pH 6.4, n = 3) (Fig. A.2). Assuming that the number of channels did 
not change in the membrane patch subject to acute application of protons, 
enhancement of hTRPV1 macroscopic current must reflect an increase of channel 
open probability.  
Proton potentiation of hTRPV1 indicates that the saturating concentration of 
capsaicin alone does not activate the human capsaicin receptor maximally. In 
principle, any positive channel modulators, in our case protons, will not further 
potentiate a TRPV1 channel that is maximally activated by capsaicin. We thus 
examined the biophysical parameters relevant for capsaicin-induced channel 
activation. Our dose-response analysis of capsaicin-induced currents showed that, in 
our recording configuration, hTRPV1 and rTRPV1 have similar EC50 values for 
capsaicin (Fig. A.3 and Table A.2). Therefore, unlike the absence of the capsaicin-
binding site in chicken TRPV1 (22), the lower activation of human TRPV1 by 
capsaicin is not a consequence of a lack of ligand binding but rather is an outcome of  
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FIGURE A.2 
Protons block the hTRPV1 single channel current in the presence of 100 M 
capsaicin. A, representative traces of hTRPV1 single channel current from outside-out 
patch at pH 7.4 or 6.4 in the presence of full-dose capsaicin. Holding potential is -60 
mV. C and O indicate the closed and open states, respectively. B, amplitude histogram 
for each pH condition fitted with Gaussian functions. At -60 mV, the amplitudes of 
single channel current at pH 7.4 and pH 6.4 are -2.62±0.10 (n=3) and -1.35±0.15 pA 
(n=3), respectively. 
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FIGURE A.3 
Capsaicin dose-response curves of wild type, chimeras, and hE536Q. Hill equation 
was used for curve fitting. Half-maximal effective concentrations of capsaicin (EC50) 
are summarized in Table 2. 
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the inefficient gating process. Capsaicin activation of TRPV1 is more efficient at more 
positive membrane potentials, which is clearly observed in the voltage-dependent 
activation curve (the conductance-voltage plot, or G-V curve) of hTRPV1 currents 
evoked by 100 M capsaicin. At -60 mV, the macroscopic channel conductance of 
hTRPV1 is less than 10% of the conductance at +190 mV in the presence of 100 M 
capsaicin (Fig.A.4). In comparison, the G-V curve of rTRPV1 under the same 
recording condition is dramatically left-shifted. At -60 mV, rTRPV1 reaches higher 
channel opening when all the ligand binding sites are occupied by capsaicin (~50% of 
the maximal channel conductance, Fig. A.4). This results in almost no significant 
change of open probability of rTRPV1 from -60 to +80 mV (after correction for the 
intrinsic rectification of TRPV1 single channel conductance) in response to an 
increase of membrane voltage, consistent with the idea of nearly maximal activation of 
rTRPV1 by a high concentration of capsaicin and a consequent lack of proton 
potentiation. Moreover, proton modulation of hTRPV1 is reduced at more positive 
membrane potentials, in agreement with the model that a channel with higher open 
probability is less likely to be further potentiated. 
 
First Four Transmembrane Segments (TM1–4) in Human TRPV1 Are Required for 
Modulation of Capsaicin Efficacy by Extracellular pH 
The stimulatory effect of extracellular protons on TRPV1 arises most likely 
through interaction with the extracellular domain of the protein or the ion permeation 
pathway, which is highly water accessible. We decided to subdivide the 
transmembrane region of TRPV1 into ligand-binding and ion-permeation domains to 
locate the protons modulation site with respect to the efficacy of capsaicin. Based on 
analogy to the topological structure of voltage-gated potassium channels (26), we 
replaced the TM5–6 or TM1–4 of human receptor with the corresponding regions of  
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FIGURE A.4 
A and B, representative traces for steady-state currents of hTRPV1 and rTRPV1 
induced by a series of voltage steps in the presence of 100 M capsaicin. C, 
conductance-voltage relationships (G-V curves) of wild type, chimeras, and hE536Q 
in the presence of 100 M capsaicin (see also Table 2). 
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TABLE A.2 
Activation parameters of TRPV1 wild type and mutant receptors. The voltage of 
half-maximal activation (V1⁄2) in the presence of 100 M capsaicin and half-maximal 
effective concentration of capsaicin (EC50) for the wild type, chimeras, and hE536Q 
are as summarized (n = 4–6). 
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FIGURE A.5 
TM1–4 in hTRPV1 determines the proton augmentation of capsaicin efficacy. A, 
topology of the four chimeras generated between hTRPV1 and rTRPV1. The numbers 
in individual constructs indicate the boundary residues numbers. B, rTRPV1-based 
chimera, rTRPV1-hTM1–4, is further stimulated by protons in the presence of 100 M 
capsaicin. C, summary of the effect of protons on the saturating capsaicin (CAP)-
induced currents of chimeras at -60 mV. 
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rTRPV1 to generate chimeric channels between hTRPV1 and rTRPV1, expecting that 
the former will have a pore region similar to the rat receptor, whereas the latter will 
show capsaicin binding and gating mimicking rat TRPV1 (Fig. A.5A). These two 
chimeric channels were named hTRPV1-rTM5–6 and hTRPV1-rTM1–4. We also 
constructed the reverse chimeric channels, rTRPV1-hTM5–6 and rTRPV1-hTM1–4 
(Fig. A.5A). Because the wild type and chimeric receptors have similar EC50 values 
for capsaicin (Fig. A.3 and Table A.2), we used the standard recording protocol (100 
M capsaicin, -120 to +80 mV voltage ramp) to assess proton modulation. We found 
that only chimeras that contain the human TM1–4 are further stimulated by protons 
(Fig. A.5, B and C). Protons stimulated the 100 M capsaicin-induced currents of 
hTRPV1-rTM5–6 or rTRPV1- hTM1–4 but blocked those of hTRPV1-rTM1–4 or 
rTRPV1- hTM5–6 (Fig. A.5C and Table A.1). Apparently, TM1–4 of hTRPV1 or 
rTRPV1 determines if the receptor is potentiated or blocked by protons in the presence 
of saturating capsaicin. This is in contrast to the proton sensitization of the TRPV1 
current evoked by low doses of capsaicin, which arises from pH titration of a 
glutamate residue (Glu-600 in rTRPV1 and Glu-601 in hTRPV1) near the pore (24).  
 
Titration of Glu-536 of Human TRPV1 by Protons Mediates Its Enhancement 
of Capsaicin Efficacy  
Protons most likely exert their effect by titrating acidic residues within the TM1–4 
segments of hTRPV1.  To localize the precise site of proton action, we made single 
amino acid substitutions with nontitratable glutamine for residues with side chain pKa 
values in the acidic range and examined the effect of protons on the mutant channels. 
Within the extracellular linker between TM3 and TM4, which has also been shown to 
be critical for direct activation of TRPV1 by strong acidic pH (27), a histidine residue  
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FIGURE A.6 
Mutant E536Q of hTRPV1 eliminates the proton modulation of capsaicin efficacy. 
A, hTRPV1 and rTRPV1 sequences are aligned within the TM3 and TM4 region, 
highlighting His-533 and Glu-536 in hTRPV1. B and C, protons potentiate 100 M 
capsaicin (CAP)-induced currents of hH533Q while slightly blocking that of hE536Q. 
D, comparison of the proton effects on the capsaicin currents of hH533Q and hE536Q 
at -60 mV. 
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is present that is unique to the human receptor (Fig. A.6A). Reasoning that titration of 
this histidine residue (His-533) could lead to enhancement of capsaicin efficacy, we 
replaced it with the corresponding residue (glutamine) in the rat receptor. Surprisingly, 
hTRPV1 H533Q (hH533Q) remained substantially potentiated by acidic extracellular 
pH (Fig. A.6, B and D). We then mutated the conserved Glu-536 residue in the linker 
between TM3 and TM4 into glutamine. The mutation E536Q in the human receptor 
yields a capsaicin-gated ion channel completely resistant to proton potentiation at 100 
M capsaicin (Fig. A.6, C and D).  Therefore, the protonation of Glu-536 is necessary 
for the acid modulation of capsaicin efficacy of hTRPV1. Upon closer inspection of 
capsaicin activation of hTRPV1 E536Q, we found that its EC50 value for capsaicin is 
reduced when compared with wild type hTRPV1 (2.34 ± 0.35 versus 0.79 ± 0.03 M 
for wild type and mutant receptors, respectively; Fig. A.3, and Table A.2).  More 
importantly, the voltage for half-maximal activation (V1⁄2) of this mutant shifts 
drastically from V1⁄2 of 73 ± 4 mV for wild type hTRPV1 to -28 ± 2 mV for the E536Q 
mutant (Table A.2). Thus, E536Q apparently exhibits a sensitized phenotype regarding 
capsaicin activation. 
 
Magnesium Stimulation of Human TRPV1 Requires the TM5–6 Region of the Receptor 
At the functional level, protons and magnesium share multiple mechanisms of 
modulation on rat TRPV1. Magnesium can sensitize rTRPV1 current evoked by low 
doses of capsaicin (11). At a concentration as high as 70 mM, magnesium also directly 
activates rTRPV1 (11). A previous study suggests that the two glutamate residues 
(Glu-600 and Glu-648) critical for proton modulation of rTRPV1 are the ones also 
involved in magnesium sensitization or activation of the rat receptor (11). Similar to 
protons, Mg
2+
 only increases the capsaicin efficacy of hTRPV1. As shown in Fig. A.7, 
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at a saturating concentration of capsaicin, Mg
2+
 enhances the hTRPV1 current while 
inhibiting the rTRPV1 current.  
Given the highly similar nature of magnesium and proton modulation of hTRPV1, 
we wondered whether the opposite modulatory effects of Mg
2+
 on human and rat 
TRPV1 require the same domain as that of protons. We studied the magnesium effects 
on the same set of four chimeras: hTRPV1-rTM5–6, hTRPV1-rTM1–4, rTRPV1-
hTM5–6, and rTRPV1-hTM1–4. At the holding potential of -60 mV, magnesium 
inhibits all four chimeric channels (data not shown). A closer inspection of the 
capsaicin-evoked currents at different membrane voltages, however, reveals that 
magnesium has more than one action on these chimeric channels. Like calcium and 
other divalent cations, magnesium is a permeant blocker of TRPV1. The blocking 
effect of magnesium appeared to be voltage-dependent in the wild type rat receptor, as 
the inhibition is more pronounced in the negative than in the positive membrane 
potential range (Fig. A.7B). The slight inhibition of the rat receptor by magnesium at 
positive membrane voltages has the characteristics of a surface potential effect from a 
high concentration of divalent ions, which displays a right shifted current-voltage (I-V) 
curve with the same slope conductance (Fig. A.7B). We reasoned that it may be 
necessary to analyze the magnesium effect at more extreme membrane potentials so 
that any possible stimulatory effect will not be obscured by magnesium block, for 
example at a voltage that magnesium block either does not occur or completely 
plateaus. So we studied the magnesium effect at -110 mV. We found that at a more 
negative membrane potential of -110 mV, magnesium actually has a small stimulatory 
effect on the 100 M capsaicin-evoked currents of the chimeras with human TM5–6 
(Fig. A.8, A and C, and Table 1). In contrast, the channels with the rat TM5–6 are still 
blocked by magnesium at this voltage (Fig. A.8, B and C, and Table 1). This result 
suggests that the TM5–6 region from human TRPV1 is important for magnesium 
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FIGURE A.7 
Mg
2+
 increases the capsaicin efficacy of hTRPV1 but not that of rTRPV1.  A and B, 
left, at -60 mV, 5mM MgCl2 increases the 100 M capsaicin (CAP)-induced currents 
of hTRPV1 by 0.89 ± 0.13-fold (n = 4), whereas it blocks the rTRPV1 currents by 
0.25 ± 0.07 (n = 5). Right, current-voltage relationships at time points indicated in left 
panel. C, comparison of the Mg
2+
 effect on capsaicin currents of hTRPV1 and 
rTRPV1 at -60 mV. Capsaicin + Mg
2+
 and capsaicin, respectively, represent the 
amplitudes of current induced by capsaicin with or without Mg
2+
. 
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FIGURE A.8 
Human TM5–6 region is required for the Mg2+ potentiation of capsaicin efficacy. A, 
left, at -110 mV, 5 mM Mg
2+
 potentiates the 100 M capsaicin (CAP)-induced 
currents of rTRPV1-based chimera with human TM5–6. Right, current-voltage 
relationships show that Mg
2+
 increases the current at very negative potential. B, Mg
2+
 
blocks the capsaicin currents of chimera with rat TM5–6 within the entire range of the 
voltage ramp. C, summary of the Mg
2+
 effect on the capsaicin currents of the four 
chimeras at -110 mV. 
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augmentation of capsaicin efficacy. Compared with the wild type human receptor, 
hTRPV1-rTM1–4 and rTRPV1- hTM5–6 showed much less potentiation by 
magnesium at -110 mV (Table A.1). The reduction of magnesium stimulation in these 
two chimeras may be an outcome of their higher open probabilities at -110 mV 
compared with the wild type human receptor (Fig. A.4). If the channel has been 
strongly activated at a particular voltage, magnesium is expected to have more limited 
stimulatory effects. To test this possibility, we used a combination of acid (pH 6.4) 
and 100 M capsaicin to strongly activate hTRPV1. Under this experimental 
condition, magnesium stimulation of the wild type human receptor is largely 
diminished, with some residual stimulation seen only at more negative membrane 
potentials (e.g. -110 mV) (Fig. A.9).  
In the absence of agonist, TRPV1 also displays slight basal channel activity with 
strongly voltage dependent outward rectification (Fig. A.10, A and B). The inward 
basal current is more pronounced when we used cesium instead of sodium as the 
charge carriers in the extracellular solution for the purpose of accurate measurement. 
Protons and magnesium both enhance the basal currents of either human or rat TRPV1 
measured at room temperature.  Magnesium potentiates hTRPV1 basal currents more 
effectively than rTRPV1, whereas proton enhancement of basal currents is comparable 
for both channels (4.84±0.78-fold versus 3.05±0.19- fold, p > 0.05, n = 6). Analysis 
of four chimeras reveals that the TM5–6 region is responsible for the species 
difference in magnesium modulation of basal currents (Fig. A.10C). 
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FIGURE A.9 
Mg
2+
 effect on hTRPV1 is diminished when the channel is substantially opened by 
the combination of full-dose capsaicin and protons. A, left, at -60 mV, 100 M 
capsaicin (CAP)-induced current of hTRPV1 is potentiated by acid (pH 6.4), 5 mM 
Mg
2+
 blocks the current; right, at -110 mV, Mg
2+
 shows small enhancing effect on the 
current. B, current-voltage relationships at time points indicated by numbers in A. C, at 
-60 mV, Mg
2+
 blocks the current by 0.10 ± 0.03-fold, although at -110 mV, Mg
2+
 
increases the current by 0.20 ± 0.02-fold. 
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FIGURE A.10 
TM5–6 determines the differential Mg2+ effects on the whole cell basal currents 
of human and rat TRPV1. A and B, left, hTRPV1 and rTRPV1 basal currents at -60 
mV. Basal Cs
+
 current is more pronounced than Na
+
 current and 5 mM Mg
2+
 
potentiates both basal currents of hTRPV1 and rTRPV1. Right, the current-voltage 
relationships at time points indicated by the numbers in the left panel. C, summary of 
the Mg
2+
 effect on the basal currents of wild types and chimeras at -60 mV. In the Cs
+
 
solution, Mg
2+
 increases the hTRPV1 and rTRPV1 basal currents to 8.65 ± 1.45-fold 
(n = 12) and 2.16 ± 0.16-fold (n = 15), respectively. Mg
2+
 also potentiates the basal 
currents of hTRPV1-rTM1–4 and rTRPV1-hTM5–6 more effectively than that of rat 
receptor (*, p_0.05, compared with rTRPV1, n = 5–10). There is no significant 
difference between rTRPV1 and hTRPV1-rTM5–6 or rTRPV1-hTM1–4. 
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DISCUSSION 
TRPV1 is the principal transduction channel modulating the excitability of pain-
sensing neurons in vertebrate species. Although TRPV1s from all species sense 
noxious heat and tissue acidosis, the repertoire of chemical agonists for each species 
homologues displays substantial variability (22, 28–30). The efficacies of capsaicin as 
well as other small organic TRPV1 agonists are both species- and micro- 
environment-dependent (13, 17). It is therefore relevant to elucidate the molecular 
basis of differential sensitivity to chemical ligands or integration mechanisms between 
different modalities for a full appreciation of the protective and incapacitating aspects 
of pain sensation in physiological or pathological settings.  
The similarity between human and rat TRPV1 at the primary sequence level is 
remarkable. The glutamate residue near the pore loop (Glu-600) responsible for 
enhancement of agonist potency of capsaicin is functionally conserved among species. 
One might expect the existence of some titratable amino acid residues unique to the 
human receptor accounting for proton modulation of agonist efficacy of capsaicin. 
However, we identified a conserved Glu-536 as the critical residue for proton 
stimulation of capsaicin efficacy in hTRPV1. Rather than losing its ability to be 
properly activated by capsaicin due to nonspecific perturbation of the overall structure 
of the TM1–4 domain, the hE536Q mutant channel behaves as a fully protonated wild 
type hTRPV1 channel. In support of this view, hE536Q has higher apparent affinity 
for capsaicin and shows higher channel open probability at saturating concentrations 
of capsaicin, mimicking a wild type hTRPV1 channel in an acidic environment (pH 
6.4). However, the Glu-536 residue is also present in the rat receptor that shows no 
change in capsaicin efficacy by acidic pH. One possible explanation is that channel 
open probability of rTRPV1 by capsaicin has already reached itsmaximum within the 
voltage range of our recordings so that it is impossible to further enhance the rat 
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receptor current with any positive modulators. As long as saturating capsaicin is 
present, for membrane potential higher than -60 mV, rat TRPV1 open probability does 
not even increase in response to voltage increments, a highly effective gating factor 
for TRPV1 in general.  Given that rTRPV1 activated by anandamide can still be 
potentiated by acidic pH at saturating concentrations of this agonist (13, 16), titration 
of the Glu-536 residue of the rat receptor may play a role in facilitating channel 
opening by much lower efficacy agonists, such as anandamide or oxidative lipids. 
Previous studies indicate that at the transition between TM3 and the intracellular 
loop (TM2–3 linker), amino acid residues, including the Tyr-511 and Ser-512, are 
critical for capsaicin gating of the channel (22). Our results suggest that an amino acid 
(hGlu-536) within the extracellular loop (linker between TM3 and TM4) serves as a 
molecular switch to increase the open probability of ligand-bound human receptors. 
This linker, although short, constrains the structure of the TM1–4 domain of TRPV1 
to impact its function significantly. Amino acid substitutions within this linker had 
been shown to obliterate the activation of TRPV1 by extremely acidic pH, even if the 
residues involved are not directly titratable by protons (27). Although modulatory 
effects of magnesium on human TRPV1 phenocopy those of protons in both the 
polarity and the magnitude, immediate sites of actions of these two cations are 
different. The stimulatory effect of magnesium is associated with pore domains in 
chimeras. Primary sequences of TRPV1 pore regions among species are even more 
conserved than other parts of the receptor, the only variation being a small 
hypervariable segment connecting the distal end of TM5 helix and the completely 
conserved “pore” loop. This segment likely contributes to refining the positions of 
several previously identified amino acid residues implicated in magnesium activation 
of TRPV1 by affecting its binding. The ligand-independent basal currents of TRPV1 
from both species variants are stimulated by magnesium. However, there is a 
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significant quantitative difference between human and rat receptors. In contrast, 
protons stimulate basal currents of both receptors to a similar level.  
Multimodal gating is an essential feature of TRP channels. Here, we demonstrated 
protons and magnesium can further stimulate fully capsaicin-bound hTRPV1 through 
actions on distinct structures. Various kinetic paradigms have been proposed to 
explain the generalized gating of the thermo-sensitive transient receptor potential 
channels (31–34). These models likely will need refinements when more structural or 
biochemical data become available to correlate with proposed functional states. These 
models can be quantitatively adjusted to explain differential capsaicin sensitivity of 
TRPV1 from different species. For example, the efficacy of capsaicin as a TRPV1 
agonist is lower for the human receptor than the rat receptor. This is not because 
capsaicin fails to bind hTRPV1 as well as rTRPV1, as EC50 values of capsaicin for 
both channels are similar. Instead, capsaicin-binding processes are comparable 
between hTRPV1 and rTRPV1, but hTRPV1 channel is harder to open. It can be due 
to either a higher energetic barrier for hTRPV1 to open or because of less efficient 
coupling between binding and gating in hTRPV1. When we inspect the G-V curves of 
wild type and mutant channels in this study, it is obvious that maximal left shifts of 
these curves by capsaicin are determined by the entirety of all six transmembrane 
segments but not the further subdivided TM1–4 ligand-binding or TM5–6 ion-
permeating domain alone. The chimeric channels, no matter with transfer of the TM1–
4 capsaicin-binding domain or the TM5–6 pore domain, have the G-V curves fall 
between the boundaries defined by the two wild type receptors. However, if we 
compare the pair with the same TM1–6 segments, e.g. the hTRPV1-rTM5–6 and 
rTRPV1-hTM1–4, they actually have very close V1⁄2 values for G-V curves. The 
human receptor has a TM1–4 domain harder to open by capsaicin. Only by 
substitution of the Glu-536 residue with a neutral amino acid in hTRPV1, an 
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equivalent of titration of Glu-536 residues in all four channel subunits, can the mutant 
channel reach theV1⁄2 value comparable with the chimeric channels containing rat 
TM1–4 domain, and it acquires resistance to proton modulation. A reduced model 
where temperature and chemical agonists are treated as gating modifiers to shift the 
intrinsic voltage-dependent gate of the TRPV1 channel cannot accommodate all the 
data we obtained without further assumptions (31). Different positive regulators of 
TRPV1 gating must operate independently so that when one of them reaches its 
maximal capacity of modulation, the rest of them can still further increase channel 
opening (32–34). One apparent example is the hTRPV1 E536Q mutant, although 
protons essentially have no effect on full dose capsaicin-activated currents, an increase 
in transmembrane voltage still leads to further channel opening. It is expected that for 
each TRPV1 receptor, wild type or mutants, there must be an upper limit for channel 
openings even with all possible activators present simultaneously. This upper limit of 
probability for channel opening may differ from one construct to another. However, a 
common principle will hold for all kinds of TRPV1 channels that the relative receptor 
potentiation by a modulator gets smaller when other positive regulators are already 
present, illustrated by a reduction of Mg
2+
 effects on proton-potentiated hTRPV1. At 
the other extreme, one can also view capsaicin as an exceptionally strong activator for 
rodent receptors. Pepper plants acquire the ability to synthesize this powerful agonist 
for survival in their ecological niches during evolution. Being an effective deterrent 
against rodents, capsaicin does not require any other positive regulators to maximally 
activate rat TRPV1. It is thus tempting to hypothesize that different sensors for 
agonistic stimuli (capsaicin, heat, protons, and magnesium) are contained in different 
structural motifs. Although the physical natures of these sensors are currently 
unknown, our site mapping work will provide some candidate regions to examine once 
the high resolution structures of TRPV1 are available.  
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It is worth noting that protons have more complex effects on the capsaicin 
activation of human TRPV1 than that of rat TRPV1, a property attributable to 
relatively weak activation of hTRPV1 by capsaicin, namely partial agonism. A lower 
efficacy of capsaicin on human TRPV1 allows us to appreciate Nature‟s design of a 
signal integrator. Although most physiological activators, including elevation of 
extracellular acidity, excitatory cations, and endogenous agonists, are all weak 
activators of TRPV1, synergism of these stimuli can broaden the sensory dimensions 
of an injury-detecting receptor. Execution of the stimulatory effects through different 
structural domains of the sensor molecule increases the coding complexity and 
dynamic range of different categories of signal inputs and its overall efficiency in final 
receptor activation, particularly when all the stimuli are sub-threshold. This is 
exemplified in human TRPV1 by a plethora of interactions of protons and magnesium 
ions on the capsaicin-activated currents, the former through the Glu- 600 residue near 
the pore and the Glu-536 residue in the linker between TM3 and TM4, as well as the 
latter acting within the pore. It will be interesting to determine whether the same 
principle also applied to other endogenously produced TRPV1 agonists with even less 
efficacy compared with capsaicin. 
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